Oncol	O
Rep	O
2001	O
Jan	O
-	O
Feb	O
;	O
8	O
(	O
1	O
)	O
:	O
89	O
-	O
92	O
Characterization	O
of	O
the	O
mutations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
in	O
15	O
human	O
pancreatic	O
cancer	O
cell	O
lines	O
.	O
Sun	O
C	O
,	O
Yamato	O
T	O
,	O
Furukawa	O
T	O
,	O
Ohnishi	O
Y	O
,	O
Kijima	O
H	O
,	O
Horii	O
A	O
.	O
Department	O
of	O
Molecular	O
Pathology	O
,	O
Tohoku	O
University	O
School	O
of	O
Medicine	O
,	O
Aoba-ku	O
,	O
Sendai	O
980	O
-	O
8575	O
,	O
Japan	O
.	O
Human	O
pancreatic	O
cancer	O
is	O
one	O
of	O
the	O
most	O
malignant	O
diseases	O
in	O
the	O
world	O
.	O
In	O
order	O
to	O
save	O
patients	O
with	O
pancreatic	O
cancer	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
novel	O
methods	O
for	O
treatment	O
.	O
For	O
such	O
a	O
purpose	O
,	O
a	O
series	O
of	O
well	O
-	O
characterized	O
cancer	O
cell	O
lines	O
are	O
of	O
great	O
help	O
for	O
in	O
vitro	O
studies	O
that	O
are	O
generally	O
the	O
first	O
step	O
in	O
approaching	O
the	O
invention	O
of	O
novel	O
methods	O
for	O
treatment	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
15	O
human	O
pancreatic	O
cancer	O
cell	O
lines	O
for	O
genetic	O
alterations	O
of	O
the	O
K-ras	O
,	O
p53	O
,	O
p16	O
,	O
and	O
SMAD4	O
genes	O
,	O
which	O
are	O
very	O
frequent	O
targets	O
for	O
mutation	O
in	O
pancreatic	O
cancer	O
;	O
these	O
cell	O
lines	O
are	O
useful	O
resources	O
in	O
cancer	O
research	O
.	O
PMID	O
:	O
11115575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Hematol	O
2000	O
Dec	O
;	O
65	O
(	O
4	O
)	O
:	O
307-9	O
Mast	O
cell	O
disease	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
:	O
detection	O
of	O
a	O
new	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
His	B-state-altered
.	O
Pullarkat	O
VA	O
,	O
Pullarkat	O
ST	O
,	O
Calverley	O
DC	O
,	O
Brynes	O
RK	O
.	O
Division	O
of	O
Hematology	O
,	O
University	O
of	O
Southern	O
California	O
School	O
of	O
Medicine	O
,	O
Los	O
Angeles	O
,	O
California	O
90033-	O
0804	O
,	O
USA	O
.	O
vinodpullarkat@pol.net	O
Mast	O
cell	O
disease	O
(	O
MCD	O
)	O
,	O
a	O
proliferation	O
of	O
mast	O
cells	O
(	O
MC	O
)	O
,	O
is	O
occasionally	O
associated	O
with	O
hematologic	O
malignancies	O
.	O
Neoplastic	O
MC	O
have	O
activating	O
c-kit	O
mutations	O
.	O
c-kit	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
required	O
for	O
the	O
development	O
,	O
proliferation	O
,	O
and	O
survival	O
of	O
MC	O
.	O
Interaction	O
of	O
c-kit	O
with	O
its	O
ligand	O
stem	O
cell	O
factor	O
induces	O
dimerization	O
,	O
receptor	O
phosphorylation	O
,	O
and	O
signal	O
transduction	O
.	O
The	O
most	O
common	O
c-kit	O
mutation	O
detected	O
in	O
neoplastic	O
MCD	O
is	O
Asp	B-state-original
816	B-location
Val	B-state-altered
,	O
which	O
results	O
in	O
ligand	O
-	O
independent	O
autophosphorylation	O
of	O
the	O
receptor	O
leading	O
to	O
MC	O
proliferation	O
.	O
We	O
describe	O
the	O
rare	O
occurrence	O
of	O
MCD	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
report	O
a	O
novel	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
His	B-state-altered
,	O
and	O
discuss	O
the	O
pathogenesis	O
of	O
MCD	O
associated	O
with	O
hematologic	O
malignancies	O
.	O
Copyright	O
2000	O
Wiley	O
-	O
Liss	O
,	O
Inc.	O
PMID	O
:	O
11074560	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Epidemiol	O
Biomarkers	O
Prev	O
2000	O
Oct	O
;	O
9	O
(	O
10	O
)	O
:	O
1027-35	O
Molecular	O
changes	O
in	O
second	O
primary	O
lung	O
and	O
breast	O
cancers	O
after	O
therapy	O
for	O
Hodgkin	O
's	O
disease	O
.	O
Behrens	O
C	O
,	O
Travis	O
LB	O
,	O
Wistuba	O
II	O
,	O
Davis	O
S	O
,	O
Maitra	O
A	O
,	O
Clarke	O
EA	O
,	O
Lynch	O
CF	O
,	O
Glimelius	O
B	O
,	O
Wiklund	O
T	O
,	O
Tarone	O
R	O
,	O
Gazdar	O
AF	O
.	O
Hamon	O
Center	O
for	O
Therapeutic	O
Oncology	O
Research	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
,	O
Dallas	O
75390-8593	O
,	O
USA	O
.	O
The	O
risk	O
of	O
lung	O
and	O
breast	O
cancer	O
is	O
significantly	O
increased	O
after	O
therapy	O
for	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
,	O
but	O
there	O
are	O
few	O
data	O
that	O
describe	O
the	O
molecular	O
profiles	O
of	O
these	O
tumors	O
.	O
We	O
investigated	O
the	O
genetic	O
abnormalities	O
in	O
second	O
primary	O
lung	O
(	O
n	O
=	O
19	O
)	O
and	O
breast	O
cancers	O
(	O
n	O
=	O
19	O
)	O
that	O
follow	O
therapy	O
for	O
HD	O
(	O
"	O
post	O
-	O
HD	O
cancers	O
"	O
)	O
and	O
compared	O
these	O
with	O
changes	O
observed	O
in	O
corresponding	O
tumor	O
types	O
(	O
57	O
lung	O
and	O
20	O
breast	O
cancers	O
)	O
arising	O
in	O
the	O
general	O
population	O
(	O
"	O
sporadic	O
cancers	O
"	O
)	O
.	O
DNA	O
obtained	O
from	O
archival	O
tissues	O
was	O
examined	O
using	O
PCR	O
-	O
based	O
analyses	O
for	O
loss	B-type
of	I-type
heterozygosity	I-type
and	O
microsatellite	O
alterations	O
(	O
MAs	O
)	O
at	O
several	O
chromosomal	O
regions	O
,	O
TP53	O
and	O
K-ras	O
gene	O
mutations	O
,	O
and	O
frameshift	B-type
mutations	B-event
at	O
minisatellite	O
sequences	O
at	O
the	O
coding	O
regions	O
of	O
several	O
genes	O
(	O
TGF-betaRII	O
,	O
IGFIIR	O
,	O
BAX	O
,	O
hMSH6	O
,	O
and	O
hMSH3	O
)	O
.	O
The	O
occurrence	O
of	O
loss	B-type
of	I-type
heterozygosity	I-type
at	O
all	O
chromosomal	O
regions	O
taken	O
together	O
and	O
frequencies	O
at	O
most	O
individual	O
areas	O
were	O
similar	O
for	O
the	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
for	O
both	O
lung	O
and	O
breast	O
sites	O
.	O
The	O
overall	O
frequency	O
of	O
MAs	O
in	O
the	O
post	O
-	O
HD	O
tumors	O
was	O
substantially	O
greater	O
(	O
lung	O
,	O
2.4	O
-	O
fold	O
,	O
P	O
=	O
0.004	O
;	O
breast	O
,	O
4.2	O
-	O
fold	O
,	O
P	O
=	O
0.16	O
)	O
than	O
that	O
in	O
the	O
respective	O
sporadic	O
cancers	O
.	O
No	O
differences	O
in	O
the	O
pattern	O
of	O
TP53	O
and	O
K-ras	O
mutations	O
were	O
detected	O
between	O
post	O
-	O
HD	O
and	O
sporadic	O
cancers	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
the	O
minisatellite	O
sequences	O
examined	O
.	O
MAs	O
,	O
which	O
reflect	O
widespread	O
genomic	O
instability	O
,	O
occur	O
at	O
greatly	O
increased	O
frequency	O
in	O
post	O
-	O
HD	O
lung	O
and	O
breast	O
cancers	O
.	O
Although	O
the	O
mechanisms	O
underlying	O
the	O
development	O
of	O
increased	O
MAs	O
are	O
unknown	O
,	O
they	O
have	O
been	O
associated	O
with	O
immunosuppression	O
and	O
radiation	O
exposure	O
.	O
Future	O
research	O
should	O
address	O
the	O
role	O
that	O
MAs	O
,	O
as	O
well	O
as	O
other	O
influences	O
,	O
may	O
play	O
in	O
the	O
development	O
of	O
neoplasias	O
that	O
occur	O
after	O
therapy	O
for	O
HD	O
.	O
PMID	O
:	O
11045784	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mol	O
Pathol	O
2000	O
Aug	O
;	O
53	O
(	O
4	O
)	O
:	O
188	O
-	O
93	O
Detection	O
of	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
to	O
Val	B-state-altered
in	O
microdissected	O
bone	O
marrow	O
infiltrates	O
in	O
a	O
case	O
of	O
systemic	O
mastocytosis	O
associated	O
with	O
chronic	O
myelomonocytic	O
leukaemia	O
.	O
Sotlar	O
K	O
,	O
Marafioti	O
T	O
,	O
Griesser	O
H	O
,	O
Theil	O
J	O
,	O
Aepinus	O
C	O
,	O
Jaussi	O
R	O
,	O
Stein	O
H	O
,	O
Valent	O
P	O
,	O
Horny	O
HP	O
.	O
Institute	O
of	O
Pathology	O
,	O
University	O
Hospital	O
Tubingen	O
,	O
Germany	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
The	O
occurrence	O
of	O
myeloid	O
leukaemia	O
in	O
patients	O
with	O
systemic	O
mastocytosis	O
is	O
a	O
well	O
recognised	O
phenomenon	O
.	O
However	O
,	O
the	O
pathophysiological	O
basis	O
of	O
such	O
a	O
coevolution	O
has	O
not	O
been	O
clarified	O
.	O
Recent	O
data	O
have	O
shown	O
that	O
the	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
to	O
Val	B-state-altered
is	O
detectable	O
in	O
neoplastic	O
mast	O
cells	O
in	O
most	O
patients	O
with	O
systemic	O
mastocytosis	O
,	O
including	O
those	O
who	O
have	O
associated	O
haematological	O
disorders	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
clonal	O
disease	O
evolution	O
by	O
analysing	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	O
mastocytosis	O
and	O
associated	O
chronic	O
myelomonocytic	O
leukaemia	O
(	O
CMML	O
)	O
for	O
the	O
presence	O
of	O
this	O
mutation	B-event
.	O
METHODS	O
:	O
The	O
DNA	O
of	O
microdissected	O
bone	O
marrow	O
cells	O
from	O
a	O
patient	O
with	O
systemic	O
mastocytosis	O
and	O
associated	O
CMML	O
was	O
analysed	O
for	O
the	O
presence	O
of	O
the	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
to	O
Val	B-state-altered
by	O
means	O
of	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O
RESULTS	O
:	O
The	O
two	O
neoplasms	O
could	O
easily	O
be	O
identified	O
and	O
discriminated	O
in	O
paraffin	O
wax	O
embedded	O
bone	O
marrow	O
sections	O
by	O
tryptase	O
and	O
chloroacetate	O
esterase	O
staining	O
.	O
A	O
total	O
number	O
of	O
10	O
tryptase	O
positive	O
systemic	O
mastocytosis	O
infiltrates	O
and	O
10	O
tryptase	O
negative	O
CMML	O
infiltrates	O
were	O
removed	O
by	O
microdissection	O
.	O
As	O
assessed	O
by	O
HinfI	O
digestion	O
and	O
direct	O
sequencing	O
of	O
semi	O
-	O
nested	O
PCR	O
products	O
,	O
the	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
to	O
Val	B-state-altered
was	O
detected	O
in	O
five	O
of	O
seven	O
systemic	O
mastocytosis	O
infiltrates	O
and	O
four	O
of	O
six	O
CMML	O
infiltrates	O
.	O
By	O
contrast	O
,	O
no	O
c-kit	O
mutation	O
Asp	B-state-original
816	B-location
to	O
Val	B-state-altered
was	O
found	O
in	O
bone	O
marrow	O
infiltrates	O
in	O
patients	O
with	O
CMML	O
without	O
associated	O
systemic	O
mastocytosis	O
(	O
n	O
=	O
20	O
)	O
.	O
CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
monoclonal	O
evolution	O
of	O
systemic	O
mastocytosis	O
and	O
concurrent	O
CMML	O
in	O
the	O
patient	O
studied	O
.	O
PMID	O
:	O
11040941	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Cancer	O
Lett	O
2000	O
Oct	O
16	O
;	O
159	O
(	O
1	O
)	O
:	O
73	O
-	O
8	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	B-type
involving	O
exon	B-location
3	I-location
as	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Murata	O
M	O
,	O
Iwao	O
K	O
,	O
Miyoshi	O
Y	O
,	O
Nagasawa	O
Y	O
,	O
Yabu	O
M	O
,	O
Himeno	O
S	O
,	O
Imanishi	O
K	O
,	O
Ohsawa	O
M	O
,	O
Wada	O
H	O
,	O
Tominaga	O
S	O
,	O
Shimano	O
T	O
,	O
Kobayashi	O
T	O
,	O
Nakamura	O
Y	O
.	O
Department	O
of	O
Surgery	O
,	O
Ikeda	O
Municipal	O
Hospital	O
,	O
3-1-18	O
Jyonan	O
,	O
Ikeda-shi	O
,	O
563-8510	O
,	O
Osaka	O
,	O
Japan	O
.	O
muratamasaru@mth.biglobe.ne.jp	O
beta-Catenin	O
has	O
been	O
identified	O
as	O
an	O
oncogene	O
in	O
several	O
tumors	O
including	O
colorectal	O
cancers	O
.	O
beta-Catenin	O
gene	O
is	O
activated	O
by	O
interstitial	O
deletions	B-type
involving	O
exon	B-location
3	I-location
in	O
colorectal	O
carcinomas	O
of	O
Japanese	O
population	O
,	O
in	O
contrast	O
to	O
amino	O
acid	O
substitutions	B-type
detected	O
among	O
Caucasian	O
population	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
type	O
and	O
frequency	O
of	O
beta-catenin	O
gene	O
mutation	O
during	O
early	O
stages	O
of	O
colorectal	O
tumorigenesis	O
.	O
We	O
screened	O
100	O
colorectal	O
adenomas	O
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
method	O
,	O
as	O
well	O
as	O
polymerase	O
chain	O
reaction	O
amplification	O
.	O
In	O
cases	O
with	O
mutations	O
,	O
sequencing	O
analyses	O
and	O
immunohistochemical	O
staining	O
were	O
also	O
performed	O
.	O
Somatic	O
interstitial	O
deletions	B-type
of	O
272	O
-	O
413	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
parts	O
of	O
exon	B-location
3	I-location
,	O
were	O
detected	O
in	O
three	O
tumors	O
.	O
However	O
,	O
no	O
adenoma	O
carried	O
missense	B-type
mutations	I-type
.	O
We	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
adenoma	O
cells	O
by	O
immunohistochemical	O
analysis	O
.	O
Our	O
results	O
suggested	O
that	O
activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	B-type
involving	O
exon	B-location
3	I-location
might	O
be	O
less	O
frequent	O
compared	O
with	O
frequent	O
alterations	O
of	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
but	O
could	O
be	O
an	O
early	O
event	O
in	O
colorectal	O
tumorigenesis	O
equivalent	O
to	O
APC	O
gene	O
alterations	O
in	O
the	O
Japanese	O
population	O
.	O
PMID	O
:	O
10974408	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Pathol	O
1999	O
Jun;154	O
(	O
6	O
)	O
:1643-7	O
Activating	O
c-kit	O
gene	O
mutations	O
in	O
human	O
germ	O
cell	O
tumors	O
.	O
Tian	O
Q	O
,	O
Frierson	O
HF	O
Jr	O
,	O
Krystal	O
GW	O
,	O
Moskaluk	O
CA.	O
Departments	O
of	O
Pathology	O
,	O
University	O
of	O
Virginia	O
Health	O
Sciences	O
Center	O
,	O
Charlottesville	O
,	O
USA	O
.	O
The	O
c-kit	O
gene	O
encodes	O
a	O
tyrosine	O
kinase	O
receptor	O
(	O
KIT	O
)	O
that	O
is	O
required	O
in	O
normal	O
spermatogenesis	O
and	O
is	O
expressed	O
in	O
seminomas	O
and	O
dysgerminomas	O
,	O
a	O
subset	O
of	O
human	O
germ	O
cell	O
tumors	O
(	O
GCTs	O
)	O
.	O
To	O
determine	O
whether	O
activating	O
mutations	O
of	O
the	O
c-kit	O
gene	O
occur	O
in	O
GCTs	O
,	O
primary	O
tissue	O
samples	O
of	O
33	O
testicular	O
and	O
ovarian	O
tumors	O
were	O
examined	O
for	O
mutations	O
in	O
the	O
juxtamembrane	O
and	O
phosphotransferase	O
domains	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
DNA	O
sequencing	O
.	O
A	O
novel	O
missense	B-type
mutation	I-type
(	O
D	B-state-original
816	B-location
H	B-state-altered
)	O
was	O
found	O
in	O
the	O
phosphotransferase	O
domain	O
in	O
tumors	O
of	O
seminoma	O
/	O
dysgerminoma	O
differentiation	O
.	O
The	O
c-kit	O
alleles	O
in	O
nonneoplastic	O
tissues	O
from	O
these	O
patients	O
were	O
wild	O
type	O
,	O
suggesting	O
that	O
the	O
mutant	O
alleles	O
were	O
acquired	O
and	O
selected	O
for	O
during	O
malignant	O
transformation	O
.	O
In	O
cell	O
transfection	O
experiments	O
,	O
the	O
D	B-state-original
816	B-location
H	B-state-altered
mutant	O
protein	O
was	O
a	O
constitutively	O
activated	O
kinase	O
and	O
was	O
constitutively	O
phosphorylated	O
on	O
tyrosine	O
residues	O
.	O
This	O
is	O
the	O
first	O
description	O
of	O
an	O
activating	O
c-kit	O
mutation	O
in	O
GCTs	O
and	O
is	O
evidence	O
that	O
the	O
KIT	O
signal	O
transduction	O
pathway	O
is	O
important	O
in	O
the	O
pathogenesis	O
of	O
neoplasms	O
with	O
seminoma	O
differentiation	O
.	O
PMID	O
:	O
10362788	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1999	O
May	O
;12(	O
5	O
)	O
:	O
518	O
-28	O
A	O
clinicopathologic	O
and	O
immunohistochemical	O
study	O
of	O
22	O
intraductal	O
papillary	O
mucinous	O
neoplasms	O
of	O
the	O
pancreas	O
,	O
with	O
a	O
review	O
of	O
the	O
literature	O
.	O
Paal	O
E	O
,	O
Thompson	O
LD	O
,	O
Przygodzki	O
RM	O
,	O
Bratthauer	O
GL	O
,	O
Heffess	O
CS	O
.	O
American	O
Registry	O
of	O
Pathology	O
,	O
Washington	O
,	O
DC	O
,	O
USA	O
.	O
Intraductal	O
papillary	O
-	O
mucinous	O
neoplasms	O
(	O
IPMNs	O
)	O
of	O
the	O
pancreas	O
are	O
rare	O
lesions	O
.	O
We	O
undertook	O
this	O
study	O
to	O
analyze	O
these	O
tumors	O
by	O
focusing	O
on	O
the	O
diagnostic	O
criteria	O
and	O
correlating	O
the	O
histologic	O
features	O
with	O
clinical	O
prognosis	O
.	O
Twenty-two	O
cases	O
of	O
IPMN	O
were	O
retrieved	O
from	O
the	O
Endocrine	O
Tumor	O
Registry	O
of	O
the	O
Armed	O
Forces	O
Institute	O
of	O
Pathology	O
.	O
Blocks	O
or	O
unstained	O
slides	O
were	O
available	O
for	O
histochemical	O
and	O
immunohistochemical	O
studies	O
(	O
including	O
proliferative	O
markers	O
and	O
cell	O
cycle	O
regulators	O
)	O
and	O
K-ras	O
oncogene	O
mutations	O
in	O
15	O
cases	O
.	O
Patient	O
follow	O
-	O
up	O
was	O
obtained	O
in	O
all	O
of	O
the	O
cases	O
.	O
IPMN	O
occurs	O
in	O
both	O
genders	O
with	O
a	O
slight	O
male	O
predominance	O
,	O
with	O
a	O
mean	O
age	O
at	O
presentation	O
of	O
64.4	O
years	O
(	O
range	O
,	O
48	O
-	O
85	O
yr	O
)	O
.	O
The	O
patients	O
presented	O
with	O
abdominal	O
pain	O
.	O
The	O
neoplasms	O
were	O
radiologically	O
and	O
grossly	O
cystic	O
,	O
usually	O
(	O
18	O
cases	O
of	O
22	O
)	O
located	O
in	O
the	O
head	O
of	O
the	O
pancreas	O
.	O
Histologically	O
,	O
the	O
tumors	O
consisted	O
of	O
intraductal	O
papillary	O
proliferations	O
protruding	O
into	O
and	O
expanding	O
the	O
pancreatic	O
ducts	O
.	O
Invasion	O
into	O
the	O
surrounding	O
pancreatic	O
parenchyma	O
was	O
detected	O
in	O
15	O
cases	O
.	O
Chronic	O
pancreatitis	O
was	O
present	O
in	O
all	O
of	O
the	O
cases	O
.	O
p27	O
immunoreactivity	O
always	O
exceeded	O
the	O
immunoreactivity	O
of	O
cyclin	O
E	O
.	O
K-ras	O
oncogene	O
mutations	O
were	O
detected	O
in	O
two	O
cases	O
.	O
Patients	O
were	O
treated	O
with	O
a	O
complete	O
surgical	O
resection	O
(	O
n	O
=	O
7	O
)	O
or	O
a	O
Whipple	O
procedure	O
(	O
n	O
=	O
13	O
)	O
.	O
Only	O
2	O
of	O
22	O
patients	O
died	O
of	O
disease	O
(	O
3	O
died	O
immediately	O
postoperatively	O
and	O
3	O
died	O
of	O
unrelated	O
causes	O
)	O
,	O
whereas	O
the	O
remaining	O
14	O
patients	O
were	O
alive	O
at	O
last	O
follow	O
-	O
up	O
,	O
without	O
evidence	O
of	O
disease	O
,	O
an	O
average	O
of	O
58.2	O
months	O
after	O
initial	O
presentation	O
.	O
IPMNs	O
are	O
rare	O
,	O
distinctive	O
neoplasms	O
,	O
with	O
complex	O
intraductal	O
papillae	O
,	O
that	O
can	O
be	O
easily	O
separated	O
from	O
in	O
situ	O
ductal	O
adenocarcinoma	O
and	O
mucinous	O
cystic	O
neoplasms	O
.	O
The	O
high	O
ratio	O
of	O
p27	O
protein	O
to	O
cyclin	O
E	O
supports	O
the	O
excellent	O
prognosis	O
of	O
these	O
neoplasms	O
,	O
despite	O
the	O
presence	O
of	O
invasion	O
and	O
K-ras	O
oncogene	O
mutation	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
Literature	O
PMID	O
:	O
10349991	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Oncol	O
1999	O
Feb;17(	O
2	O
)	O
:	O
668	O
-	O
75	O
Prognostic	O
significance	O
of	O
K-ras	O
codon	B-location
12	I-location
mutations	O
in	O
patients	O
with	O
resected	O
stage	O
I	O
and	O
II	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O
Graziano	O
SL	O
,	O
Gamble	O
GP	O
,	O
Newman	O
NB	O
,	O
Abbott	O
LZ	O
,	O
Rooney	O
M,	O
Mookherjee	O
S	O
,	O
Lamb	O
ML	O
,	O
Kohman	O
LJ	O
,	O
Poiesz	O
BJ.	O
Department	O
of	O
Medicine	O
,	O
State	O
University	O
of	O
New	O
York	O
Health	O
Science	O
Center	O
and	O
Veterans	O
Affairs	O
Medical	O
Center	O
,	O
Syracuse	O
13210	O
,	O
USA	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prognostic	O
importance	O
of	O
codon	B-location
12	I-location
K-ras	O
mutations	O
in	O
patients	O
with	O
early	O
-	O
stage	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
identified	O
260	O
patients	O
with	O
surgically	O
resected	O
stage	O
I	O
(	O
n	O
=	O
193	O
)	O
and	O
stage	O
II	O
(	O
n	O
=	O
67	O
)	O
NSCLC	O
with	O
at	O
least	O
a	O
5	O
-	O
year	O
follow	O
-	O
up	O
.	O
We	O
performed	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
DNA	O
obtained	O
from	O
paraffin	O
-	O
embedded	O
NSCLC	O
tissue	O
,	O
using	O
mutation	O
-	O
specific	O
probes	O
for	O
codon	B-location
12	I-location
K-ras	O
.	O
RESULTS	O
:	O
K-ras	O
mutations	O
were	O
detected	O
in	O
35	O
of	O
213	O
assessable	O
specimens	O
(	O
16.4	O
%	O
)	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
27	O
of	O
93	O
adenocarcinomas	O
(	O
29.0	O
%	O
)	O
,	O
one	O
of	O
61	O
squamous	O
cell	O
carcinomas	O
(	O
1.6	O
%	O
)	O
,	O
five	O
of	O
39	O
large	O
-	O
cell	O
carcinomas	O
(	O
12.8	O
%	O
)	O
,	O
and	O
two	O
of	O
20	O
adenosquamous	O
carcinomas	O
(	O
10	O
%	O
)	O
(	O
P	O
=	O
.001	O
)	O
.	O
G	B-state-original
to	O
T	B-state-altered
transversions	B-type
accounted	O
for	O
71	O
%	O
of	O
the	O
mutations	B-event
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
survival	O
for	O
all	O
patients	O
with	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
39	O
months	O
)	O
compared	O
with	O
patients	O
without	O
K-ras	O
mutations	O
(	O
median	O
survival	O
,	O
53	O
months	O
;	O
P	O
=	O
.33	O
)	O
.	O
There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
overall	O
or	O
disease	O
-	O
free	O
survival	O
for	O
subgroups	O
with	O
stage	O
I	O
disease	O
,	O
adenocarcinoma	O
,	O
or	O
non	O
-	O
squamous	O
cell	O
carcinoma	O
or	O
for	O
specific	O
amino	O
acid	O
substitutions	B-type
.	O
The	O
median	O
survival	O
time	O
for	O
stage	O
II	O
patients	O
with	O
K-ras	O
mutations	O
was	O
13	O
months	O
,	O
compared	O
with	O
38	O
months	O
for	O
patients	O
without	O
K-ras	O
mutations	O
(	O
P	O
=	O
.03	O
)	O
.	O
CONCLUSION	O
:	O
Codon	B-location
12	I-location
K-ras	O
mutations	O
were	O
more	O
common	O
in	O
adenocarcinomas	O
than	O
in	O
squamous	O
cell	O
carcinomas	O
.	O
For	O
the	O
subgroup	O
with	O
stage	O
II	O
NSCLC	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
adverse	O
effect	O
on	O
survival	O
for	O
the	O
presence	O
of	O
K-ras	O
mutations	O
.	O
However	O
,	O
when	O
the	O
entire	O
group	O
was	O
considered	O
,	O
the	O
presence	O
of	O
K-ras	O
mutations	O
was	O
not	O
of	O
prognostic	O
significance	O
in	O
this	O
cohort	O
of	O
patients	O
with	O
resected	O
early	O
-	O
stage	O
NSCLC	O
.	O
PMID	O
:	O
10080613	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1999	O
Feb;154	O
(	O
2	O
)	O
:	O
32	O
5-9	O
Frequent	O
nuclear	O
/	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
without	O
exon	B-location
3	I-location
mutations	O
in	O
malignant	O
melanoma	O
.	O
Rimm	O
DL	O
,	O
Caca	O
K,	O
Hu	O
G	O
,	O
Harrison	O
FB	O
,	O
Fearon	O
ER	O
.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06510	O
,	O
USA	O
.	O
david	O
.rimm@yale	O
.edu	O
Beta-Catenin	O
has	O
a	O
critical	O
role	O
in	O
E-cadherin	O
-	O
mediated	O
cell	O
-	O
cell	O
adhesion	O
,	O
and	O
it	O
also	O
functions	O
as	O
a	O
downstream	O
signaling	O
molecule	O
in	O
the	O
wnt	O
pathway	O
.	O
Mutations	O
in	O
the	O
putative	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
sites	O
near	O
the	O
beta-catenin	O
amino	O
terminus	O
have	O
been	O
found	O
in	O
some	O
cancers	O
and	O
cancer	O
cell	O
lines	O
.	O
The	O
mutations	O
render	O
beta-catenin	O
resistant	O
to	O
regulation	O
by	O
a	O
complex	O
containing	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
,	O
adenomatous	O
polyposis	O
coli	O
,	O
and	O
axin	O
proteins	O
.	O
As	O
a	O
result	O
,	O
beta-catenin	O
accumulates	O
in	O
the	O
cytosol	O
and	O
nucleus	O
and	O
activates	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancing	O
factor	O
transcription	O
factors	O
.	O
Previously	O
,	O
6	O
of	O
27	O
melanoma	O
cell	O
lines	O
were	O
found	O
to	O
have	O
beta-catenin	O
exon	B-location
3	I-location
mutations	O
affecting	O
the	O
N	O
-	O
terminal	O
phosphorylation	O
sites	O
(	O
Rubinfeld	O
B	O
,	O
Robbins	O
P	O
,	O
Elgamil	O
M	O
,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P	O
:	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	O
cell	O
lines	O
.	O
Science	O
1997	O
,	O
275	O
:	O
1790	O
-	O
1792	O
)	O
.	O
To	O
assess	O
the	O
role	O
of	O
beta-catenin	O
defects	O
in	O
primary	O
melanomas	O
,	O
we	O
undertook	O
immunohistochemical	O
and	O
DNA	O
sequencing	O
studies	O
in	O
65	O
melanoma	O
specimens	O
.	O
Nuclear	O
and/or	O
cytoplasmic	O
localization	O
of	O
beta-catenin	O
,	O
a	O
potential	O
indicator	O
of	O
wnt	O
pathway	O
activation	O
,	O
was	O
seen	O
focally	O
within	O
roughly	O
one	O
third	O
of	O
the	O
tumors	O
,	O
though	O
a	O
clonal	O
somatic	O
mutation	O
in	O
beta-catenin	O
was	O
found	O
in	O
only	O
one	O
case	O
(	O
codon	B-location
45	I-location
Ser	B-state-original
-->	O
Pro	B-state-altered
)	O
.	O
Our	O
findings	O
demonstrate	O
that	O
beta-catenin	O
mutations	O
are	O
rare	O
in	O
primary	O
melanoma	O
,	O
in	O
contrast	O
to	O
the	O
situation	O
in	O
melanoma	O
cell	O
lines	O
.	O
Nonetheless	O
,	O
activation	O
of	O
beta-catenin	O
,	O
as	O
indicated	O
by	O
its	O
nuclear	O
and/or	O
cytoplasmic	O
localization	O
,	O
appears	O
to	O
be	O
frequent	O
in	O
melanoma	O
,	O
and	O
in	O
some	O
cases	O
,	O
it	O
may	O
reflect	O
focal	O
and	O
transient	O
activation	O
of	O
the	O
wnt	O
pathway	O
within	O
the	O
tumor	O
.	O
PMID	O
:	O
10027390	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Jun	O
15	O
;58	O
(	O
12	O
)	O
:2520-3	O
Beta-catenin	O
mutations	O
in	O
human	O
prostate	O
cancer	O
.	O
Voeller	O
HJ	O
,	O
Truica	O
CI	O
,	O
Gelmann	O
EP	O
.	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Lombardi	O
Cancer	O
Center	O
,	O
Georgetown	O
University	O
School	O
of	O
Medicine	O
,	O
Washington	O
,	O
DC	O
20007	O
-	O
2197	O
,	O
USA	O
.	O
Beta-catenin	O
plays	O
essential	O
roles	O
in	O
both	O
intercellular	O
adhesion	O
and	O
signal	O
transduction	O
.	O
As	O
a	O
signaling	O
molecule	O
,	O
beta-catenin	O
supplies	O
an	O
activating	O
domain	O
to	O
the	O
T-cell	O
factor	O
/	O
lymphoid	O
enhancer	O
-	O
binding	O
factor	O
family	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
activates	O
gene	O
transcription	O
.	O
Posttranslational	O
stabilization	O
of	O
beta-catenin	O
,	O
leading	O
to	O
elevated	O
protein	O
levels	O
and	O
constitutive	O
gene	O
activation	O
,	O
has	O
been	O
proposed	O
as	O
an	O
important	O
step	O
in	O
oncogenesis	O
.	O
Stabilization	O
of	O
beta-catenin	O
can	O
occur	O
through	O
mutation	O
to	O
highly	O
conserved	O
amino	O
acids	O
encoded	O
in	O
exon	B-location
3	I-location
of	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
.	O
To	O
determine	O
whether	O
this	O
pathway	O
of	O
malignant	O
transformation	O
is	O
important	O
in	O
prostate	O
cancer	O
,	O
we	O
analyzed	O
104	O
prostate	O
cancer	O
tissue	O
specimens	O
,	O
4	O
prostate	O
cancer	O
cell	O
lines	O
,	O
and	O
3	O
prostate	O
tumor	O
xenografts	O
for	O
activating	O
mutations	O
in	O
exon	B-location
3	I-location
of	O
CTNNB1	O
.	O
Mutations	O
were	O
detected	O
in	O
5	O
of	O
the	O
104	O
prostate	O
cancer	O
tissue	O
samples	O
.	O
Four	O
of	O
the	O
five	O
mutations	O
involved	O
serine	O
or	O
threonine	O
residues	O
implicated	O
in	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
A	O
fifth	O
tumor	O
had	O
a	O
mutation	B-event
at	O
codon	B-location
32	I-location
,	O
changing	O
a	O
highly	O
conserved	O
aspartic	B-state-original
acid	I-state-original
to	O
a	O
tyrosine	B-state-altered
.	O
Mutational	O
analysis	O
of	O
multiple	O
regions	O
from	O
several	O
tumor	O
samples	O
showed	O
that	O
the	O
beta-catenin	O
mutations	O
were	O
present	O
focally	O
and	O
therefore	O
may	O
occur	O
during	O
tumor	O
progression	O
.	O
PMID	O
:	O
9635571	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
10	O
;126	O
(	O
1	O
)	O
:	O
59	O
-	O
65	O
K-ras	O
mutations	O
in	O
sinonasal	O
adenocarcinomas	O
in	O
patients	O
occupationally	O
exposed	O
to	O
wood	O
or	O
leather	O
dust	O
.	O
Saber	O
AT	O
,	O
Nielsen	O
LR	O
,	O
Dictor	O
M,	O
Hagmar	O
L,	O
Mikoczy	O
Z	O
,	O
Wallin	O
H.	O
National	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Copenhagen	O
,	O
Denmark	O
.	O
Of	O
39	O
males	O
diagnosed	O
with	O
sinonasal	O
adenocarcinomas	O
over	O
30	O
years	O
in	O
the	O
Lund	O
University	O
Hospital	O
catchment	O
area	O
(	O
1.5	O
million	O
inhabitants	O
)	O
,	O
archival	O
tumor	O
tissue	O
was	O
available	O
from	O
29	O
.	O
Of	O
these	O
,	O
16	O
had	O
been	O
exposed	O
to	O
wood	O
dust	O
and	O
three	O
had	O
been	O
exposed	O
to	O
leather	O
dust	O
.	O
The	O
intestinal	O
-	O
type	O
and	O
papillary	O
adenocarcinomas	O
were	O
more	O
common	O
in	O
the	O
exposed	O
patients	O
(	O
P	O
=	O
0.0002	O
,	O
Fisher	O
's	O
exact	O
test	O
)	O
.	O
The	O
tumors	O
from	O
all	O
but	O
one	O
of	O
the	O
29	O
sinonasal	O
adenocarcinomas	O
could	O
be	O
analyzed	O
for	O
point	B-type
mutations	I-type
at	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
of	O
the	O
K-ras	O
gene	O
.	O
Four	O
mutations	O
were	O
detected	O
in	O
the	O
28	O
tumors	O
.	O
The	O
three	O
mutations	O
in	O
the	O
patients	O
exposed	O
to	O
wood	O
and	O
leather	O
dust	O
were	O
all	O
G	B-state-original
:	O
C	B-state-original
-->	O
A	B-state-altered
:	O
T	B-state-altered
transitions	B-type
,	O
with	O
two	O
at	O
position	B-location
2	I-location
of	I-location
codon	I-location
12	I-location
and	O
one	O
at	O
position	B-location
2	I-location
of	I-location
codon	I-location
13	I-location
.	O
The	O
high	O
proportion	O
of	O
G	B-state-original
:	O
C	B-state-original
-->	O
A	B-state-altered
:	O
T	B-state-altered
mutations	O
in	O
this	O
rare	O
tumor	O
may	O
reflect	O
a	O
genotoxic	O
agent	O
in	O
wood	O
and	O
leather	O
dust	O
.	O
PMID	O
:	O
9563649	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
15	O
;58	O
(	O
6	O
)	O
:	O
1130	O
-4	O
Mutational	O
analysis	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
colorectal	O
cancer	O
.	O
Sparks	O
AB	O
,	O
Morin	O
PJ	O
,	O
Vogelstein	O
B	O
,	O
Kinzler	O
KW	O
.	O
Johns	O
Hopkins	O
Oncology	O
Center	O
,	O
Baltimore	O
,	O
Maryland	O
21231	O
,	O
USA	O
.	O
Mutation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
tumor	O
suppressor	O
gene	O
initiates	O
the	O
majority	O
of	O
colorectal	O
(	O
CR	O
)	O
cancers	O
.	O
One	O
consequence	O
of	O
this	O
inactivation	O
is	O
constitutive	O
activation	O
of	O
beta-catenin	O
/	O
Tcf	O
-	O
mediated	O
transcription	O
.	O
To	O
further	O
explore	O
the	O
role	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
Tcf	O
pathway	O
in	O
CR	O
tumorigenesis	O
,	O
we	O
searched	O
for	O
mutations	O
in	O
genes	O
implicated	O
in	O
this	O
pathway	O
in	O
CR	O
tumors	O
lacking	O
APC	O
mutations	O
.	O
No	O
mutations	O
of	O
the	O
gamma-catenin	O
(	O
CTNNG1	O
)	O
,	O
GSK-3alpha	O
(	O
GSK3A	O
)	O
,	O
or	O
GSK-3beta	O
(	O
GSK3B	O
)	O
genes	O
were	O
detected	O
.	O
In	O
contrast	O
,	O
mutations	O
in	O
the	O
NH2	O
-	O
terminal	O
regulatory	O
domain	O
of	O
beta-catenin	O
(	O
CTNNB1	O
)	O
were	O
found	O
in	O
13	O
of	O
27	O
(	O
48	O
%	O
)	O
CR	O
tumors	O
lacking	O
APC	O
mutations	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
regulatory	O
domain	O
and	O
APC	O
were	O
observed	O
to	O
be	O
mutually	O
exclusive	O
,	O
consistent	O
with	O
their	O
equivalent	O
effects	O
on	O
beta-catenin	O
stability	O
and	O
Tcf	O
transactivation	O
.	O
In	O
addition	O
,	O
we	O
found	O
that	O
CTNNB1	O
mutations	O
can	O
occur	O
in	O
the	O
early	O
,	O
adenomatous	O
stage	O
of	O
CR	O
neoplasia	O
,	O
as	O
has	O
been	O
observed	O
previously	O
with	O
APC	O
mutations	O
.	O
These	O
results	O
suggest	O
that	O
CTNNB1	O
mutations	O
can	O
uniquely	O
substitute	O
for	O
APC	O
mutations	O
in	O
CR	O
tumors	O
and	O
that	O
beta-catenin	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
CR	O
tumorigenesis	O
.	O
PMID	O
:	O
9515795	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1998	O
Mar;77	O
(	O
5	O
)	O
:720-3	O
K-ras	O
point	B-type
mutation	I-type
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
in	O
lung	O
cancer	O
.	O
Sagawa	O
M,	O
Saito	O
Y	O
,	O
Fujimura	O
S	O
,	O
Linnoila	O
RI.	O
Biomarkers	O
and	O
Prevention	O
Research	O
Branch	O
,	O
National	O
Cancer	O
Institute	O
,	O
Rockville	O
,	O
Maryland	O
20850	O
,	O
USA	O
.	O
In	O
order	O
to	O
determine	O
the	O
topographical	O
distribution	O
of	O
the	O
K-ras	O
codon	B-location
12	I-location
mutations	O
in	O
carcinoma	O
and	O
preneoplastic	O
lesions	O
of	O
the	O
lung	O
,	O
selective	O
ultraviolet	O
radiation	O
fractionation	O
,	O
as	O
well	O
as	O
microdissection	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RELP	O
)	O
,	O
was	O
performed	O
.	O
Fourteen	O
of	O
61	O
samples	O
amplified	O
(	O
23.0	O
%	O
)	O
had	O
a	O
mutation	B-event
in	O
the	O
K-ras	O
codon	B-location
12	I-location
.	O
Of	O
41	O
adenocarcinoma	O
,	O
12	O
samples	O
(	O
29.3	O
%	O
)	O
had	O
a	O
mutation	O
,	O
whereas	O
none	O
of	O
the	O
squamous	O
cell	O
carcinomas	O
had	O
a	O
mutation	O
.	O
One	O
of	O
six	O
large	O
-	O
cell	O
carcinomas	O
,	O
one	O
of	O
three	O
carcinoid	O
tumours	O
and	O
none	O
of	O
three	O
other	O
carcinomas	O
had	O
a	O
mutation	B-event
.	O
Direct	O
sequencing	O
revealed	O
that	O
K-ras	O
codon	B-location
12	I-location
of	O
six	O
samples	O
were	O
TGT	B-state-generic
(	O
Cys	B-state-generic
)	O
,	O
five	O
samples	O
were	O
GTT	B-state-generic
(	O
Val	B-state-generic
)	O
,	O
two	O
samples	O
were	O
GCT	B-state-generic
(	O
Ala	B-state-generic
)	O
and	O
one	O
sample	O
was	O
TTT	B-state-generic
(	O
Phe	B-state-generic
)	O
.	O
A	O
total	O
of	O
113	O
lesions	O
of	O
13	O
cases	O
covered	O
by	O
dot	O
were	O
amplified	O
after	O
UV	O
radiation	O
.	O
All	O
of	O
74	O
carcinoma	O
lesions	O
had	O
the	O
mutation	B-event
,	O
and	O
intratumour	O
heterogeneity	O
was	O
not	O
observed	O
.	O
Of	O
39	O
non	O
-	O
malignant	O
lesions	O
,	O
one	O
type	O
II	O
cell	O
hyperplasia	O
had	O
the	O
mutation	B-event
,	O
which	O
suggests	O
that	O
the	O
K-ras	O
mutation	O
occurs	O
in	O
the	O
early	O
stage	O
of	O
carcinogenesis	O
.	O
The	O
lack	O
of	O
intratumour	O
heterogeneity	O
supports	O
the	O
hypothesis	O
.	O
PMID	O
:	O
9514049	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1997	O
Nov	O
14;73	O
(	O
4	O
)	O
:	O
492	O
-	O
6	O
Molecular	O
analysis	O
of	O
occupational	O
cancer	O
:	O
infrequent	O
p53	O
and	O
ras	O
mutations	O
in	O
renal	O
-	O
cell	O
cancer	O
in	O
workers	O
exposed	O
to	O
gasoline	O
.	O
Roth	O
S	O
,	O
Partanen	O
T	O
,	O
Suitiala	O
T	O
,	O
Anttila	O
S	O
,	O
Ojajarvi	O
A	O
,	O
Hemminki	O
K,	O
Vainio	O
H,	O
Husgafvel	O
-	O
Pursiainen	O
K.	O
Department	O
of	O
Epidemiology	O
and	O
Biostatistics	O
,	O
Finnish	O
Institute	O
of	O
Occupational	O
Health	O
,	O
Helsinki	O
.	O
Occupational	O
exposure	O
to	O
gasoline	O
has	O
been	O
identified	O
in	O
several	O
studies	O
as	O
a	O
risk	O
factor	O
for	O
renal	O
-	O
cell	O
cancer	O
.	O
Cases	O
of	O
renal	O
-	O
cell	O
cancer	O
with	O
and	O
without	O
work	O
-	O
related	O
exposure	O
to	O
gasoline	O
or	O
gasoline	O
and	O
diesel	O
fuel	O
were	O
studied	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
tumour	O
-	O
suppressor	O
gene	O
p53	O
(	O
n	O
=	O
23	O
exposed	O
and	O
30	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
and	O
ras	O
oncogene	O
(	O
n	O
=	O
30	O
exposed	O
and	O
36	O
non	O
-	O
exposed	O
cases	O
studied	O
)	O
.	O
An	O
average	O
cumulative	O
exposure	O
was	O
estimated	O
at	O
10	O
ppm	O
-	O
years	O
benzene	O
among	O
the	O
exposed	O
.	O
Three	O
p53	O
mutations	O
were	O
detected	O
by	O
denaturing	O
-	O
gradient	O
gel	O
electrophoresis	O
(	O
DGGE	O
)	O
among	O
the	O
23	O
exposed	O
cases	O
(	O
3	O
/	O
23	O
,	O
13	O
%	O
)	O
.	O
Of	O
the	O
non	O
-	O
exposed	O
referent	O
cases	O
,	O
4	O
had	O
a	O
mutation	O
(	O
4	O
/	O
30	O
,	O
13	O
%	O
)	O
.	O
All	O
but	O
one	O
of	O
the	O
cases	O
with	O
a	O
p53	O
mutation	O
had	O
smoked	O
.	O
A	O
ras	O
gene	O
(	O
K-ras	O
or	O
N-ras	O
)	O
mutation	O
was	O
found	O
in	O
3	O
(	O
3	O
/	O
66	O
,	O
4.5	O
%	O
)	O
cases	O
,	O
all	O
of	O
whom	O
were	O
smoker	O
referents	O
.	O
We	O
conclude	O
that	O
p53	O
and	O
ras	O
mutations	O
are	O
infrequent	O
in	O
renal	O
-	O
cell	O
cancer	O
associated	O
with	O
occupational	O
exposure	O
to	O
gasoline	O
.	O
However	O
,	O
the	O
majority	O
of	O
the	O
mutations	O
(	O
6	O
/	O
7	O
for	O
p53	O
,	O
and	O
3	O
/	O
3	O
for	O
ras	O
genes	O
)	O
were	O
seen	O
in	O
smokers	O
.	O
PMID	O
:	O
9389561	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1997	O
Aug;21(	O
8	O
)	O
:69	O
7	O
-	O
701	O
Mutations	O
of	O
the	O
RAS	O
genes	O
in	O
childhood	O
acute	O
myeloid	O
leukemia	O
,	O
myelodysplastic	O
syndrome	O
and	O
juvenile	O
chronic	O
myelocytic	O
leukemia	O
.	O
Sheng	O
XM	O
,	O
Kawamura	O
M,	O
Ohnishi	O
H,	O
Ida	O
K,	O
Hanada	O
R	O
,	O
Kojima	O
S	O
,	O
Kobayashi	O
M,	O
Bessho	O
F	O
,	O
Yanagisawa	O
M,	O
Hayashi	O
Y	O
.	O
Department	O
of	O
Pediatrics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Japan	O
.	O
Using	O
the	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
method	O
and	O
direct	O
sequencing	O
,	O
12	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
cell	O
lines	O
and	O
108	O
fresh	O
childhood	O
myeloid	O
tumor	O
specimens	O
,	O
including	O
67	O
AML	O
,	O
29	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
,	O
and	O
12	O
juvenile	O
chronic	O
myelocytic	O
leukemia	O
(	O
JCML	O
)	O
were	O
examined	O
for	O
mutation	O
in	O
H	O
-	O
,	O
K	O
-	O
,	O
and	O
N	O
-	O
RAS	O
genes	O
.	O
The	O
mutation	O
was	O
found	O
in	O
eight	O
of	O
the	O
120	O
samples	O
(	O
6.7	O
%	O
)	O
,	O
which	O
consisted	O
of	O
four	O
cell	O
lines	O
(	O
33.3	O
%	O
)	O
and	O
four	O
fresh	O
myeloid	O
tumors	O
(	O
3.7	O
%	O
)	O
.	O
The	O
frequency	O
of	O
the	O
mutation	O
in	O
the	O
cell	O
lines	O
was	O
apparently	O
higher	O
than	O
that	O
in	O
fresh	O
myeloid	O
tumors	O
.	O
K-RAS	O
gene	O
mutations	O
were	O
found	O
in	O
two	O
of	O
the	O
67	O
fresh	O
AML	O
specimens	O
(	O
3	O
%	O
)	O
.	O
Interestingly	O
,	O
these	O
two	O
patients	O
had	O
11q23	B-location
translocations	B-type
.	O
The	O
N-RAS	O
gene	O
mutation	O
was	O
found	O
in	O
one	O
of	O
the	O
29	O
specimens	O
(	O
3.4	O
%	O
)	O
of	O
MDS	O
and	O
in	O
one	O
of	O
the	O
12	O
specimens	O
(	O
8.3	O
%	O
)	O
of	O
JCML	O
.	O
All	O
mutations	B-event
were	O
found	O
in	O
codon	B-location
12	I-location
,	O
13	B-location
or	O
61	B-location
of	O
the	O
N-RAS	O
and	O
K-RAS	O
genes	O
.	O
Frequency	O
of	O
mutation	O
of	O
RAS	O
genes	O
in	O
fresh	O
myeloid	O
malignancies	O
was	O
very	O
low	O
.	O
These	O
findings	O
suggest	O
that	O
mutation	O
of	O
RAS	O
genes	O
does	O
not	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
childhood	O
myeloid	O
malignancies	O
.	O
PMID	O
:	O
9379676	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1997	O
Sep	O
;	O
88	O
(	O
9	O
)	O
:	O
846	O
-	O
54	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
APC	O
and	O
p53	O
genes	O
in	O
sporadic	O
ampullary	O
carcinomas	O
.	O
Imai	O
Y	O
,	O
Oda	O
H	O
,	O
Tsurutani	O
N	O
,	O
Nakatsuru	O
Y	O
,	O
Inoue	O
T	O
,	O
Ishikawa	O
T	O
.	O
Department	O
of	O
Pathology	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
.	O
Although	O
a	O
close	O
relation	O
of	O
somatic	O
mutations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
with	O
ampullary	O
carcinomas	O
in	O
familial	O
adenomatous	O
polyposis	O
patients	O
has	O
been	O
reported	O
,	O
the	O
possible	O
association	O
with	O
sporadic	O
ampullary	O
neoplasms	O
has	O
not	O
been	O
fully	O
examined	O
.	O
We	O
have	O
therefore	O
investigated	O
loss	B-type
of	I-type
heterozygosity	I-type
at	O
the	O
adenomatous	O
polyposis	O
coli	O
locus	O
and	O
the	O
mutational	O
status	O
of	O
a	O
portion	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
,	O
including	O
the	O
mutation	O
cluster	O
region	O
,	O
in	O
17	O
ampullary	O
carcinomas	O
of	O
non	O
-	O
familial	O
adenomatous	O
polyposis	O
patients	O
.	O
Alteration	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
was	O
found	O
in	O
8	O
of	O
17	O
(	O
47.1	O
%	O
)	O
cases	O
,	O
as	O
missense	B-type
or	O
insertion	B-type
mutations	B-event
,	O
with	O
or	O
without	O
loss	B-type
of	I-type
heterozygosity	I-type
.	O
Additional	O
investigation	O
of	O
p53	O
(	O
exons	B-location
5	I-location
-	I-location
8	I-location
)	O
and	O
K-ras	O
(	O
codons	B-location
12	I-location
and	O
13	B-location
)	O
gene	O
mutations	O
revealed	O
a	O
striking	O
mutational	O
pattern	O
of	O
the	O
p53	O
gene	O
.	O
Nine	O
of	O
the	O
17	O
cases	O
demonstrated	O
a	O
total	O
of	O
12	O
mutations	B-event
,	O
6	O
clustered	O
at	O
codon	B-location
189	I-location
and	O
3	O
at	O
codon	B-location
166	I-location
.	O
Furthermore	O
,	O
5	O
of	O
the	O
12	O
mutations	B-event
were	O
nonsense	B-type
mutations	I-type
.	O
Regarding	O
the	O
K-ras	O
gene	O
,	O
4	O
of	O
the	O
17	O
(	O
23.5	O
%	O
)	O
cases	O
had	O
mutations	B-event
in	O
codon	B-location
12	I-location
,	O
3	O
of	O
the	O
4	O
cases	O
being	O
derived	O
from	O
the	O
intraduodenal	O
bile	O
duct	O
.	O
The	O
findings	O
indicate	O
that	O
alterations	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
and	O
the	O
p53	O
genes	O
are	O
relatively	O
frequent	O
in	O
sporadic	O
ampullary	O
carcinomas	O
.	O
In	O
particular	O
,	O
the	O
clustering	O
at	O
specific	O
p53	O
codons	O
might	O
offer	O
an	O
etiological	O
clue	O
to	O
clarify	O
ampullary	O
carcinogenesis	O
.	O
Mutations	O
of	O
the	O
K-ras	O
gene	O
,	O
on	O
the	O
other	O
hand	O
,	O
might	O
be	O
characteristic	O
of	O
intraduodenal	O
bile	O
duct	O
origin	O
.	O
PMID	O
:	O
9369932	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leukemia	O
1997	O
Jun	O
;	O
11	O
(	O
6	O
)	O
:	O
863	O
-	O
5	O
No	O
concomitant	O
occurrence	O
of	O
the	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
myelodysplastic	O
syndromes	O
.	O
Mitani	O
K	O
,	O
Hangaishi	O
A	O
,	O
Imamura	O
N	O
,	O
Miyagawa	O
K	O
,	O
Ogawa	O
S	O
,	O
Kanda	O
Y	O
,	O
Yazaki	O
Y	O
,	O
Hirai	O
H	O
Third	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Faculty	O
of	O
Medicine	O
,	O
University	O
of	O
Tokyo	O
,	O
Bunkyo-ku	O
,	O
Japan	O
.	O
Mutations	O
of	O
the	O
N-ras	O
oncogene	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
were	O
simultaneously	O
investigated	O
in	O
bone	O
marrow	O
cells	O
from	O
44	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
or	O
MDS	O
-	O
derived	O
leukemia	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
.	O
The	O
mutations	O
of	O
the	O
N-ras	O
gene	O
were	O
detected	O
only	O
in	O
two	O
cases	O
with	O
MDS	O
-	O
derived	O
leukemia	O
.	O
Three	O
patients	O
with	O
MDS	O
-	O
derived	O
leukemia	O
and	O
one	O
with	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
exhibited	O
five	O
mutations	O
of	O
the	O
p53	O
gene	O
.	O
No	O
concomitant	O
mutations	O
of	O
both	O
genes	O
were	O
observed	O
in	O
our	O
study	O
,	O
suggesting	O
that	O
alterations	O
of	O
both	O
genes	O
could	O
play	O
an	O
important	O
role	O
in	O
the	O
progression	O
of	O
MDS	O
in	O
a	O
non	O
-	O
cooperative	O
manner	O
.	O
PMID	O
:	O
9177441	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Apr	O
;	O
25	O
(3-4)	O
:	O
281	O
-	O
7	O
c-kit	O
Point	B-type
mutation	I-type
in	O
patients	O
with	O
myeloproliferative	O
disorders	O
.	O
Kimura	O
A	O
,	O
Nakata	O
Y	O
,	O
Katoh	O
O	O
,	O
Hyodo	O
H	O
.	O
Department	O
of	O
Hematology	O
and	O
Oncology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Myeloproliferative	O
disorders	O
(	O
MPD	O
)	O
constitute	O
a	O
group	O
of	O
hematopoietic	O
neoplasms	O
at	O
the	O
myeloid	O
stem	O
cell	O
level	O
.	O
Myeloid	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
from	O
MPD	O
have	O
been	O
considered	O
sensitive	O
to	O
hematopoietic	O
growth	O
factors	O
,	O
including	O
erythropoietin	O
,	O
thrombopoietin	O
and	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O
SCF	O
is	O
a	O
ligand	O
for	O
c-kit	O
receptor	O
with	O
tyrosine	O
kinase	O
.	O
We	O
analysed	O
the	O
gene	O
alteration	O
of	O
the	O
c-kit	O
extracellular	O
domain	O
in	O
MPD	O
patients	O
by	O
PCR	O
-	O
SSCP	O
and	O
subsequent	O
nucleotide	O
sequencing	O
.	O
The	O
point	B-type
mutation	I-type
in	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
domain	O
,	O
codon	B-location
52	I-location
(	O
Asp	B-state-original
-->	O
Asn	B-state-altered
)	O
,	O
was	O
found	O
in	O
two	O
patients	O
with	O
primary	O
myelofibrosis	O
and	O
one	O
with	O
chronic	O
myelogenous	O
leukemia	O
.	O
We	O
review	O
the	O
literature	O
regarding	O
the	O
role	O
of	O
SCF	O
/	O
c-kit	O
system	O
in	O
the	O
oncogenesis	O
of	O
leukemia	O
and	O
MPD	O
,	O
and	O
then	O
discuss	O
the	O
significance	O
of	O
our	O
finding	O
in	O
the	O
context	O
of	O
growth	O
advantage	O
of	O
the	O
mutated	O
clones	O
over	O
the	O
normal	O
clones	O
.	O
Publication	O
Types	O
:	O
Review	O
Review	O
,	O
Tutorial	O
PMID	O
:	O
9168438	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Leuk	O
Lymphoma	O
1997	O
Jan	O
;	O
24	O
(	O
3-4	O
)	O
:	O
309	O
-	O
17	O
N-ras	O
gene	O
point	B-type
mutations	I-type
in	O
Brazilian	O
acute	O
myelogenous	O
leukemia	O
patients	O
correlate	O
with	O
a	O
poor	O
prognosis	O
.	O
De	O
Melo	O
MB	O
,	O
Lorand-Metze	O
I	O
,	O
Lima	O
CS	O
,	O
Saad	O
ST	O
,	O
Costa	O
FF	O
.	O
Department	O
of	O
Clinical	O
Medicine-Hemocentro	O
,	O
School	O
of	O
Medical	O
Sciences	O
,	O
State	O
University	O
of	O
Campinas	O
(	O
UNICAMP	O
)	O
,	O
SP-Brazil	O
.	O
The	O
frequency	O
of	O
ras	O
gene	O
mutations	O
varies	O
from	O
11	O
to	O
27	O
%	O
in	O
AML	O
populations	O
from	O
the	O
United	O
States	O
and	O
Europe	O
but	O
it	O
seems	O
that	O
there	O
is	O
no	O
study	O
regarding	O
the	O
frequency	O
of	O
mutated	O
N-ras	O
gene	O
in	O
patients	O
with	O
AML	O
in	O
South	O
America	O
.	O
In	O
order	O
to	O
study	O
the	O
frequency	O
of	O
N-ras	O
gene	O
mutations	O
(	O
exons	B-location
1	I-location
and	O
2	B-location
)	I-location
in	O
Brazilian	O
patients	O
with	O
AML	O
and	O
to	O
evaluate	O
the	O
possible	O
correlation	O
between	O
the	O
presence	O
of	O
the	O
mutation	B-event
and	O
clinical	O
features	O
,	O
40	O
patients	O
were	O
analyzed	O
.	O
N-ras	O
mutations	O
were	O
identified	O
in	O
DNA	O
samples	O
from	O
eight	O
of	O
40	O
AML	O
patients	O
(	O
20	O
%	O
)	O
.	O
No	O
significant	O
correlation	O
was	O
found	O
between	O
N-ras	O
mutation	O
and	O
age	O
,	O
sex	O
,	O
race	O
,	O
response	O
to	O
therapy	O
,	O
FAB	O
subtype	O
or	O
occupational	O
exposure	O
.	O
However	O
,	O
the	O
overall	O
survival	O
and	O
AML	O
-	O
free	O
survival	O
were	O
significantly	O
shorter	O
in	O
patients	O
with	O
N-ras	O
mutations	O
than	O
in	O
those	O
without	O
these	O
abnormalities	O
.	O
PMID	O
:	O
9156660	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Nat	O
Genet	O
1997	O
May	O
;16	O
(	O
1	O
)	O
:68	O
-	O
73	O
Germline	O
and	O
somatic	O
mutations	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
proto	O
-	O
oncogene	O
in	O
papillary	O
renal	O
carcinomas	O
.	O
Schmidt	O
L,	O
Duh	O
FM	O
,	O
Chen	O
F	O
,	O
Kishida	O
T	O
,	O
Glenn	O
G	O
,	O
Choyke	O
P,	O
Scherer	O
SW	O
,	O
Zhuang	O
Z	O
,	O
Lubensky	O
I	O
,	O
Dean	O
M,	O
Allikmets	O
R	O
,	O
Chidambaram	O
A	O
,	O
Bergerheim	O
UR	O
,	O
Feltis	O
JT	O
,	O
Casadevall	O
C	O
,	O
Zamarron	O
A	O
,	O
Bernues	O
M,	O
Richard	O
S	O
,	O
Lips	O
CJ	O
,	O
Walther	O
MM	O
,	O
Tsui	O
LC	O
,	O
Geil	O
L,	O
Orcutt	O
ML	O
,	O
Stackhouse	O
T	O
,	O
Zbar	O
B	O
,	O
et	O
al	O
.	O
Intramural	O
Research	O
Support	O
Program	O
,	O
SAIC	O
Frederick	O
,	O
MD	O
,	O
USA	O
.	O
Hereditary	O
papillary	O
renal	O
carcinoma	O
(	O
HPRC	O
)	O
is	O
a	O
recently	O
recognized	O
form	O
of	O
inherited	O
kidney	O
cancer	O
characterized	O
by	O
a	O
predisposition	O
to	O
develop	O
multiple	O
,	O
bilateral	O
papillary	O
renal	O
tumours	O
.	O
The	O
pattern	O
of	O
inheritance	O
of	O
HPRC	O
is	O
consistent	O
with	O
autosomal	O
dominant	O
transmission	O
with	O
reduced	O
penetrance	O
.	O
HPRC	O
is	O
histologically	O
and	O
genetically	O
distinct	O
from	O
two	O
other	O
causes	O
of	O
inherited	O
renal	O
carcinoma	O
,	O
von	O
Hippel	O
-	O
Lindau	O
disease	O
(	O
VHL	O
)	O
and	O
the	O
chromosome	O
translocation	B-type
(	O
3	B-state-original
;	O
8	B-state-altered
)	O
.	O
Malignant	O
papillary	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
trisomy	B-type
of	O
chromosomes	B-location
7	I-location
,	O
16	B-location
and	O
17	B-location
,	O
and	O
in	O
men	O
,	O
by	O
loss	B-type
of	O
the	O
Y	B-location
chromosome	I-location
.	O
Inherited	O
and	O
sporadic	O
clear	O
cell	O
renal	O
carcinomas	O
are	O
characterized	O
by	O
inactivation	O
of	O
both	O
copies	O
of	O
the	O
VHL	O
gene	O
by	O
mutation	O
,	O
and/or	O
by	O
hypermethylation	O
.	O
We	O
found	O
that	O
the	O
HPRC	O
gene	O
was	O
located	O
at	O
chromosome	B-location
7q	I-location
31	I-location
.	I-location
1	I-location
-	I-location
34	I-location
in	I-location
a	I-location
27	I-location
-	I-location
centimorgan	I-location
(	I-location
cM	I-location
)	I-location
interval	I-location
between	I-location
D7S496	I-location
and	I-location
D7S1837	I-location
.	O
We	O
identified	O
missense	B-type
mutations	I-type
located	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
the	O
MET	O
gene	O
in	O
the	O
germline	O
of	O
affected	O
members	O
of	O
HPRC	O
families	O
and	O
in	O
a	O
subset	O
of	O
sporadic	O
papillary	O
renal	O
carcinomas	O
.	O
Three	O
mutations	O
in	O
the	O
MET	O
gene	O
are	O
located	O
in	O
codons	O
that	O
are	O
homologous	O
to	O
those	O
in	O
c-kit	O
and	O
RET	O
,	O
proto	O
-	O
oncogenes	O
that	O
are	O
targets	O
of	O
naturally	O
-	O
occurring	O
mutations	O
.	O
The	O
results	O
suggest	O
that	O
missense	B-type
mutations	I-type
located	O
in	O
the	O
MET	O
proto	O
-	O
oncogene	O
lead	O
to	O
constitutive	O
activation	O
of	O
the	O
MET	O
protein	O
and	O
papillary	O
renal	O
carcinomas	O
.	O
PMID	O
:	O
9140397	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Science	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1790	O
-2	O
Comment	O
in	O
:	O
Science	O
.	O
1997	O
Mar	O
21;275	O
(	O
5307	O
)	O
:1752-3.	O
Stabilization	O
of	O
beta-catenin	O
by	O
genetic	O
defects	O
in	O
melanoma	O
cell	O
lines	O
.	O
Rubinfeld	O
B	O
,	O
Robbins	O
P,	O
El	O
-Gamil	O
M,	O
Albert	O
I	O
,	O
Porfiri	O
E	O
,	O
Polakis	O
P.	O
Onyx	O
Pharmaceuticals	O
,	O
3031	O
Research	O
Drive	O
,	O
Richmond	O
,	O
CA	O
94806	O
,	O
USA	O
.	O
Signal	O
transduction	O
by	O
beta-catenin	O
involves	O
its	O
posttranslational	O
stabilization	O
and	O
downstream	O
coupling	O
to	O
the	O
Lef	O
and	O
Tcf	O
transcription	O
factors	O
.	O
Abnormally	O
high	O
amounts	O
of	O
beta-catenin	O
were	O
detected	O
in	O
7	O
of	O
26	O
human	O
melanoma	O
cell	O
lines	O
.	O
Unusual	O
messenger	O
RNA	O
splicing	O
and	O
missense	B-type
mutations	I-type
in	O
the	O
beta-catenin	O
gene	O
(	O
CTNNB1	O
)	O
that	O
result	O
in	O
stabilization	O
of	O
the	O
protein	O
were	O
identified	O
in	O
six	O
of	O
the	O
lines	O
,	O
and	O
the	O
adenomatous	O
polyposis	O
coli	O
tumor	O
suppressor	O
protein	O
(	O
APC	O
)	O
was	O
altered	O
or	O
missing	O
in	O
two	O
others	O
.	O
In	O
the	O
APC	O
-	O
deficient	O
cells	O
,	O
ectopic	O
expression	O
of	O
wild	O
-	O
type	O
APC	O
eliminated	O
the	O
excess	O
beta-catenin	O
.	O
Cells	O
with	O
stabilized	O
beta-catenin	O
contained	O
a	O
constitutive	O
beta-catenin	O
-	O
Lef-1	O
complex	O
.	O
Thus	O
,	O
genetic	O
defects	O
that	O
result	O
in	O
up	O
-	O
regulation	O
of	O
beta-catenin	O
may	O
play	O
a	O
role	O
in	O
melanoma	O
progression	O
.	O
PMID	O
:	O
9065403	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Thyroid	O
1996	O
Oct;	O
6	O
(	O
5	O
)	O
:	O
409	O
-	O
16	O
Prevalence	O
of	O
activating	O
ras	O
mutations	O
in	O
morphologically	O
characterized	O
thyroid	O
nodules	O
.	O
Ezzat	O
S	O
,	O
Zheng	O
L,	O
Kolenda	O
J,	O
Safarian	O
A	O
,	O
Freeman	O
JL	O
,	O
Asa	O
SL	O
.	O
Department	O
of	O
Medicine	O
,	O
Wellesley	O
Hospital	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O
Ras	O
proteins	O
are	O
signal	O
-	O
transducing	O
proteins	O
that	O
share	O
common	O
properties	O
with	O
membrane	O
-	O
anchored	O
G	O
proteins	O
.	O
Mutations	O
at	O
codon	B-location
12	I-location
/	O
13	B-location
or	O
codon	B-location
61	I-location
alter	O
GTP	O
-	O
binding	O
or	O
GTPase	O
activity	O
,	O
respectively	O
.	O
Such	O
activating	O
mutations	B-event
are	O
present	O
in	O
nearly	O
30	O
-	O
50	O
%	O
of	O
various	O
malignancies	O
including	O
colon	O
,	O
breast	O
,	O
and	O
lung	O
carcinomas	O
.	O
There	O
are	O
conflicting	O
data	O
regarding	O
the	O
prevalence	O
of	O
ras	O
mutations	O
in	O
the	O
thyroid	O
and	O
their	O
possible	O
pathogenetic	O
role	O
in	O
the	O
different	O
tumor	O
types	O
.	O
To	O
address	O
this	O
question	O
,	O
we	O
examined	O
45	O
morphologically	O
characterized	O
thyroid	O
carcinomas	O
,	O
adenomas	O
,	O
and	O
hyperplastic	O
nodules	O
using	O
a	O
highly	O
sensitive	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
approach	O
combined	O
with	O
DNA	O
-	O
sequencing	O
.	O
DNA	O
from	O
cell	O
lines	O
with	O
known	O
mutations	B-event
served	O
as	O
controls	O
.	O
A	O
G	B-state-original
to	O
A	B-state-altered
H	O
13	B-location
codon	I-location
substitution	B-type
replacing	O
an	O
Asp	B-state-original
for	O
a	O
Gly	B-state-altered
residue	O
was	O
detected	O
in	O
1	O
papillary	O
carcinoma	O
.	O
Although	O
no	O
H	O
12	B-location
or	O
H	O
61	B-location
codon	I-location
substitutions	B-type
were	O
identified	O
,	O
2	O
discrete	O
alterations	O
were	O
identified	O
in	O
codons	B-location
H	O
17	B-location
and	O
22	B-location
.	O
No	O
N	O
12	B-location
/	O
13	B-location
codon	I-location
substitutions	B-type
were	O
identified	O
.	O
N	O
61	B-location
codon	I-location
substitutions	B-type
of	O
A	B-state-original
to	O
G	B-state-altered
resulting	O
in	O
a	O
Gly	B-state-original
to	O
Arg	B-state-altered
substitution	B-type
were	O
detected	O
in	O
2	O
papillary	O
carcinomas	O
;	O
the	O
same	O
mutation	B-event
was	O
also	O
found	O
in	O
one	O
follicular	O
adenoma	O
.	O
Interestingly	O
,	O
K	O
12	B-location
/	O
13	B-location
and	O
K	O
61	B-location
ras	O
mutations	O
were	O
not	O
present	O
in	O
any	O
of	O
the	O
tumors	O
examined	O
.	O
These	O
data	O
establish	O
a	O
low	O
prevalence	O
of	O
mutations	O
in	O
all	O
ras	O
gene	O
family	O
members	O
in	O
human	O
thyroid	O
neoplasms	O
.	O
This	O
difference	O
from	O
neoplasms	O
of	O
other	O
organs	O
may	O
explain	O
the	O
relatively	O
indolent	O
biologic	O
behavior	O
of	O
many	O
thyroid	O
tumors	O
and	O
supports	O
an	O
alternate	O
early	O
genetic	O
mutation	O
that	O
is	O
more	O
characteristic	O
of	O
these	O
neoplasms	O
.	O
PMID	O
:	O
8936664	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
1996	O
Sep;149(	O
3	O
)	O
:	O
883	O
-	O
93	O
Comment	O
in	O
:	O
Am	O
J	O
Pathol	O
.	O
1996	O
Sep;149(	O
3	O
)	O
:739	O
-	O
44	O
.	O
Relevance	O
of	O
ultraviolet	O
-	O
induced	O
N-ras	O
oncogene	O
point	B-type
mutations	I-type
in	O
development	O
of	O
primary	O
human	O
cutaneous	O
melanoma	O
.	O
van	O
Elsas	O
A	O
,	O
Zerp	O
SF	O
,	O
van	O
der	O
Flier	O
S	O
,	O
Kruse	O
KM	O
,	O
Aarnoudse	O
C	O
,	O
Hayward	O
NK	O
,	O
Ruiter	O
DJ	O
,	O
Schrier	O
PI.	O
Department	O
of	O
Clinical	O
Oncology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Intermittent	O
or	O
recreational	O
exposure	O
to	O
sunlight	O
is	O
thought	O
to	O
contribute	O
to	O
development	O
of	O
human	O
cutaneous	O
melanoma	O
.	O
We	O
investigated	O
the	O
incidence	O
of	O
ras	O
oncogene	O
mutation	O
in	O
human	O
cutaneous	O
melanoma	O
in	O
connection	O
to	O
sun	O
-	O
exposed	O
body	O
sites	O
in	O
the	O
patient	O
,	O
using	O
a	O
large	O
series	O
of	O
DNA	O
samples	O
derived	O
from	O
paraffin	O
-	O
embedded	O
material	O
as	O
well	O
as	O
from	O
fresh	O
tumor	O
samples	O
and	O
cell	O
lines	O
.	O
We	O
first	O
show	O
that	O
,	O
of	O
the	O
ras	O
family	O
,	O
predominantly	O
N-ras	O
is	O
activated	O
(	O
15	O
%	O
)	O
,	O
whereas	O
rarely	O
H-ras	O
or	O
K-ras	O
are	O
mutated	O
.	O
The	O
occurrence	O
of	O
N-ras	O
mutations	O
correlates	O
with	O
continuous	O
exposure	O
to	O
sunlight	O
of	O
the	O
primary	O
tumor	O
site	O
.	O
Of	O
all	O
tumors	O
initiated	O
on	O
chronically	O
sun	O
-	O
exposed	O
body	O
sites	O
,	O
26	O
%	O
contained	O
mutated	O
N-ras	O
,	O
in	O
contrast	O
to	O
0	O
%	O
of	O
sun	O
-	O
protected	O
melanomas	O
.	O
Melanoma	O
lesions	O
obtained	O
from	O
patients	O
from	O
North	O
or	O
Central	O
Europe	O
contained	O
fewer	O
N-ras	O
mutations	O
(	O
12	O
%	O
)	O
as	O
compared	O
with	O
patients	O
from	O
Australia	O
(	O
24	O
%	O
)	O
.	O
Mutations	O
were	O
specifically	O
associated	O
with	O
nodular	O
melanoma	O
and	O
to	O
a	O
lesser	O
extent	O
with	O
lentigo	O
malignant	O
melanoma	O
.	O
N-ras	O
mutations	O
did	O
not	O
correlate	O
with	O
metastasis	O
or	O
survival	O
parameters	O
.	O
This	O
study	O
identifies	O
a	O
subset	O
of	O
cutaneous	O
melanomas	O
that	O
contain	O
in	O
the	O
primary	O
lesion	O
ultraviolet	O
-	O
induced	O
N-ras	O
mutations	O
,	O
which	O
are	O
maintained	O
through	O
further	O
progression	O
.	O
PMID	O
:	O
8780392	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Hematol	O
1995	O
Aug;	O
62(	O
2	O
)	O
:91-7	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
very	O
rare	O
events	O
in	O
multiple	O
myeloma	O
.	O
Yasuga	O
Y	O
,	O
Hirosawa	O
S	O
,	O
Yamamoto	O
K,	O
Tomiyama	O
J,	O
Nagata	O
K,	O
Aokia	O
N	O
.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Tokyo	O
Medical	O
and	O
Dental	O
University	O
,	O
Japan	O
.	O
The	O
frequencies	O
of	O
p53	O
and	O
N-ras	O
gene	O
mutations	O
were	O
examined	O
in	O
multiple	O
myeloma	O
.	O
DNA	O
samples	O
of	O
45	O
cases	O
of	O
multiple	O
myeloma	O
were	O
obtained	O
from	O
stored	O
bone	O
marrow	O
smears	O
.	O
All	O
samples	O
were	O
analyzed	O
for	O
the	O
N-ras	O
gene	O
at	O
codon	B-location
12	I-location
by	O
the	O
allele	O
specific	O
restriction	O
analysis	O
method	O
and	O
at	O
codon	B-location
61	I-location
by	O
direct	O
sequencing	O
.	O
DNA	O
was	O
screened	O
for	O
mutations	B-event
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
for	O
the	O
p53	O
gene	O
in	O
exons	B-location
5	I-location
to	I-location
8	I-location
.	O
DNA	O
fragments	O
showing	O
an	O
altered	O
electrophoretic	O
pattern	O
were	O
further	O
studied	O
by	O
direct	O
sequencing	O
to	O
confirm	O
the	O
mutations	O
.	O
Ras	O
mutations	O
were	O
found	O
in	O
two	O
cases	O
at	O
codon	B-location
61	I-location
(	O
4.4	O
%	O
)	O
.	O
A	O
point	B-type
mutation	I-type
of	O
the	O
p53	O
gene	O
was	O
detected	O
in	O
one	O
of	O
45	O
cases	O
(	O
2.2	O
%	O
)	O
.	O
These	O
3	O
cases	O
with	O
mutations	B-event
were	O
in	O
an	O
advanced	O
stage	O
.	O
In	O
conclusion	O
,	O
N-ras	O
and	O
p53	O
gene	O
mutations	O
may	O
occur	O
at	O
a	O
late	O
stage	O
of	O
multiple	O
myeloma	O
,	O
but	O
the	O
frequencies	O
of	O
the	O
mutations	B-event
are	O
very	O
low	O
.	O
PMID	O
:	O
8590778	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1995	O
Nov;30	O
Suppl	O
8	O
:	O
30-2	O
Detection	O
of	O
c-ras	O
gene	O
mutation	O
and	O
expression	O
of	O
p21	O
protein	O
in	O
dysplasias	O
and	O
carcinomas	O
complicating	O
ulcerative	O
colitis	O
.	O
Tsuda	O
T	O
,	O
Mochizuki	O
M,	O
Wakasa	O
H.	O
Department	O
of	O
Pathology	O
,	O
Fukushima	O
Medical	O
College	O
,	O
Japan	O
.	O
Point	B-type
mutations	I-type
of	O
c-ras	O
genes	O
and	O
the	O
expression	O
of	O
p21	O
protein	O
were	O
analyzed	O
in	O
13	O
patients	O
with	O
colorectal	O
carcinoma	O
complicating	O
ulcerative	O
colitis	O
;	O
in	O
12	O
of	O
the	O
13	O
,	O
there	O
were	O
dysplastic	O
lesions	O
close	O
to	O
the	O
carcinomas	O
.	O
Point	B-type
mutations	I-type
of	O
c-ras	O
genes	O
were	O
studied	O
by	O
polymerase	O
chain	O
reaction	O
and	O
dot	O
blot	O
hybridization	O
with	O
32p	O
-	O
labeled	O
oligonucleotide	O
probes	O
.	O
Findings	O
indicated	O
mutations	O
of	O
c-Ki-ras	O
at	O
condons	B-location
12	I-location
,	O
13	B-location
,	O
and	O
61	B-location
and	O
c-Ha-ras	O
and	O
c-N-ras	O
at	O
condons	B-location
12	I-location
and	O
61	B-location
.	O
The	O
expression	O
of	O
p21	O
protein	O
was	O
analyzed	O
by	O
immunohistochemical	O
staining	O
using	O
a	O
monoclonal	O
antibody	O
.	O
Only	O
1	O
of	O
the	O
13	O
patients	O
with	O
carcinoma	O
showed	O
a	O
point	B-type
mutation	I-type
,	O
this	O
being	O
from	O
G	B-state-original
to	O
A	B-state-altered
transition	B-type
at	O
the	O
second	B-location
position	I-location
of	I-location
codon	I-location
12	I-location
of	O
c-Ki-ras	O
.	O
No	O
point	B-type
mutations	I-type
of	O
c-Ki-ras	O
,	O
c-Ha-ras	O
,	O
or	O
c-N-ras	O
were	O
found	O
in	O
other	O
carcinomatous	O
lesions	O
and	O
dysplasias	O
.	O
In	O
the	O
dysplastic	O
or	O
carcinomatous	O
lesions	O
of	O
11	O
patients	O
,	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
was	O
observed	O
.	O
These	O
results	O
suggest	O
that	O
point	B-type
mutations	I-type
of	O
c-ras	O
genes	O
are	O
rare	O
in	O
dysplasias	O
and	O
carcinomas	O
complicating	O
ulcerative	O
colitis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
p21	O
protein	O
is	O
not	O
always	O
correlated	O
with	O
point	B-type
mutations	I-type
of	O
c-ras	O
genes	O
.	O
PMID	O
:	O
8563883	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1993	O
Apr;8	O
4	O
(	O
4	O
)	O
:	O
379	O
-	O
87	O
Clonal	O
analysis	O
of	O
multiple	O
point	B-type
mutations	I-type
in	O
the	O
N-ras	O
gene	O
in	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
.	O
Kubo	O
K,	O
Naoe	O
T	O
,	O
Kiyoi	O
H,	O
Fukutani	O
H,	O
Kato	O
Y	O
,	O
Oguri	O
T	O
,	O
Yamamori	O
S	O
,	O
Akatsuka	O
Y	O
,	O
Kodera	O
Y	O
,	O
Ohno	O
R.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Nagoya	O
University	O
Branch	O
Hospital	O
.	O
We	O
have	O
screened	O
mutations	O
of	O
the	O
N-ras	O
gene	O
at	O
codons	B-location
12	I-location
,	O
13	B-location
,	O
and	O
61	B-location
in	O
leukemia	O
cells	O
obtained	O
from	O
100	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
and	O
found	O
mutated	O
N-ras	O
alleles	O
in	O
9	O
patients	O
.	O
We	O
further	O
analyzed	O
the	O
polyclonality	O
of	O
multiple	O
N-ras	O
gene	O
mutations	O
in	O
4	O
AML	O
patients	O
.	O
One	O
patient	O
,	O
who	O
had	O
the	O
monoclonal	O
karyotype	O
,	O
t	B-type
(	O
11	B-state-original
;	O
17	B-state-altered
)	O
,	O
had	O
two	O
types	O
of	O
double	O
missense	B-type
mutations	I-type
at	O
codons	B-location
13	I-location
and	O
61	B-location
in	O
the	O
same	O
allele	O
.	O
Each	O
of	O
the	O
remaining	O
three	O
patients	O
,	O
one	O
of	O
whom	O
had	O
t	B-type
(	O
15	B-state-original
;	O
17	B-state-altered
)	O
with	O
a	O
monoclonal	O
rearrangement	O
of	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
and	O
PML	O
genes	O
,	O
carried	O
two	O
missense	B-type
mutations	I-type
in	O
a	O
relatively	O
small	O
population	O
of	O
leukemia	O
cells	O
.	O
We	O
have	O
demonstrated	O
that	O
multiple	O
clonality	O
of	O
the	O
N-ras	O
gene	O
is	O
occasionally	O
observed	O
in	O
leukemia	O
with	O
a	O
monoclonal	O
karyotype	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
N-ras	O
mutations	O
may	O
not	O
always	O
be	O
characterized	O
simply	O
by	O
an	O
accumulative	O
process	O
and	O
that	O
the	O
activated	O
N-ras	O
gene	O
alone	O
is	O
not	O
sufficient	O
to	O
cause	O
leukemia	O
.	O
PMID	O
:	O
8514604	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1993	O
Apr	O
1;53(	O
7)	O
:1625	O
-	O
9	O
High	O
mutation	O
frequency	O
in	O
ras	O
genes	O
of	O
skin	O
tumors	O
isolated	O
from	O
DNA	O
repair	O
deficient	O
xeroderma	O
pigmentosum	O
patients	O
.	O
Daya	O
-	O
Grosjean	O
L,	O
Robert	O
C	O
,	O
Drougard	O
C	O
,	O
Suarez	O
H	O
,	O
Sarasin	O
A.	O
Laboratory	O
of	O
Molecular	O
Genetics	O
,	O
Institut	O
de	O
Recherches	O
Scientifiques	O
sur	O
le	O
Cancer	O
,	O
Villejuif	O
,	O
France	O
.	O
Xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
patients	O
are	O
clinically	O
characterized	O
by	O
a	O
very	O
high	O
incidence	O
of	O
skin	O
cancers	O
on	O
exposed	O
skin	O
,	O
at	O
an	O
early	O
age	O
.	O
XP	O
cells	O
in	O
vitro	O
are	O
strongly	O
deficient	O
in	O
excision	O
-	O
repair	O
and	O
highly	O
mutagenized	O
by	O
UV	O
light	O
.	O
We	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
measuring	O
mutation	O
frequency	O
and	O
in	O
determining	O
mutation	O
spectra	O
in	O
patients	O
'	O
tumors	O
exposed	O
to	O
UV	O
lesions	O
.	O
We	O
chose	O
to	O
look	O
at	O
oncogene	O
activation	O
in	O
skin	O
tumors	O
with	O
the	O
idea	O
that	O
more	O
mutations	O
,	O
particularly	O
of	O
the	O
ras	O
gene	O
family	O
,	O
would	O
be	O
found	O
in	O
XP	O
tumors	O
where	O
lesions	O
remain	O
unrepaired	O
compared	O
to	O
normal	O
individuals	O
.	O
Our	O
results	O
clearly	O
show	O
that	O
more	O
than	O
a	O
2	O
-	O
fold	O
significantly	O
higher	O
mutation	O
frequency	O
(	O
50	O
%	O
)	O
of	O
the	O
ras	O
genes	O
was	O
found	O
in	O
XP	O
in	O
contrast	O
to	O
control	O
tumors	O
(	O
22	O
%	O
)	O
.	O
The	O
majority	O
of	O
the	O
mutations	O
were	O
found	O
at	O
codon	B-location
12	I-location
of	O
all	O
three	O
ras	O
genes	O
with	O
a	O
preponderance	O
for	O
N-ras	O
in	O
XP	O
samples	O
.	O
The	O
mutation	O
spectra	O
indicate	O
that	O
all	O
mutations	B-event
found	O
were	O
located	O
opposite	O
pyrimidine	O
-	O
pyrimidine	O
sequences	O
which	O
represent	O
a	O
hot	O
spot	O
for	O
UV	O
-	O
induced	O
DNA	B-state-generic
lesions	I-state-generic
.	O
Most	O
of	O
the	O
mutations	B-event
were	O
of	O
the	O
type	O
expected	O
from	O
studies	O
performed	O
in	O
vitro	O
with	O
model	O
systems	O
.	O
This	O
high	O
mutation	O
frequency	O
in	O
XP	O
was	O
accompanied	O
by	O
a	O
very	O
high	O
level	O
of	O
Ha-ras	O
and	O
c-myc	O
gene	O
amplification	B-type
and	O
rearrangement	O
.	O
All	O
these	O
data	O
are	O
consistent	O
with	O
a	O
fundamental	O
role	O
of	O
unrepaired	O
UV	O
-	O
induced	O
DNA	B-state-generic
lesions	I-state-generic
as	O
an	O
initiating	O
event	O
in	O
human	O
skin	O
tumors	O
on	O
exposed	O
parts	O
of	O
the	O
body	O
.	O
PMID	O
:	O
8453633	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Aug;8(	O
8	O
)	O
:1331	O
-	O
6	O
N-ras	O
mutation	O
and	O
karyotypic	O
evolution	O
are	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
in	O
myelodysplastic	O
syndrome	O
.	O
Horiike	O
S,	O
Misawa	O
S,	O
Nakai	O
H	O
,	O
Kaneko	O
H	O
,	O
Yokota	O
S,	O
Taniwaki	O
M,	O
Yamane	O
Y	O
,	O
Inazawa	O
J,	O
Abe	O
T	O
,	O
Kashima	O
K.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
performed	O
a	O
longitudinal	O
analysis	O
of	O
the	O
karyotypes	O
and	O
N-ras	O
gene	O
configuration	O
of	O
bone	O
marrow	O
cells	O
in	O
35	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O
Karyotypic	O
evolution	O
was	O
found	O
in	O
eight	O
patients	O
,	O
and	O
was	O
associated	O
with	O
disease	O
progression	O
,	O
including	O
leukemic	O
transformation	O
,	O
in	O
all	O
the	O
patients	O
.	O
We	O
identified	O
N-ras	O
mutations	O
in	O
six	O
patients	O
,	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
technique	O
,	O
in	O
which	O
oligonucleotide	O
primers	O
were	O
constructed	O
with	O
induced	O
mismatches	O
,	O
followed	O
by	O
endonuclease	O
digestion	O
.	O
Direct	O
sequencing	O
confirmed	O
single	B-type
base	I-type
substitutions	I-type
at	O
codon	B-location
12	I-location
in	O
two	O
patients	O
and	O
at	O
codon	B-location
13	I-location
in	O
four	O
.	O
The	O
incidence	O
of	O
N-ras	O
gene	O
mutations	O
was	O
significantly	O
higher	O
in	O
the	O
karyotypically	O
evolved	O
group	O
(	O
five	O
of	O
eight	O
patients	O
)	O
than	O
in	O
the	O
stable	O
group	O
(	O
one	O
of	O
27	O
patients	O
)	O
.	O
All	O
of	O
five	O
patients	O
harboring	O
both	O
karyotypic	O
evolution	O
and	O
an	O
N-ras	O
mutation	O
showed	O
concomitant	O
disease	O
progression	O
to	O
overt	O
leukemia	O
or	O
refractory	O
anemia	O
with	O
excess	O
of	O
blasts	O
in	O
transformation	O
(	O
RAEB-T	O
)	O
.	O
Two	O
of	O
four	O
patients	O
with	O
either	O
karyotypic	O
evolution	O
or	O
N-ras	O
mutation	O
and	O
six	O
of	O
26	O
patients	O
without	O
any	O
of	O
these	O
alterations	O
also	O
progressed	O
to	O
overt	O
leukemia	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
accumulation	O
of	O
these	O
genetic	O
alterations	O
is	O
closely	O
associated	O
with	O
leukemic	O
transformation	O
of	O
MDS	O
,	O
although	O
other	O
genetic	O
alterations	O
may	O
also	O
play	O
a	O
key	O
role	O
in	O
the	O
remaining	O
patients	O
.	O
PMID	O
:	O
8057669	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Dermatol	O
1994	O
Jul;131(	O
1	O
)	O
:72	O
-	O
7	O
Point	B-type
mutations	I-type
in	O
the	O
N-ras	O
oncogene	O
in	O
malignant	O
melanoma	O
and	O
congenital	O
naevi	O
.	O
Carr	O
J,	O
Mackie	O
RM	O
.	O
Department	O
of	O
Dermatology	O
,	O
University	O
of	O
Glasgow	O
,	O
U.K.	O
DNA	O
from	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
processed	O
samples	O
from	O
100	O
melanocytic	O
lesions	O
(	O
39	O
malignant	O
melanomas	O
,	O
18	O
cases	O
of	O
dysplastic	O
naevi	O
,	O
and	O
43	O
congenital	O
naevi	O
)	O
was	O
extracted	O
,	O
and	O
the	O
sequences	O
around	O
codons	B-location
12	I-location
/	O
13	B-location
and	O
61	B-location
of	O
the	O
N-ras	O
oncogene	O
were	O
amplified	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
The	O
amplified	O
product	O
was	O
then	O
analysed	O
both	O
by	O
dot	O
-	O
blotting	O
and	O
by	O
direct	O
sequencing	O
for	O
point	B-type
mutations	I-type
.	O
By	O
the	O
dot	O
-	O
blotting	O
technique	O
,	O
mutations	O
were	O
seen	O
in	O
18	O
of	O
100	O
lesions	O
.	O
These	O
were	O
in	O
one	O
of	O
five	O
distant	O
metastases	O
(	O
20	O
%	O
)	O
,	O
in	O
one	O
of	O
three	O
nodal	O
metastases	O
(	O
33	O
%	O
)	O
,	O
in	O
four	O
of	O
31	O
(	O
13	O
%	O
)	O
primary	O
melanomas	O
,	O
in	O
none	O
of	O
18	O
dysplastic	O
naevi	O
,	O
and	O
in	O
12	O
of	O
43	O
(	O
28	O
%	O
)	O
congenital	O
naevi	O
,	O
all	O
at	O
codon	B-location
61	I-location
.	O
On	O
direct	O
sequencing	O
,	O
nine	O
of	O
18	O
mutations	O
were	O
confirmed	O
,	O
in	O
two	O
of	O
31	O
(	O
6	O
%	O
)	O
primary	O
tumours	O
,	O
one	O
distant	O
metastasis	O
,	O
and	O
six	O
of	O
43	O
(	O
14	O
%	O
)	O
congenital	O
naevi	O
.	O
Of	O
the	O
23	O
superficial	O
spreading	O
melanomas	O
examined	O
,	O
eight	O
were	O
on	O
sun	O
-	O
exposed	O
skin	O
.	O
A	O
superficial	O
spreading	O
melanoma	O
,	O
in	O
which	O
the	O
N-ras	O
mutation	O
at	O
codon	B-location
61	I-location
was	O
confirmed	O
,	O
was	O
on	O
non	O
-	O
exposed	O
skin	O
,	O
and	O
an	O
unconfirmed	O
mutation	O
was	O
from	O
an	O
exposed	O
site	O
.	O
One	O
of	O
three	O
nodular	O
melanomas	O
with	O
a	O
confirmed	O
mutation	O
was	O
on	O
a	O
light	O
-	O
exposed	O
site	O
,	O
and	O
the	O
other	O
two	O
nodular	O
melanomas	O
were	O
from	O
non	O
-	O
exposed	O
areas	O
.	O
All	O
four	O
lentigo	O
maligna	O
melanomas	O
were	O
from	O
exposed	O
sites	O
,	O
and	O
one	O
of	O
these	O
had	O
an	O
unconfirmed	O
mutation	O
.	O
The	O
only	O
acral	O
lentiginous	O
melanoma	O
,	O
which	O
had	O
no	O
mutation	O
,	O
was	O
from	O
a	O
sun	O
-	O
exposed	O
area	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
PMID	O
:	O
8043423	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1994	O
Oct;8(	O
10	O
)	O
:1682	O
-	O
7	O
The	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	B-event
in	O
codon	B-location
13	I-location
of	O
the	O
N-ras	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O
Coghlan	O
DW	O
,	O
Morley	O
AA	O
,	O
Matthews	O
JP	O
,	O
Bishop	O
JF.	O
Department	O
of	O
Haematology	O
,	O
Flinders	O
Medical	O
Centre	O
,	O
Bedford	O
Park	O
,	O
South	O
Australia	O
.	O
To	O
determine	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutation	O
in	O
the	O
N-ras	O
gene	O
in	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
we	O
performed	O
an	O
analysis	O
of	O
bone	O
marrow	O
smears	O
from	O
219	O
patients	O
with	O
de	O
novo	O
AML	O
treated	O
between	O
1984	O
and	O
1986	O
and	O
followed	O
for	O
at	O
least	O
six	O
years	O
.	O
DNA	O
extracted	O
from	O
bone	O
marrow	O
smears	O
taken	O
at	O
diagnosis	O
was	O
screened	O
for	O
the	O
presence	O
of	O
mutations	B-event
in	O
codons	B-location
12	B-location
and	O
13	B-location
of	O
exon	B-location
1	I-location
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
to	O
insert	O
an	O
Hph1	O
restriction	O
enzyme	O
site	O
into	O
DNA	O
.	O
Presumptive	O
mutations	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
.	O
Mutations	B-event
were	O
detected	O
in	O
a	O
total	O
of	O
26	O
patients	O
(	O
12	O
%	O
)	O
;	O
in	O
nine	O
patients	O
(	O
4	O
%	O
)	O
in	O
codon	B-location
12	I-location
only	O
,	O
in	O
ten	O
patients	O
(	O
5	O
%	O
)	O
in	O
codon	B-location
13	I-location
only	O
,	O
and	O
in	O
seven	O
patients	O
(	O
3	O
%	O
)	O
in	O
both	B-location
codons	I-location
.	O
Mutations	B-event
in	O
codon	B-location
12	I-location
or	O
codon	B-location
13	I-location
were	O
not	O
associated	O
with	O
any	O
clinical	O
features	O
.	O
Mutations	B-event
in	O
codon	B-location
12	I-location
had	O
no	O
prognostic	O
significance	O
but	O
mutations	B-event
in	O
codon	B-location
13	I-location
were	O
associated	O
with	O
an	O
increased	O
remission	O
rate	O
,	O
a	O
more	O
durable	O
remission	O
,	O
and	O
a	O
significantly	O
prolonged	O
survival	O
which	O
appeared	O
to	O
be	O
independent	O
of	O
other	O
prognostic	O
factors	O
.	O
PMID	O
:	O
7934163	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Acta	O
Oncol	O
1995	O
;34(	O
6)	O
:759	O
-	O
65	O
Glutathione	O
transferase	O
P1-1	O
expression	O
in	O
human	O
melanoma	O
metastases	O
:	O
correlation	O
to	O
N-RAS	O
mutations	O
and	O
expression	O
.	O
Platz	O
A	O
,	O
Jungnelius	O
U	O
,	O
Grafstrom	O
E	O
,	O
Lagerlof	O
B	O
,	O
Mannervik	O
B	O
,	O
Ringborg	O
U.	O
Department	O
of	O
Oncology	O
,	O
Radiumhemmet	O
,	O
Karolinska	O
Hospital	O
,	O
Stockholm	O
,	O
Sweden	O
.	O
Expression	O
of	O
the	O
detoxication	O
enzyme	O
glutathione	O
transferase	O
P1-1	O
(	O
GST	O
P1-1	O
)	O
at	O
elevated	O
levels	O
has	O
been	O
noted	O
in	O
many	O
types	O
of	O
human	O
tumors	O
,	O
including	O
melanomas	O
.	O
The	O
products	O
of	O
the	O
human	O
H-RAS	O
,	O
K-RAS	O
and	O
N-RAS	O
genes	O
play	O
a	O
key	O
role	O
in	O
intracellular	O
signal	O
transduction	O
leading	O
to	O
transcriptional	O
activation	O
of	O
AP-1	O
(	O
Fos	O
/	O
Jun	O
)	O
responsive	O
genes	O
.	O
The	O
oncogenic	O
mutated	O
forms	O
of	O
the	O
ras	O
proteins	O
are	O
constitutively	O
active	O
and	O
interfere	O
with	O
normal	O
signal	O
transduction	O
.	O
Mutated	O
RAS	O
genes	O
as	O
well	O
as	O
increased	O
expression	O
of	O
wild	O
-	O
type	O
ras	O
proteins	O
are	O
common	O
features	O
in	O
human	O
tumors	O
including	O
melanoma	O
.	O
We	O
have	O
characterized	O
30	O
melanoma	O
metastases	O
from	O
23	O
melanoma	O
patients	O
with	O
reference	O
to	O
N-RAS	O
expression	O
and	O
mutation	O
as	O
well	O
as	O
to	O
GST	O
P1	O
expression	O
(	O
immunohistochemistry	O
and	O
genetic	O
analysis	O
)	O
.	O
Twenty-three	O
of	O
30	O
samples	O
(	O
70	O
%	O
)	O
had	O
high	O
N-Ras	O
p21	O
and/or	O
N-RAS	O
codon	B-location
61	I-location
mutations	B-event
and	O
18	O
of	O
these	O
23	O
samples	O
also	O
had	O
high	O
GST	O
P1-1	O
immunoreactivity	O
.	O
Seven	O
of	O
30	O
(	O
23	O
%	O
)	O
samples	O
had	O
low	O
N-Ras	O
p21	O
immunoreactivity	O
and	O
no	O
detectable	O
N-RAS	O
codon	B-location
61	I-location
mutations	B-event
.	O
Six	O
of	O
these	O
7	O
samples	O
(	O
86	O
%	O
)	O
also	O
had	O
low	O
GST	O
P1-1	O
immunoreactivity	O
.	O
The	O
results	O
indicate	O
a	O
statistically	O
significant	O
correlation	O
(	O
Spearman	O
correlation	O
coefficient	O
,	O
r	O
=	O
0.56	O
,	O
p	O
=	O
0.001	O
,	O
2	O
-	O
tailed	O
test	O
)	O
and	O
provide	O
,	O
for	O
the	O
first	O
time	O
,	O
indirect	O
evidence	O
for	O
a	O
possible	O
coregulation	O
of	O
N-RAS	O
and	O
GST	O
P1	O
in	O
human	O
malignant	O
melanoma	O
which	O
should	O
be	O
further	O
evaluated	O
.	O
PMID	O
:	O
7576742	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nippon	O
Shokakibyo	O
Gakkai	O
Zasshi	O
1989	O
Nov;86(	O
11	O
)	O
:2566	O
-	O
71	O
[	O
Detection	O
of	O
ras	O
gene	O
mutations	O
of	O
pancreatic	O
tumors	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
]	O
[Article	O
in	O
Japanese	O
]	O
Tada	O
M,	O
Yokosuka	O
O	O
,	O
Omata	O
M,	O
Ohto	O
M,	O
Isono	O
K.	O
Ras	O
genes	O
(	O
H	O
-	O
,	O
K	O
-	O
,	O
N	O
-	O
ras	O
)	O
are	O
converted	O
to	O
active	O
oncogenes	O
by	O
point	B-type
mutations	I-type
occurring	O
in	O
either	O
codon	B-location
12	B-location
,	O
13	B-location
or	O
61	B-location
.	O
We	O
analyzed	O
19	O
pancreatic	O
tumors	O
(	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
)	O
of	O
these	B-location
codons	I-location
by	O
a	O
method	O
to	O
directly	O
sequence	O
nucleotides	O
around	O
codons	B-location
12	B-location
/	O
13	B-location
and	O
61	B-location
of	O
the	O
three	O
ras	O
genes	O
,	O
using	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
method	O
.	O
Of	O
19	O
pancreatic	O
tumors	O
,	O
all	O
17	O
duct	O
cell	O
carcinomas	O
involving	O
2	O
mucous	O
producing	O
pancreatic	O
cancers	O
had	O
point	B-type
mutations	I-type
of	O
the	O
K-ras	O
codon	B-location
12	I-location
,	O
but	O
2	O
islet	O
cell	O
tumors	O
had	O
ano	O
point	B-type
mutation	I-type
around	O
codons	B-location
12	B-location
,	O
13	B-location
,	O
61	B-location
of	O
the	O
three	O
ras	O
genes	O
.	O
Extremely	O
high	O
incidence	O
of	O
ras	O
gene	O
mutation	O
may	O
be	O
relevant	O
to	O
certain	O
pathogenesis	O
of	O
pancreatic	O
cancers	O
.	O
PMID	O
:	O
2689731	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1989	O
Jul;3(	O
7)	O
:511	O
-	O
5	O
c-myc	O
amplification	B-type
coexistent	O
with	O
activating	O
N-ras	O
point	B-type
mutation	I-type
in	O
the	O
biphenotypic	O
leukemic	O
cell	O
line	O
RED-3	O
.	O
Mallet	O
MK	O
,	O
Mane	O
SM	O
,	O
Meltzer	O
SJ	O
,	O
Needleman	O
SW.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
Maryland	O
Hospital	O
,	O
Baltimore	O
21201	O
.	O
While	O
activation	O
of	O
the	O
protooncogene	O
c-N-ras	O
is	O
observed	O
regularly	O
in	O
acute	O
myelogenous	O
leukemia	O
,	O
amplification	B-type
of	O
c-myc	O
in	O
AML	O
cells	O
or	O
derived	O
lines	O
is	O
uncommon	O
.	O
In	O
particular	O
,	O
concurrent	O
ras	O
/	O
myc	O
activation	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
critical	O
in	O
several	O
elegant	O
models	O
of	O
malignancy	O
,	O
has	O
been	O
demonstrated	O
in	O
a	O
very	O
small	O
number	O
of	O
human	O
tumors	O
or	O
derivative	O
cell	O
lines	O
.	O
A	O
cell	O
line	O
,	O
RED-3	O
,	O
is	O
described	O
which	O
was	O
derived	O
from	O
cells	O
of	O
a	O
patient	O
with	O
aggressive	O
acute	O
leukemia	O
which	O
exhibits	O
many	O
markers	O
of	O
lineage	O
infidelity	O
.	O
DNA	O
from	O
this	O
cell	O
line	O
contains	O
an	O
activating	O
point	B-type
mutation	I-type
of	O
c-N-ras	O
as	O
well	O
as	O
20	O
-	O
30	O
-	O
fold	O
amplification	B-type
of	O
c-myc	O
.	O
After	O
HL-60	O
,	O
this	O
is	O
the	O
second	O
example	O
of	O
ras	O
/	O
myc	O
activation	O
in	O
AML	O
derived	O
cells	O
and	O
demonstrates	O
that	O
this	O
lesion	O
is	O
not	O
unique	O
to	O
HL-60	O
.	O
Rather	O
,	O
it	O
may	O
be	O
important	O
in	O
leukemogenesis	O
in	O
a	O
small	O
proportion	O
of	O
AML	O
patients	O
.	O
PMID	O
:	O
2659902	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
Feb;4(	O
2	O
)	O
:159	O
-	O
64	O
High	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
in	O
all	O
stages	O
of	O
human	O
thyroid	O
tumorigenesis	O
.	O
Lemoine	O
NR	O
,	O
Mayall	O
ES	O
,	O
Wyllie	O
FS	O
,	O
Williams	O
ED	O
,	O
Goyns	O
M,	O
Stringer	O
B	O
,	O
Wynford	O
-	O
Thomas	O
D.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Health	O
Park	O
,	O
Cardiff	O
,	O
UK.	O
Using	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
oligonucleotide	O
probing	O
,	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
24	O
benign	O
and	O
20	O
malignant	O
human	O
thyroid	O
neoplasms	O
was	O
examined	O
.	O
The	O
frequency	O
of	O
ras	O
oncogene	O
activation	O
was	O
similar	O
at	O
all	O
stages	O
of	O
tumorigenesis	O
in	O
this	O
system	O
,	O
being	O
found	O
in	O
33	O
%	O
of	O
adenomas	O
overall	O
(	O
50	O
%	O
of	O
microfollicular	O
tumours	O
)	O
,	O
53	O
%	O
of	O
differentiated	O
follicular	O
carcinomas	O
and	O
60	O
%	O
of	O
undifferentiated	O
carcinomas	O
.	O
This	O
supports	O
the	O
contention	O
that	O
mutation	O
of	O
these	O
oncogenes	O
occurs	O
at	O
an	O
early	O
step	O
in	O
tumorigenesis	O
.	O
The	O
predominant	O
amino	B-type
acid	I-type
substitution	I-type
in	O
the	O
differentiated	O
tumours	O
was	O
glutamine	B-state-original
to	O
arginine	B-state-altered
at	O
position	B-location
61	I-location
of	O
Ha-ras	O
or	O
N-ras	O
,	O
but	O
this	O
mutation	B-event
was	O
not	O
found	O
in	O
any	O
of	O
the	O
undifferentiated	O
tumours	O
.	O
It	O
was	O
noted	O
that	O
while	O
transition	B-type
mutations	I-type
predominated	O
in	O
differentiated	O
tumours	O
(	O
both	O
benign	O
and	O
malignant	O
)	O
,	O
transversions	B-type
were	O
more	O
common	O
in	O
the	O
undifferentiated	O
tumours	O
.	O
PMID	O
:	O
2648253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1989	O
Jan	O
15	O
;49(	O
2	O
)	O
:357	O
-	O
60	O
Incidence	O
of	O
activating	O
ras	O
oncogene	O
mutations	O
associated	O
with	O
primary	O
and	O
metastatic	O
human	O
breast	O
cancer	O
.	O
Rochlitz	O
CF	O
,	O
Scott	O
GK	O
,	O
Dodson	O
JM	O
,	O
Liu	O
E	O
,	O
Dollbaum	O
C	O
,	O
Smith	O
HS	O
,	O
Benz	O
CC.	O
Cancer	O
Research	O
Institute	O
,	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
94143	O
.	O
To	O
test	O
the	O
hypothesis	O
that	O
ras	O
activation	O
is	O
involved	O
in	O
the	O
final	O
stages	O
of	O
breast	O
cancer	O
progression	O
,	O
we	O
analyzed	O
tumor	O
DNA	O
derived	O
from	O
60	O
different	O
patients	O
and	O
extracted	O
from	O
40	O
invasive	O
primary	O
breast	O
tumors	O
,	O
seven	O
lymph	O
node	O
and	O
skin	O
metastases	O
,	O
nine	O
metastatic	O
effusions	O
,	O
and	O
five	O
established	O
breast	O
cancer	O
cell	O
lines	O
.	O
The	O
polymerase	O
chain	O
reaction	O
technique	O
was	O
used	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
Kirsten	O
-	O
(	O
Ki	O
-	O
)	O
,	O
Harvey	O
-	O
(	O
Ha	O
-	O
)	O
,	O
and	O
N	O
-	O
ras	O
codons	B-location
12	I-location
,	O
13	B-location
,	O
and	O
61	B-location
which	O
were	O
then	O
probed	O
on	O
slot	O
-	O
blots	O
with	O
labeled	O
synthetic	O
oligomers	O
to	O
detect	O
nonconservative	O
single	B-type
base	I-type
mutations	I-type
.	O
Activating	O
mutations	B-event
were	O
found	O
in	O
one	O
of	O
40	O
primary	O
tumors	O
(	O
Ki-ras	O
codon	B-location
13	I-location
)	O
,	O
zero	O
of	O
seven	O
lymph	O
node	O
and	O
skin	O
metastases	O
,	O
one	O
of	O
nine	O
metastatic	O
effusions	O
(	O
Ki-ras	O
codon	B-location
12	I-location
)	O
,	O
and	O
two	O
of	O
five	O
cell	O
lines	O
(	O
Ki-ras	O
codons	B-location
12	I-location
and	O
13	B-location
)	O
.	O
These	O
results	O
indicate	O
that	O
activating	O
ras	O
mutations	O
are	O
rarely	O
involved	O
in	O
either	O
the	O
initiation	O
or	O
metastatic	O
progression	O
of	O
human	O
breast	O
cancer	O
.	O
PMID	O
:	O
2642738	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1990	O
Mar;61(	O
3	O
)	O
:365	O
-	O
8	O
Low	O
incidence	O
of	O
ras	O
oncogene	O
activation	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
.	O
Rumsby	O
G	O
,	O
Carter	O
RL	O
,	O
Gusterson	O
BA.	O
Department	O
of	O
Chemical	O
Pathology	O
,	O
Royal	O
Marsden	O
Hospital	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O
Activation	O
of	O
the	O
ras	O
gene	O
family	O
by	O
point	B-type
mutation	I-type
at	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
has	O
been	O
demonstrated	O
in	O
up	O
to	O
20	O
%	O
of	O
unselected	O
series	O
of	O
human	O
tumours	O
.	O
The	O
present	O
study	O
was	O
carried	O
out	O
to	O
assess	O
the	O
incidence	O
of	O
ras	O
activation	O
in	O
37	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
head	O
and	O
neck	O
,	O
seven	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
skin	O
and	O
eight	O
squamous	O
carcinoma	O
cell	O
lines	O
.	O
Oligonucleotide	O
probes	O
and	O
the	O
polymerase	O
chain	O
reaction	O
were	O
used	O
on	O
DNA	O
extracted	O
from	O
achival	O
paraffin	O
embedded	O
material	O
.	O
Mutations	O
in	O
codon	B-location
12	I-location
of	O
the	O
Harvey	O
ras	O
gene	O
was	O
found	O
in	O
a	O
carcinoma	O
of	O
the	O
larynx	O
and	O
a	O
carcinoma	O
of	O
the	O
lip	O
,	O
both	O
of	O
which	O
had	O
received	O
prior	O
irradiation	O
.	O
A	O
cell	O
line	O
(	O
LICR-LON-HN8	O
)	O
established	O
from	O
the	O
same	O
laryngeal	O
cancer	O
showed	O
the	O
same	O
mutation	B-event
.	O
This	O
study	O
indicates	O
that	O
there	O
is	O
a	O
low	O
incidence	O
of	O
ras	O
mutation	O
in	O
human	O
squamous	O
cell	O
carcinomas	O
and	O
that	O
activation	O
of	O
this	O
family	O
of	O
genes	O
is	O
probably	O
not	O
a	O
common	O
factor	O
in	O
the	O
development	O
of	O
this	O
group	O
of	O
tumours	O
.	O
PMID	O
:	O
2183872	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1990	O
Mar;5(	O
3	O
)	O
:411	O
-	O
6	O
RAS	O
mutations	O
in	O
patients	O
following	O
cytotoxic	O
therapy	O
for	O
lymphoma	O
.	O
Carter	O
G	O
,	O
Hughes	O
DC	O
,	O
Clark	O
RE	O
,	O
McCormick	O
F	O
,	O
Jacobs	O
A	O
,	O
Whittaker	O
JA	O
,	O
Padua	O
RA.	O
Department	O
of	O
Haematology	O
,	O
University	O
of	O
Wales	O
College	O
of	O
Medicine	O
,	O
Cardiff	O
,	O
UK.	O
The	O
occurrence	O
of	O
Myelodysplastic	O
Syndrome	O
(	O
MDS	O
)	O
and	O
Acute	O
Myeloblastic	O
Leukaemia	O
(	O
AML	O
)	O
following	O
cytotoxic	O
therapy	O
for	O
neoplastic	O
disease	O
is	O
well	O
recognised	O
.	O
RAS	O
mutations	O
are	O
common	O
in	O
patients	O
with	O
MDS	O
and	O
AML	O
.	O
To	O
determine	O
whether	O
these	O
lesions	O
are	O
found	O
as	O
early	O
markers	O
of	O
secondary	O
disease	O
,	O
we	O
have	O
studied	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
the	O
peripheral	O
blood	O
of	O
70	O
patients	O
in	O
complete	O
remission	O
from	O
lymphoma	O
.	O
Patients	O
were	O
treated	O
by	O
standard	O
chemotherapy	O
regimes	O
and/or	O
localised	O
radiotherapy	O
.	O
Treatment	O
had	O
been	O
given	O
6	O
months	O
to	O
14	O
1	O
/	O
2	O
years	O
previously	O
and	O
no	O
patient	O
showed	O
any	O
sign	O
of	O
residual	O
disease	O
.	O
Genomic	O
DNA	O
from	O
peripheral	O
blood	O
leukocytes	O
was	O
amplified	O
in	O
vitro	O
at	O
target	O
codons	O
of	O
N	O
,	O
K	O
and	O
H	O
RAS	O
genes	O
,	O
and	O
mutations	O
detected	O
by	O
hybridisation	O
with	O
oligonucleotide	O
probes	O
.	O
RAS	O
mutations	B-event
were	O
detected	O
in	O
9	O
subjects	O
.	O
One	O
patient	O
with	O
an	O
N	O
12	B-location
valine	B-state-generic
(	O
Val	B-state-generic
)	O
substitution	B-type
had	O
been	O
in	O
complete	O
remission	O
from	O
Hodgkin	O
's	O
disease	O
(	O
HD	O
)	O
for	O
9	O
years	O
.	O
DNA	O
from	O
this	O
patient	O
registered	O
in	O
a	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
NMT	O
)	O
.	O
The	O
N	O
12	B-location
Val	B-state-generic
mutation	B-event
was	O
not	O
detected	O
in	O
the	O
original	O
tumour	O
tissue	O
from	O
the	O
same	O
patient	O
.	O
A	O
second	O
patient	O
in	O
remission	O
from	O
HD	O
showed	O
evidence	O
of	O
co	O
-	O
existent	O
N	O
12	B-location
cysteine	B-state-generic
(	O
Cys	B-state-generic
)	O
and	O
N	O
13	B-location
valine	B-state-generic
(	O
Val	B-state-generic
)	O
substitutions	B-type
which	O
were	O
not	O
detected	O
in	O
presentation	O
material	O
or	O
unaffected	O
tissues	O
.	O
All	O
patients	O
are	O
currently	O
haematologically	O
normal	O
,	O
indicating	O
that	O
clones	O
of	O
mutant	O
RAS	O
bearing	O
cells	O
may	O
be	O
detected	O
prior	O
to	O
any	O
overt	O
sign	O
of	O
disease	O
.	O
PMID	O
:	O
2179819	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1990	O
Apr;94(	O
4)	O
:423	O
-	O
5	O
Ras	O
oncogene	O
mutations	O
in	O
basal	O
cell	O
carcinomas	O
and	O
squamous	O
cell	O
carcinomas	O
of	O
human	O
skin	O
.	O
van	O
der	O
Schroeff	O
JG	O
,	O
Evers	O
LM	O
,	O
Boot	O
AJ	O
,	O
Bos	O
JL.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Hospital	O
Leiden	O
,	O
The	O
Netherlands	O
.	O
Activated	O
ras	O
oncogenes	O
have	O
been	O
detected	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O
Activation	O
of	O
ras	O
oncogenes	O
usually	O
occurs	O
by	O
point	B-type
mutations	I-type
within	O
specific	O
codons	O
of	O
the	O
H-ras	O
,	O
N-ras	O
,	O
and	O
K-ras	O
genes	O
.	O
For	O
the	O
present	O
study	O
,	O
DNA	O
was	O
isolated	O
from	O
30	O
basal	O
cell	O
carcinomas	O
(	O
BCC	O
)	O
and	O
12	O
squamous	O
cell	O
carcinomas	O
(	O
SCC	O
)	O
.	O
After	O
amplification	O
of	O
genomic	O
DNA	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
the	O
occurrence	O
of	O
point	B-type
mutations	I-type
was	O
investigated	O
with	O
32P	O
-	O
labeled	O
synthetic	O
oligonucleotides	O
.	O
These	O
probes	O
are	O
complementary	O
to	O
the	O
known	O
point	O
-	O
mutated	O
nucleotide	O
sequences	O
of	O
the	O
ras	O
genes	O
.	O
In	O
four	O
out	O
of	O
the	O
30	O
BCC	O
studied	O
,	O
point	B-type
mutations	I-type
were	O
detected	O
at	O
codon	B-location
12	I-location
of	O
the	O
K-ras	O
gene	O
and	O
at	O
codon	B-location
61	I-location
of	O
the	O
H-ras	O
gene	O
.	O
The	O
K-ras	O
mutations	B-event
involve	O
glycine	B-state-original
to	O
cysteine	B-state-altered
and	O
glycine	B-state-original
to	O
asparagine	B-state-altered
amino	B-type
acid	I-type
changes	I-type
.	O
The	O
mutation	B-event
at	O
codon	B-location
61	I-location
of	O
the	O
H-ras	O
gene	O
is	O
consistent	O
with	O
a	O
replacement	O
of	O
glutamine	B-state-original
by	O
histidine	B-state-altered
.	O
In	O
one	O
SCC	O
,	O
a	O
point	B-type
mutation	I-type
was	O
detected	O
at	O
codon	B-location
12	I-location
of	O
the	O
K-ras	O
gene	O
,	O
involving	O
a	O
glycine	B-state-original
to	O
cysteine	B-state-altered
substitution	B-type
in	O
the	O
gene	O
product	O
.	O
These	O
findings	O
demonstrate	O
that	O
mutational	O
activation	O
of	O
ras	O
genes	O
takes	O
place	O
in	O
skin	O
carcinomas	O
,	O
but	O
the	O
rate	O
at	O
which	O
these	O
mutations	B-event
occur	O
seems	O
to	O
be	O
relatively	O
low	O
.	O
PMID	O
:	O
2179417	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Cancer	O
1991	O
Apr;63(	O
4)	O
:573	O
-	O
8	O
High	O
frequency	O
mutation	O
in	O
codons	B-location
12	I-location
and	O
61	B-location
of	O
H-ras	O
oncogene	O
in	O
chewing	O
tobacco	O
-	O
related	O
human	O
oral	O
carcinoma	O
in	O
India	O
.	O
Saranath	O
D	O
,	O
Chang	O
SE	O
,	O
Bhoite	O
LT	O
,	O
Panchal	O
RG	O
,	O
Kerr	O
IB	O
,	O
Mehta	O
AR	O
,	O
Johnson	O
NW	O
,	O
Deo	O
MG.	O
Cell	O
and	O
Developmental	O
Pathology	O
Division	O
,	O
Cancer	O
Research	O
Institute	O
,	O
Bombay	O
,	O
India	O
.	O
57	O
primary	O
tumour	O
samples	O
from	O
Indian	O
oral	O
cancer	O
patients	O
with	O
a	O
5	O
-	O
15	O
year	O
tobacco	O
chewing	O
habit	O
,	O
were	O
examined	O
for	O
mutational	O
activation	O
in	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
of	O
the	O
H-ras	O
,	O
K-ras	O
and	O
N-ras	O
oncogenes	O
.	O
The	O
highly	O
sensitive	O
assay	O
based	O
on	O
specific	O
oligonucleotide	O
hybridisation	O
following	O
in	O
vitro	O
amplification	O
of	O
unique	O
sequences	O
by	O
polymerase	O
chain	O
reaction	O
was	O
employed	O
.	O
Mutations	B-event
were	O
detected	O
in	O
twenty	O
(	O
35	O
%	O
)	O
of	O
the	O
samples	O
and	O
were	O
restricted	O
to	O
H-ras	O
,	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
.	O
Two	O
cases	O
had	O
concurrent	O
mutations	B-event
in	O
codons	B-location
12	I-location
and	O
61	B-location
.	O
The	O
majority	O
of	O
the	O
mutations	B-event
were	O
at	O
H-ras	O
61.2	B-location
(	O
Glutamine	B-state-original
to	O
Arginine	B-state-altered
)	O
and	O
H-ras	O
12.2	B-location
(	O
Glycine	B-state-original
to	O
Valine	B-state-altered
)	O
.	O
Three	O
of	O
the	O
less	O
frequent	O
mutations	B-event
are	O
apparently	O
novel	O
.	O
Interestingly	O
,	O
eight	O
of	O
the	O
samples	O
with	O
H-ras	O
mutations	O
also	O
showed	O
loss	O
of	O
wild	O
-	O
type	O
H-ras	O
,	O
as	O
judged	O
by	O
absence	O
of	O
signals	O
for	O
wild	O
-	O
type	O
codons	B-location
12	I-location
or	O
61	B-location
on	O
dot	O
blots	O
.	O
The	O
specific	O
H-ras	O
mutations	O
in	O
these	O
oral	O
malignancies	O
associated	O
with	O
tobacco	O
chewing	O
,	O
may	O
represent	O
an	O
important	O
example	O
of	O
an	O
environmental	O
carcinogen	O
-	O
induced	O
step	O
,	O
in	O
a	O
pathway	O
leading	O
to	O
malignant	O
transformation	O
.	O
PMID	O
:	O
2021541	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Jan	O
15;75(	O
2	O
)	O
:453	O
-	O
7	O
Alteration	O
of	O
N-ras	O
gene	O
mutation	O
after	O
relapse	O
in	O
acute	O
lymphoblastic	O
leukemia	O
.	O
Terada	O
N	O
,	O
Miyoshi	O
J,	O
Kawa	O
-	O
Ha	O
K	O
,	O
Sasai	O
H	O
,	O
Orita	O
S,	O
Yumura	O
-	O
Yagi	O
K	O
,	O
Hara	O
J,	O
Fujinami	O
A	O
,	O
Kakunaga	O
T.	O
Department	O
of	O
Oncogene	O
Research	O
,	O
Osaka	O
University	O
,	O
Japan	O
.	O
We	O
investigated	O
N-ras	O
activation	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
dALL	O
)	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
the	O
oligonucleotide	O
hybridization	O
method	O
.	O
The	O
frequency	O
of	O
point	B-type
-	I-type
mutation	I-type
of	O
the	O
N-ras	O
gene	O
was	O
not	O
high	O
(	O
2	O
of	O
15	O
)	O
,	O
and	O
one	O
positive	O
case	O
who	O
relapsed	O
was	O
analyzed	O
in	O
detail	O
.	O
Although	O
N-ras	O
gene	O
activation	O
was	O
detected	O
at	O
both	O
onset	O
and	O
relapse	O
,	O
the	O
mutation	O
sites	O
were	O
different	O
.	O
At	O
onset	O
,	O
Gly	B-state-original
(	O
GGT	B-state-original
)	O
was	O
changed	O
to	O
Ser	B-state-altered
(	O
AGT	B-state-altered
)	O
at	O
codon	B-location
12	I-location
,	O
and	O
at	O
relapse	O
,	O
Gly	B-state-original
(	O
GGT	B-state-original
)	O
to	O
Asp	B-state-altered
(	O
GAT	B-state-altered
)	O
was	O
observed	O
at	O
the	B-location
same	I-location
codon	I-location
.	O
In	O
addition	O
,	O
the	O
DNA	O
at	O
relapse	O
showed	O
a	O
remarkably	O
higher	O
transforming	O
activity	O
than	O
the	O
DNA	O
at	O
onset	O
on	O
two	O
independent	O
recipient	O
cell	O
lines	O
.	O
The	O
identical	O
cell	O
surface	O
phenotype	O
and	O
the	O
same	O
rearrangement	O
patterns	O
of	O
both	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
heavy	O
chain	O
and	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
gamma	O
chain	O
genes	O
indicated	O
that	O
the	O
leukemic	O
cells	O
at	O
onset	O
and	O
those	O
at	O
relapse	O
were	O
derived	O
from	O
the	O
same	O
precursor	O
cell	O
.	O
Therefore	O
,	O
this	O
case	O
supports	O
the	O
concept	O
that	O
ras	O
activation	O
is	O
not	O
the	O
event	O
initiating	O
leukemogenesis	O
,	O
but	O
may	O
be	O
involved	O
in	O
leukemic	O
progression	O
.	O
PMID	O
:	O
1967219	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1991	O
Sep;59(	O
3	O
)	O
:231	O
-	O
5	O
Low	O
incidence	O
of	O
Ha-ras	O
oncogene	O
mutations	O
in	O
human	O
epidermal	O
tumors	O
.	O
Lieu	O
FM	O
,	O
Yamanishi	O
K	O
,	O
Konishi	O
K	O
,	O
Kishimoto	O
S,	O
Yasuno	O
H.	O
Department	O
of	O
Dermatology	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
Activation	O
of	O
the	O
Ha-ras	O
oncogene	O
by	O
point	B-type
mutations	I-type
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
animal	O
skin	O
carcinogenesis	O
models	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
the	O
Ha-ras	O
mutations	O
in	O
human	O
epidermal	O
tumors	O
.	O
DNAs	O
from	O
paraffin	O
-	O
embedded	O
tissues	O
of	O
benign	O
and	O
malignant	O
human	O
epidermal	O
tumors	O
(	O
27	O
samples	O
from	O
25	O
patients	O
)	O
were	O
prepared	O
and	O
examined	O
for	O
point	B-type
mutations	I-type
of	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
of	O
Ha-ras	O
gene	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Only	O
one	O
sample	O
of	O
basal	O
cell	O
carcinoma	O
and	O
one	O
sample	O
of	O
keratoacanthoma	O
were	O
found	O
to	O
carry	O
an	O
A	B-state-original
to	O
T	B-state-altered
transversion	B-type
at	O
the	O
second	B-location
position	I-location
of	I-location
codon	I-location
61	I-location
.	O
This	O
low	O
incidence	O
of	O
Ha-ras	O
mutations	O
suggests	O
that	O
the	O
mutational	O
activation	O
of	O
the	O
gene	O
may	O
not	O
be	O
primarily	O
involved	O
in	O
human	O
epidermal	O
tumorigenesis	O
.	O
PMID	O
:	O
1913619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Cancer	O
1992	O
Feb	O
1;50(	O
3	O
)	O
:382	O
-	O
5	O
Infrequent	O
mutation	O
of	O
the	O
ras	O
genes	O
in	O
skin	O
tumors	O
of	O
xeroderma	O
pigmentosum	O
patients	O
in	O
Japan	O
.	O
Ishizaki	O
K	O
,	O
Tsujimura	O
T	O
,	O
Nakai	O
M,	O
Nishigori	O
C	O
,	O
Sato	O
K	O
,	O
Katayama	O
S,	O
Kurimura	O
O	O
,	O
Yoshikawa	O
K	O
,	O
Imamura	O
S,	O
Ikenaga	O
M.	O
Radiation	O
Biology	O
Center	O
,	O
Kyoto	O
University	O
,	O
Japan	O
.	O
By	O
using	O
PCR	O
amplification	O
and	O
oligonucleotide	O
mismatch	O
hybridization	O
,	O
base	B-type
-	I-type
substitution	I-type
mutations	O
of	O
the	O
ras	O
genes	O
in	O
26	O
skin	O
tumors	O
of	O
Japanese	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
patients	O
were	O
studied	O
.	O
Thin	O
sections	O
of	O
tumor	O
tissues	O
which	O
were	O
fixed	O
and	O
embedded	O
in	O
paraffin	O
blocks	O
were	O
used	O
in	O
this	O
study	O
.	O
After	O
analyzing	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
of	O
the	O
H	O
-	O
,	O
K	O
-	O
and	O
N	O
-	O
ras	O
genes	O
by	O
using	O
66	O
oligomer	O
probes	O
,	O
we	O
detected	O
only	O
one	O
mutation	B-event
of	O
the	O
K-ras	O
gene	O
at	O
codon	B-location
61	I-location
in	O
one	O
tumor	O
sample	O
.	O
All	O
the	O
other	O
tumors	O
were	O
therefore	O
considered	O
not	O
to	O
have	O
a	O
mutation	O
in	O
the	O
ras	O
genes	O
.	O
These	O
results	O
suggest	O
that	O
mutations	O
of	O
the	O
ras	O
genes	O
are	O
not	O
particularly	O
associated	O
with	O
skin	O
tumors	O
of	O
Japanese	O
XP	O
patients	O
.	O
PMID	O
:	O
1735606	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Keio	O
J	O
Med	O
1992	O
Jun;41(	O
2	O
)	O
:80	O
-	O
6	O
Detection	O
of	O
H-ras	O
gene	O
point	B-type
mutations	I-type
in	O
transitional	O
cell	O
carcinoma	O
of	O
human	O
urinary	O
bladder	O
using	O
polymerase	O
chain	O
reaction	O
.	O
Saito	O
S.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Keio	O
University	O
,	O
Tokyo	O
,	O
Japan	O
.	O
It	O
has	O
been	O
reported	O
that	O
the	O
H-ras	O
gene	O
is	O
activated	O
as	O
oncogene	O
in	O
human	O
bladder	O
cancer	O
cases	O
,	O
and	O
that	O
codon	B-location
12	I-location
and	O
codon	B-location
61	I-location
are	O
the	O
major	O
"	O
hot	O
spots	O
"	O
of	O
its	O
activation	O
.	O
A	O
simple	O
method	O
to	O
detect	O
point	B-type
mutations	I-type
in	O
these	O
codons	B-location
of	O
H-ras	O
gene	O
was	O
established	O
for	O
the	O
use	O
of	O
clinical	O
diagnosis	O
.	O
In	O
this	O
method	O
,	O
the	O
DNA	O
segments	O
including	O
codon	B-location
12	I-location
or	O
codon	B-location
61	I-location
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and	O
the	O
reaction	O
products	O
were	O
examined	O
for	O
their	O
susceptibility	O
to	O
the	O
restriction	O
enzyme	O
NaeI	O
or	O
BstNI	O
,	O
and	O
by	O
dot	O
blot	O
hybridization	O
assay	O
with	O
oligonucleotide	O
probes	O
.	O
Point	B-type
mutations	I-type
were	O
detectable	O
in	O
small	O
amounts	O
of	O
DNAs	O
isolated	O
from	O
fresh	O
or	O
frozen	O
tumor	O
tissues	O
,	O
urine	O
cells	O
and	O
paraffin	O
sections	O
.	O
The	O
method	O
was	O
applied	O
for	O
a	O
clinical	O
sample	O
and	O
a	O
case	O
that	O
had	O
a	O
point	B-type
mutation	I-type
at	O
codon	B-location
12	I-location
of	O
H-ras	O
gene	O
was	O
detected	O
.	O
The	O
point	B-type
mutation	I-type
was	O
existed	O
in	O
DNAs	O
of	O
primary	O
tumor	O
tissue	O
,	O
all	O
recurrent	O
tumor	O
tissues	O
and	O
cells	O
isolated	O
from	O
urine	O
of	O
this	O
case	O
.	O
PMID	O
:	O
1619852	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1992	O
May	O
15;52(	O
10	O
)	O
:2777	O
-	O
81	O
Clinical	O
implications	O
of	O
K-ras	O
mutations	O
in	O
malignant	O
epithelial	O
tumors	O
of	O
the	O
endometrium	O
.	O
Mizuuchi	O
H	O
,	O
Nasim	O
S,	O
Kudo	O
R,	O
Silverberg	O
SG	O
,	O
Greenhouse	O
S,	O
Garrett	O
CT.	O
Department	O
of	O
Pathology	O
,	O
George	O
Washington	O
University	O
,	O
Washington	O
,	O
DC	O
20037	O
.	O
Tumorigenesis	O
in	O
humans	O
and	O
experimental	O
animals	O
appears	O
to	O
involve	O
the	O
activation	O
of	O
ras	O
protooncogenes	O
for	O
a	O
number	O
of	O
organ	O
systems	O
and	O
seems	O
to	O
be	O
important	O
to	O
the	O
development	O
of	O
the	O
metastatic	O
phenotype	O
in	O
several	O
model	O
systems	O
.	O
Clinically	O
,	O
the	O
presence	O
of	O
activated	O
ras	O
protooncogenes	O
has	O
been	O
reported	O
to	O
be	O
a	O
negative	O
prognostic	O
factor	O
in	O
the	O
myelodysplastic	O
syndrome	O
and	O
in	O
adenocarcinoma	O
of	O
the	O
lung	O
.	O
In	O
the	O
present	O
study	O
we	O
examined	O
49	O
cases	O
of	O
endometrial	O
carcinoma	O
for	O
mutations	B-event
in	O
the	O
first	B-location
exon	I-location
of	O
K-ras	O
using	O
the	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O
Mutations	B-event
in	O
codon	B-location
12	I-location
or	O
13	B-location
of	O
K-ras	O
were	O
detected	O
in	O
6	O
of	O
49	O
cases	O
(	O
12.2	O
%	O
)	O
.	O
These	O
six	O
cases	O
consisted	O
of	O
five	O
endometrioid	O
endometrial	O
carcinomas	O
,	O
each	O
of	O
which	O
had	O
a	O
mutation	B-event
in	O
codon	B-location
12	I-location
,	O
and	O
one	O
case	O
of	O
clear	O
cell	O
carcinoma	O
,	O
which	O
had	O
a	O
mutation	B-event
in	O
codon	B-location
13	I-location
.	O
In	O
our	O
study	O
the	O
presence	O
of	O
mutations	O
in	O
K-ras	O
appeared	O
to	O
be	O
an	O
unfavorable	O
prognostic	O
factor	O
.	O
Three	O
of	O
six	O
patients	O
with	O
the	O
mutation	B-event
died	O
during	O
follow	O
-	O
up	O
,	O
while	O
only	O
7	O
%	O
of	O
the	O
43	O
patients	O
without	O
K-ras	O
mutations	O
expired	O
during	O
this	O
same	O
period	O
.	O
In	O
multivariate	O
analysis	O
using	O
the	O
Cox	O
proportional	O
hazard	O
model	O
,	O
K-ras	O
activation	O
appeared	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
when	O
compared	O
with	O
clinical	O
stage	O
,	O
depth	O
of	O
myometrial	O
invasion	O
,	O
and	O
patient	O
age	O
.	O
Thus	O
,	O
our	O
findings	O
support	O
the	O
hypothesis	O
that	O
K-ras	O
protooncogene	O
activation	O
plays	O
an	O
important	O
role	O
in	O
determining	O
the	O
aggressiveness	O
of	O
endometrial	O
carcinoma	O
.	O
PMID	O
:	O
1581890	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
1992	O
Nov;23(	O
11	O
)	O
:1199	O
-	O
204	O
Concurrent	O
mutations	O
of	O
coding	O
and	O
regulatory	O
sequences	O
of	O
the	O
Ha-ras	O
gene	O
in	O
urinary	O
bladder	O
carcinomas	O
.	O
Czerniak	O
B	O
,	O
Cohen	O
GL	O
,	O
Etkind	O
P	O
,	O
Deitch	O
D	O
,	O
Simmons	O
H	O
,	O
Herz	O
F	O
,	O
Koss	O
LG.	O
Department	O
of	O
Pathology	O
,	O
Montefiore	O
Medical	O
Center	O
,	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
Bronx	O
,	O
NY	O
10467	O
.	O
This	O
report	O
concerns	O
the	O
study	O
of	O
Ha-ras	O
gene	O
mutations	O
and	O
ras	O
p21	O
expression	O
in	O
primary	O
tumors	O
of	O
the	O
urinary	O
bladder	O
.	O
Polymerase	O
chain	O
reaction	O
-	O
based	O
techniques	O
and	O
computerized	O
image	O
analysis	O
were	O
used	O
.	O
The	O
data	O
obtained	O
were	O
related	O
to	O
tumor	O
grade	O
,	O
DNA	O
ploidy	O
,	O
and	O
tumor	O
invasion	O
.	O
A	O
point	B-type
mutation	I-type
(	O
G	B-state-original
-->	O
T	B-state-altered
)	O
at	O
Ha-ras	O
codon	B-location
12	I-location
was	O
found	O
in	O
30	O
of	O
67	O
tumors	O
.	O
The	O
mutation	O
frequency	O
was	O
greater	O
in	O
grade	O
III	O
(	O
65	O
%	O
)	O
than	O
in	O
grade	O
II	O
(	O
44	O
%	O
)	O
tumors	O
;	O
no	O
mutations	O
were	O
observed	O
in	O
grade	O
I	O
tumors	O
.	O
The	O
mutation	B-event
was	O
observed	O
more	O
often	O
in	O
aneuploid	O
(	O
58	O
%	O
)	O
than	O
in	O
diploid	O
(	O
28	O
%	O
)	O
tumors	O
.	O
No	O
other	O
substitution	B-type
at	O
codon	B-location
12	I-location
was	O
seen	O
and	O
no	O
codon	B-location
61	I-location
mutation	B-event
was	O
detected	O
.	O
The	O
tumors	O
were	O
also	O
tested	O
for	O
the	O
A	B-state-original
-->	O
G	B-state-altered
mutation	B-event
at	O
position	B-location
2719	I-location
of	I-location
Ha-ras	O
intron	B-location
D	I-location
.	O
Concurrent	O
codon	B-location
12	I-location
and	O
intron	B-location
D	I-location
mutations	B-event
were	O
identified	O
in	O
seven	O
high	O
-	O
grade	O
aneuploid	O
tumors	O
;	O
six	O
were	O
invasive	O
.	O
The	O
levels	O
of	O
the	O
ras	O
gene	O
product	O
p21	O
were	O
approximately	O
10	O
times	O
higher	O
in	O
tumors	O
with	O
intron	B-location
D	I-location
mutation	B-event
than	O
in	O
those	O
without	O
.	O
These	O
findings	O
confirm	O
on	O
human	O
bladder	O
tumors	O
the	O
observations	O
of	O
the	O
effect	O
of	O
synchronous	O
exon	O
-	O
intron	O
mutations	O
reported	O
on	O
the	O
bladder	O
cancer	O
cell	O
line	O
T24	O
.	O
Our	O
results	O
are	O
the	O
first	O
demonstration	O
of	O
Ha-ras	O
intron	B-location
D	I-location
alterations	B-event
in	O
human	O
tumor	O
tissues	O
and	O
suggest	O
that	O
concurrent	O
mutations	B-event
at	O
codon	B-location
12	I-location
and	O
intron	B-location
D	I-location
of	O
this	O
gene	O
within	O
the	O
same	O
tumor	O
may	O
contribute	O
to	O
the	O
aggressive	O
behavior	O
of	O
human	O
bladder	O
carcinomas	O
.	O
PMID	O
:	O
1427748	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Genes	O
Chromosomes	O
Cancer	O
1992	O
Sep;5(	O
2	O
)	O
:109	O
-	O
18	O
Detection	O
of	O
RAS	O
mutations	O
in	O
archival	O
testicular	O
germ	O
cell	O
tumors	O
by	O
polymerase	O
chain	O
reaction	O
and	O
oligonucleotide	O
hybridization	O
.	O
Moul	O
JW	O
,	O
Theune	O
SM	O
,	O
Chang	O
EH.	O
Department	O
of	O
Surgery	O
,	O
Uniformed	O
Services	O
University	O
of	O
the	O
Health	O
Sciences	O
,	O
Bethesda	O
,	O
Maryland	O
20814	O
-	O
4799	O
.	O
Preliminary	O
studies	O
of	O
RAS	O
mutational	O
activation	O
in	O
human	O
testicular	O
germ	O
cell	O
neoplasms	O
have	O
yielded	O
conflicting	O
results	O
.	O
Whereas	O
two	O
studies	O
of	O
clinical	O
material	O
revealed	O
a	O
significant	O
incidence	O
of	O
N	O
-	O
and	O
K	O
RAS	O
mutations	O
,	O
two	O
studies	O
of	O
a	O
variety	O
of	O
germ	O
cell	O
lines	O
failed	O
to	O
document	O
RAS	O
mutations	O
.	O
To	O
clarify	O
the	O
incidence	O
of	O
RAS	O
mutations	O
in	O
these	O
tumors	O
,	O
we	O
studied	O
archival	O
paraffin	O
-	O
embedded	O
,	O
formalin	O
-	O
fixed	O
orchiectomy	O
specimens	O
from	O
25	O
nonseminomas	O
(	O
NSGCT	O
)	O
,	O
18	O
seminomas	O
(	O
SEM	O
)	O
,	O
and	O
one	O
Leydig	O
cell	O
tumor	O
.	O
For	O
14	O
of	O
the	O
44	O
neoplasms	O
,	O
DNA	O
was	O
also	O
available	O
from	O
nonmalignant	O
testis	O
adjacent	O
to	O
the	O
tumor	O
.	O
Six	O
age	O
-	O
matched	O
patients	O
had	O
testes	O
removed	O
because	O
of	O
nonmalignant	O
disease	O
and	O
were	O
studied	O
as	O
controls	O
.	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
the	O
K	O
-	O
,	O
N	O
-	O
,	O
and	O
H	O
RAS	O
12	B-location
,	O
13	B-location
,	O
and	O
61	B-location
codons	I-location
of	O
these	O
specimens	O
,	O
and	O
mutations	B-event
were	O
detected	O
with	O
mutation	O
-	O
specific	O
oligonucleotide	O
probe	O
hybridization	O
of	O
Southern	O
and	O
slot	O
blots	O
.	O
Four	O
mutations	B-event
were	O
found	O
in	O
KRAS	O
12	B-location
(	O
4	O
/	O
44	O
;	O
[	O
9.1	O
%	O
]	O
)	O
.	O
One	O
seminoma	O
[	O
1	O
/	O
18	O
(	O
5.6	O
%	O
)	O
]	O
contained	O
the	O
mutation	B-event
GGT	B-state-original
(	O
GLY	B-state-original
)	O
----	O
CGT	B-state-altered
(	O
ARG	B-state-altered
)	O
,	O
and	O
three	O
NSGCT	O
[	O
3	O
/	O
25	O
(	O
12	O
%	O
)	O
]	O
were	O
found	O
to	O
have	O
GGT	B-state-original
(	O
GLY	B-state-original
)	O
----	O
GAT	B-state-altered
(	O
ASP	B-state-altered
)	O
mutations	B-event
.	O
One	O
of	O
the	O
NSGCT	O
mutations	B-event
was	O
detected	O
in	O
adjacent	O
nonmalignant	O
tissue	O
,	O
but	O
the	O
corresponding	O
tumor	O
did	O
not	O
contain	O
any	O
detectable	O
mutation	O
.	O
No	O
mutations	O
were	O
detected	O
at	O
KRAS	O
13	B-location
or	O
61	B-location
,	O
in	O
NRAS	O
or	O
HRAS	O
12	B-location
,	O
13	B-location
,	O
or	O
61	B-location
,	O
or	O
in	O
the	O
control	O
normal	O
testes	O
.	O
PCR	O
,	O
slot	O
blots	O
,	O
and	O
hybridizations	O
were	O
performed	O
twice	O
by	O
two	O
separate	O
investigators	O
for	O
confirmation	O
of	O
results	O
.	O
PCR	O
-	O
generated	O
mutation	O
-	O
specific	O
positive	O
controls	O
were	O
created	O
for	O
all	O
possible	O
RAS	O
mutations	O
,	O
and	O
these	O
along	O
with	O
wild	O
-	O
type	O
DNA	O
controls	O
were	O
integral	O
to	O
interpretation	O
of	O
the	O
oligonucleotide	O
mismatch	O
hybridization	O
assay	O
.	O
By	O
using	O
positive	O
and	O
negative	O
controls	O
,	O
we	O
have	O
detected	O
a	O
relatively	O
low	O
incidence	O
of	O
RAS	O
mutations	O
in	O
archival	O
human	O
testicular	O
germ	O
cell	O
tumors	O
.	O
PMID	O
:	O
1381946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Pancreatology	O
2002	O
;2	O
(	O
1	O
)	O
:17-25	O
Frequent	O
deletions	B-type
of	O
tumor	O
suppressor	O
genes	O
in	O
pure	O
pancreatic	O
juice	O
from	O
patients	O
with	O
tumoral	O
or	O
nontumoral	O
pancreatic	O
diseases	O
.	O
Costentin	O
L,	O
Pages	O
P,	O
Bouisson	O
M,	O
Berthelemy	O
P,	O
Buscail	O
L,	O
Escourrou	O
J,	O
Pradayrol	O
L,	O
Vaysse	O
N	O
.	O
INSERM	O
,	O
U531	O
Biologie	O
,	O
Pathologie	O
Digestive	O
et	O
Departement	O
de	O
Gastroenterologie	O
,	O
CHU	O
Rangueil	O
,	O
1	O
,	O
avenue	O
J.-Poulhes	O
F-31403	O
Toulouse	O
,	O
France	O
.	O
BACKGROUND	O
/	O
AIMS	O
:	O
K-ras	O
codon	B-location
12	I-location
mutation	O
is	O
the	O
most	O
frequent	O
genetic	O
alteration	O
in	O
pancreatic	O
cancer	O
.	O
Sensitivity	O
and	O
specificity	O
of	O
K-ras	O
are	O
not	O
high	O
enough	O
to	O
detect	O
all	O
pancreatic	O
cancers	O
,	O
especially	O
at	O
early	O
stage	O
.	O
This	O
study	O
investigated	O
whether	O
detection	O
of	O
p16	O
and/or	O
DPC4	O
deletions	B-type
along	O
with	O
K-ras	O
mutation	O
in	O
DNA	O
samples	O
could	O
improve	O
the	O
definition	O
of	O
patients	O
at	O
risk	O
of	O
pancreatic	O
cancer	O
.	O
METHODS	O
:	O
K-ras	O
mutations	O
were	O
investigated	O
by	O
sequencing	O
.	O
p16	O
and	O
DPC4	O
homozygous	O
deletions	B-type
were	O
studied	O
using	O
comparative	O
multiplex	O
polymerase	O
chain	O
reaction	O
of	O
DNA	O
in	O
pancreatic	O
juice	O
sampled	O
during	O
endoscopic	O
retrograde	O
pancreatography	O
in	O
57	O
patients	O
with	O
either	O
pancreatic	O
cancer	O
(	O
group	O
I	O
,	O
18	O
patients	O
)	O
,	O
chronic	O
pancreatitis	O
(	O
group	O
II	O
,	O
20	O
patients	O
)	O
,	O
or	O
nontumoral	O
pancreatobiliary	O
disease	O
(	O
group	O
III	O
,	O
19	O
patients	O
)	O
.	O
RESULTS	O
:	O
The	O
frequencies	O
of	O
Ki-ras	O
mutations	O
were	O
61	O
%	O
in	O
group	O
I	O
,	O
10	O
%	O
in	O
group	O
II	O
,	O
and	O
10.5	O
%	O
in	O
group	O
III	O
.	O
The	O
frequencies	O
of	O
p16	O
exon	B-location
2	I-location
and	O
DPC4	O
deletions	B-type
were	O
,	O
respectively	O
,	O
28	O
and	O
36	O
%	O
in	O
group	O
I	O
,	O
50	O
and	O
58	O
%	O
in	O
group	O
II	O
,	O
and	O
24	O
and	O
36	O
%	O
in	O
group	O
III	O
.	O
CONCLUSIONS	O
:	O
The	O
combination	O
of	O
p16	O
and	O
DPC4	O
deletions	B-type
with	O
K-ras	O
mutation	O
does	O
not	O
improve	O
the	O
diagnosis	O
of	O
pancreatic	O
cancer	O
based	O
on	O
K-ras	O
mutation	O
alone	O
.	O
These	O
data	O
suggest	O
that	O
tumor	O
suppressor	O
gene	O
inactivation	O
can	O
occur	O
with	O
a	O
high	O
frequency	O
during	O
nonmalignant	O
pancreatic	O
diseases	O
.	O
PMID	O
:	O
12120000	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Radiat	O
Oncol	O
Biol	O
Phys	O
1996	O
Jan	O
1;34(	O
1	O
)	O
:161	O
-	O
6	O
C-Ki-ras	O
mutations	O
in	O
peripheral	O
blood	O
of	O
pancreatic	O
cancer	O
patients	O
:	O
a	O
marker	O
for	O
early	O
tumor	O
metastasis	O
.	O
Mohiuddin	O
M,	O
Ahmed	O
MM	O
,	O
Venkatasubbarao	O
K.	O
Department	O
of	O
Radiation	O
Medicine	O
,	O
University	O
of	O
Kentucky	O
,	O
Lexington	O
40536	O
-0084	O
,	O
USA	O
.	O
PURPOSE	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
circulating	O
minimal	O
malignant	O
clone	O
(	O
CMMC	O
)	O
(	O
harboring	O
c-Ki-ras-2	O
mutation	O
)	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
samples	O
of	O
untreated	O
pancreatic	O
cancer	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
analysis	O
of	O
c-Ki-ras-2	O
oncogene	O
.	O
METHODS	O
AND	O
MATERIALS	O
:	O
Experiments	O
were	O
carried	O
out	O
in	O
fresh	O
tumor	O
,	O
peritoneal	O
washings	O
(	O
PW	O
)	O
,	O
and	O
PB	O
samples	O
of	O
untreated	O
pancreatic	O
adenocarcinoma	O
patients	O
(	O
both	O
resectable	O
and	O
unresectable	O
)	O
.	O
Samples	O
were	O
taken	O
from	O
16	O
patients	O
diagnosed	O
with	O
pancreatic	O
adenocarcinoma	O
for	O
the	O
PCR	O
analysis	O
of	O
mutated	O
c-Ki-ras	O
oncogene	O
.	O
Five	O
tumor	O
samples	O
,	O
15	O
PB	O
samples	O
,	O
and	O
3	O
PW	O
samples	O
were	O
analyzed	O
for	O
point	B-type
mutation	I-type
of	O
the	O
c-Ki-ras	O
gene	O
at	O
codon	B-location
12	I-location
.	O
RESULTS	O
:	O
Out	O
of	O
five	O
tumor	O
samples	O
analyzed	O
for	O
c-Ki-ras	O
mutation	O
,	O
four	O
were	O
positive	O
at	O
the	O
12th	B-location
codon	I-location
.	O
Out	O
of	O
total	O
15	O
PB	O
samples	O
,	O
nine	O
were	O
positive	O
for	O
the	O
c-Ki-ras	O
point	B-type
mutation	I-type
at	O
the	O
12th	B-location
codon	I-location
.	O
All	O
the	O
positive	O
PB	O
samples	O
showed	O
a	O
base	O
substitution	B-type
from	O
GGT	B-state-original
to	O
GAT	B-state-altered
in	O
the	O
second	B-location
position	I-location
of	I-location
the	I-location
12th	I-location
codon	I-location
.	O
Out	O
of	O
three	O
PW	O
samples	O
,	O
two	O
showed	O
mutation	B-event
at	O
the	O
second	B-location
position	I-location
from	O
GGT	B-state-original
to	O
GAT	B-state-altered
similar	O
to	O
their	O
PB	O
and	O
tumor	O
samples	O
.	O
CONCLUSION	O
:	O
Our	O
study	O
indicated	O
the	O
presence	O
of	O
the	O
tumor	O
cells	O
(	O
CMMC	O
)	O
in	O
PB	O
of	O
pancreatic	O
adenocarcinoma	O
that	O
can	O
be	O
identified	O
by	O
PCR	O
analysis	O
of	O
c-Ki-ras	O
oncogene	O
.	O
Patients	O
with	O
presence	O
of	O
CMMC	O
in	O
PB	O
and	O
mutation	O
in	O
PW	O
had	O
aggressive	O
tumors	O
that	O
responded	O
poorly	O
to	O
treatment	O
.	O
PMID	O
:	O
12118546	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
2002	O
Mar;9	O
3	O
(	O
3	O
)	O
:	O
267	O
-	O
74	O
Mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
in	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
of	O
adrenal	O
gland	O
.	O
Nakatsuka	O
S	O
,	O
Hongyo	O
T	O
,	O
Syaifudin	O
M,	O
Nomura	O
T	O
,	O
Shingu	O
N	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Suita	O
,	O
Osaka	O
56	O
5	O
-0871	O
,	O
Japan	O
.	O
Malignant	O
lymphoma	O
of	O
the	O
adrenal	O
gland	O
is	O
a	O
rare	O
disease	O
,	O
usually	O
with	O
diffuse	O
large	O
cell	O
morphology	O
and	O
B-cell	O
immunophenotype	O
,	O
and	O
often	O
associated	O
with	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
.	O
In	O
this	O
study	O
,	O
mutations	O
of	O
p53	O
,	O
c-kit	O
,	O
K-ras	O
,	O
and	O
beta-catenin	O
gene	O
were	O
analyzed	O
in	O
17	O
cases	O
(	O
13	O
males	O
and	O
four	O
females	O
with	O
ages	O
ranging	O
from	O
25	O
to	O
84	O
years	O
)	O
of	O
such	O
lymphomas	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
followed	O
by	O
direct	O
sequencing	O
.	O
Selected	O
exons	O
in	O
each	O
gene	O
,	O
representing	O
hot	O
spots	O
,	O
were	O
analyzed	O
.	O
All	O
44	O
mutations	O
detected	O
were	O
single	O
-	O
nucleotide	O
substitutions	B-type
and	O
33	O
were	O
missense	B-type
mutations	I-type
.	O
Nineteen	O
mutations	B-event
were	O
detected	O
in	O
exon	B-location
5	I-location
and	O
/	O
or	O
7	B-location
of	O
the	O
p53	O
gene	O
in	O
nine	O
of	O
17	O
cases	O
(	O
52.9	O
%	O
)	O
and	O
21	O
in	O
exon	B-location
11	I-location
and	O
/	O
or	O
17	B-location
of	O
the	O
c-kit	O
gene	O
in	O
10	O
of	O
14	O
cases	O
(	O
71.4	O
%	O
)	O
.	O
Bilateral	O
adrenal	O
lesions	O
in	O
one	O
case	O
who	O
had	O
not	O
received	O
any	O
adjuvant	O
therapy	O
showed	O
different	O
mutational	O
patterns	O
of	O
the	O
p53	O
and	O
c-kit	O
genes	O
,	O
suggesting	O
different	O
clonal	O
evolution	O
of	O
lymphoma	O
between	O
the	O
left	O
and	O
right	O
sides	O
.	O
Mutation	O
at	O
codon	B-location
13	I-location
of	O
the	O
K-ras	O
gene	O
was	O
detected	O
in	O
one	O
of	O
14	O
cases	O
(	O
7.1	O
%	O
)	O
,	O
and	O
in	O
exon	B-location
3	I-location
of	O
the	O
beta-catenin	O
gene	O
in	O
three	O
of	O
12	O
cases	O
(	O
25	O
%	O
)	O
.	O
All	O
but	O
one	O
mutation	O
were	O
transition	B-type
mutations	O
,	O
indicating	O
that	O
some	O
endogenous	O
mutagens	O
act	O
in	O
lymphomagenesis	O
in	O
the	O
adrenal	O
gland	O
.	O
Our	O
results	O
suggest	O
that	O
p53	O
and	O
c-kit	O
gene	O
mutations	O
might	O
play	O
a	O
role	O
in	O
adrenal	O
lymphomagenesis	O
.	O
PMID	O
:	O
11927008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
2002	O
Mar;82	O
(	O
3	O
)	O
:257	O
-64	O
Gene	O
mutations	O
in	O
lymphoproliferative	O
disorders	O
of	O
T	O
and	O
NK	O
/	O
T	O
cell	O
phenotypes	O
developing	O
in	O
renal	O
transplant	O
patients	O
.	O
Hoshida	O
Y	O
,	O
Hongyo	O
T	O
,	O
Nakatsuka	O
S	O
,	O
Nishiu	O
M,	O
Takakuwa	O
T	O
,	O
Tomita	O
Y	O
,	O
Nomura	O
T	O
,	O
Aozasa	O
K.	O
Department	O
of	O
Pathology	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
,	O
Osaka	O
,	O
Japan	O
.	O
Post	O
-	O
transplantation	O
lymphoproliferative	O
disorder	O
(	O
PT-LPD	O
)	O
is	O
characterized	O
by	O
lymphoid	O
proliferation	O
after	O
organ	O
or	O
bone	O
marrow	O
transplantation	O
.	O
In	O
Western	O
countries	O
,	O
most	O
cases	O
of	O
PT-LPD	O
are	O
B-cell	O
-	O
derived	O
and	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
,	O
in	O
which	O
alterations	O
of	O
c-myc	O
,	O
p53	O
,	O
and	O
N-ras	O
genes	O
might	O
play	O
a	O
role	O
in	O
disease	O
progression	O
.	O
In	O
Japan	O
,	O
PT-LPD	O
of	O
T	O
-	O
and	O
NK	O
/	O
T	O
-	O
cell	O
types	O
are	O
not	O
uncommon	O
in	O
renal	O
transplant	O
patients	O
.	O
Mutations	O
of	O
p53	O
(	O
exons	B-location
4	I-location
through	I-location
8	I-location
)	O
,	O
K-ras	O
(	O
exons	B-location
1	I-location
and	O
2	B-location
)	O
,	O
c-kit	O
(	O
exons	B-location
11	I-location
and	O
17	B-location
)	O
,	O
and	O
beta-catenin	O
genes	O
(	O
exon	B-location
3	I-location
)	O
in	O
12	O
cases	O
of	O
these	O
diseases	O
were	O
analyzed	O
by	O
PCR	O
single	O
strand	O
conformation	O
polymorphism	O
and	O
then	O
by	O
direct	O
sequencing	O
.	O
p53	O
gene	O
mutations	O
were	O
detected	O
in	O
5	O
of	O
5	O
cases	O
of	O
peripheral	O
T-cell	O
lymphoma	O
,	O
3	O
(	O
60	O
%	O
)	O
of	O
5	O
cases	O
of	O
adult	O
T-cell	O
leukemia	O
/	O
lymphoma	O
,	O
and	O
1	O
of	O
2	O
cases	O
of	O
NK	O
/	O
T	O
cell	O
lymphoma	O
.	O
Twenty-five	O
percent	O
of	O
T	O
and	O
NK	O
/	O
T	O
cell	O
lymphomas	O
showed	O
K-ras	O
mutations	O
.	O
Mutations	O
of	O
c-kit	O
and	O
beta-catenin	O
genes	O
were	O
found	O
in	O
33	O
%	O
of	O
cases	O
.	O
Among	O
a	O
total	O
of	O
42	O
substitution	B-type
mutations	O
,	O
40	O
were	O
transitions	B-type
with	O
involvement	O
of	O
CpG	O
sites	O
in	O
20	O
to	O
30	O
%	O
of	O
cases	O
.	O
Most	O
cases	O
had	O
at	O
least	O
one	O
mutation	O
that	O
changed	O
an	O
amino	O
acid	O
,	O
which	O
might	O
have	O
provided	O
the	O
selection	O
pressure	O
for	O
expansion	O
.	O
These	O
findings	O
suggested	O
that	O
p53	O
gene	O
mutations	O
might	O
play	O
a	O
central	O
role	O
in	O
development	O
of	O
peripheral	O
T-cell	O
lymphoma	O
including	O
adult	O
T-cell	O
leukemia	O
/	O
lymphoma	O
in	O
renal	O
transplant	O
patients	O
.	O
PMID	O
:	O
11896204	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2002	O
Jan	O
1;94	O
(	O
1	O
)	O
:	O
219	O
-	O
27	O
Detection	O
of	O
genetic	O
alterations	O
in	O
the	O
p53	O
suppressor	O
gene	O
and	O
the	O
K-ras	O
oncogene	O
among	O
different	O
grades	O
of	O
dysplasia	O
in	O
patients	O
with	O
colorectal	O
adenomas	O
.	O
Hosaka	O
S	O
,	O
Aoki	O
Y	O
,	O
Akamatsu	O
T	O
,	O
Nakamura	O
N	O
,	O
Hosaka	O
N	O
,	O
Kiyosawa	O
K.	O
Second	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Shinshu	O
University	O
School	O
of	O
Medicine	O
,	O
Matsumoto	O
,	O
Nagano	O
,	O
Japan	O
.	O
BACKGROUND	O
:	O
Although	O
it	O
is	O
believed	O
that	O
p53	O
suppressor	O
gene	O
mutations	O
,	O
compared	O
with	O
mutations	O
in	O
the	O
K-ras	O
oncogene	O
,	O
occur	O
at	O
a	O
later	O
stage	O
of	O
colorectal	O
tumorigenesis	O
,	O
the	O
distribution	O
of	O
these	O
genetic	O
alterations	O
at	O
an	O
early	O
stage	O
remains	O
poorly	O
characterized	O
.	O
METHODS	O
:	O
The	O
authors	O
analyzed	O
the	O
immunoreactivity	O
for	O
p53	O
protein	O
(	O
p53	O
protein	O
expression	O
)	O
,	O
which	O
reflects	O
the	O
functionally	O
altered	O
p53	O
gene	O
,	O
and	O
K-ras	O
mutations	O
at	O
codons	B-location
12	B-location
in	O
68	B-location
colorectal	O
adenomas	O
with	O
both	O
low	O
-	O
grade	O
and	O
high	O
-	O
grade	O
dysplasia	O
obtained	O
from	O
62	O
patients	O
.	O
RESULTS	O
:	O
The	O
prevalence	O
of	O
p53	O
positive	O
immunostaining	O
was	O
significantly	O
greater	O
compared	O
with	O
the	O
prevalence	O
of	O
K-ras	O
mutations	O
both	O
in	O
low	O
-	O
grade	O
dysplasia	O
and	O
in	O
high	O
-	O
grade	O
dysplasia	O
.	O
Twenty-two	O
adenomas	O
(	O
32.3	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
also	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
20	O
adenomas	O
(	O
29.4	O
%	O
)	O
showed	O
positive	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
negative	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
8	O
adenomas	O
(	O
11.7	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
high	O
-	O
grade	O
dysplasia	O
and	O
were	O
positive	O
for	O
p53	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
;	O
and	O
18	O
adenomas	O
(	O
26.4	O
%	O
)	O
showed	O
negative	O
immunostaining	O
for	O
p53	O
protein	O
in	O
both	O
high	O
-	O
grade	O
dysplasia	O
and	O
in	O
surrounding	O
low	O
-	O
grade	O
dysplastic	O
tissues	O
.	O
On	O
the	O
whole	O
,	O
a	O
significant	O
difference	O
(	O
P	O
<	O
0.05	O
)	O
was	O
seen	O
in	O
the	O
frequency	O
of	O
p53	O
positive	O
immunostaining	O
between	O
low	O
-	O
grade	O
dysplasia	O
and	O
high	O
-	O
grade	O
dysplasia	O
(	O
44.1	O
%	O
and	O
61.8	O
%	O
,	O
respectively	O
)	O
but	O
not	O
in	O
that	O
of	O
K-ras	O
mutations	O
(	O
20.3	O
%	O
and	O
23.4	O
%	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
mutation	O
of	O
the	O
p53	O
suppressor	O
gene	O
occurs	O
earlier	O
in	O
the	O
adenoma	O
-	O
carcinoma	O
sequence	O
than	O
K-ras	O
mutation	O
,	O
providing	O
a	O
clue	O
for	O
further	O
understanding	O
of	O
the	O
role	O
of	O
the	O
p53	O
gene	O
in	O
the	O
early	O
stage	O
of	O
colorectal	O
tumorigenesis	O
.	O
Copyright	O
2002	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11815980	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Virchows	O
Arch	O
2001	O
Dec;439	O
(	O
6	O
)	O
:	O
798-802	O
Genetic	O
profile	O
of	O
22	O
pancreatic	O
carcinoma	O
cell	O
lines	O
.	O
Analysis	O
of	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
/	O
Smad4	O
.	O
Moore	O
PS	O
,	O
Sipos	O
B	O
,	O
Orlandini	O
S	O
,	O
Sorio	O
C	O
,	O
Real	O
FX	O
,	O
Lemoine	O
NR	O
,	O
Gress	O
T	O
,	O
Bassi	O
C	O
,	O
Kloppel	O
G	O
,	O
Kalthoff	O
H,	O
Ungefroren	O
H,	O
Lohr	O
M,	O
Scarpa	O
A	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Verona	O
,	O
Italy	O
.	O
The	O
K-ras	O
,	O
p53	O
,	O
p16	O
and	O
DPC4	O
genes	O
are	O
among	O
those	O
most	O
frequently	O
altered	O
in	O
pancreatic	O
ductal	O
carcinoma	O
.	O
We	O
analyzed	O
22	O
cell	O
lines	O
for	O
alterations	O
in	O
these	O
genes	O
by	O
direct	O
sequence	O
analysis	O
and	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O
These	O
cell	O
lines	O
showed	O
mutations	O
in	O
K-ras	O
and	O
p53	O
at	O
frequencies	O
of	O
91	O
%	O
and	O
95	O
%	O
,	O
respectively	O
.	O
Alterations	B-event
in	O
p16INK4a	O
were	O
found	O
in	O
all	O
cases	O
and	O
included	O
nine	O
homozygous	B-type
deletions	I-type
,	O
seven	O
mutations	B-event
and	O
promoter	O
methylation	O
in	O
six	O
cases	O
.	O
Eight	O
cell	O
lines	O
(	O
36	O
%	O
)	O
had	O
an	O
alteration	O
of	O
DPC4	O
,	O
including	O
one	O
mutation	B-event
and	O
seven	O
homozygous	B-type
deletions	I-type
.	O
The	O
most	O
typical	O
mutational	O
profile	O
involved	O
K-ras	O
,	O
p53	O
,	O
and	O
p16INK4a	O
,	O
concurrently	O
aberrated	O
in	O
20	O
cases	O
(	O
91	O
%	O
)	O
.	O
Eight	O
cell	O
lines	O
had	O
alterations	O
in	O
all	O
four	O
genes	O
.	O
Inactivation	O
of	O
DPC4	O
was	O
always	O
accompanied	O
by	O
alteration	O
of	O
all	O
of	O
the	O
other	O
three	O
genes	O
.	O
This	O
comprehensive	O
data	O
regarding	O
the	O
cumulative	O
genetic	O
alterations	O
in	O
pancreatic	O
carcinoma	O
cell	O
lines	O
will	O
be	O
of	O
great	O
value	O
for	O
studies	O
involving	O
drug	O
sensitivity	O
or	O
resistance	O
that	O
may	O
be	O
associated	O
with	O
inactivation	O
of	O
a	O
particular	O
gene	O
or	O
molecular	O
pathway	O
.	O
PMID	O
:	O
11787853	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Lymphoma	O
2001	O
Jul;42(	O
3	O
)	O
:473	O
-	O
9	O
Lack	O
of	O
association	O
between	O
N-ras	O
gene	O
mutations	O
and	O
clinical	O
prognosis	O
in	O
Brazilian	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O
Clementino	O
NC	O
,	O
Yamamoto	O
M,	O
Viana	O
MB	O
,	O
Figueiredo	O
MS	O
,	O
Kerbauy	O
J,	O
Saad	O
ST	O
,	O
Costa	O
FF.	O
Federal	O
University	O
of	O
Sao	O
Paulo	O
,	O
UNIFESP-EPM	O
,	O
Federal	O
University	O
of	O
Minas	O
Gerais	O
,	O
UFMG	O
,	O
S.	O
Paulo	O
,	O
Brazil	O
.	O
Point	B-type
mutations	I-type
in	O
codons	B-location
12	B-location
,	O
13	B-location
and	O
61	B-location
of	O
the	O
N-ras	O
proto	O
-	O
oncogene	O
have	O
been	O
detected	O
in	O
several	O
human	O
malignancies	O
.	O
We	O
studied	O
170	O
patients	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
treated	O
from	O
1988	O
to	O
1994	O
according	O
to	O
a	O
protocol	O
derived	O
from	O
BFM-83	O
studies	O
,	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
and	O
prognostic	O
significance	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
childhood	O
ALL	O
.	O
DNA	O
was	O
extracted	O
from	O
bone	O
marrow	O
smears	O
at	O
diagnosis	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O
After	O
screening	O
with	O
SSCP	O
,	O
PCR	O
products	O
were	O
hybridized	O
with	O
allele	O
specific	O
probes	O
and	O
,	O
in	O
some	O
cases	O
,	O
cloned	O
in	O
a	O
pMOS	O
Blue	O
T	O
vector	O
and	O
sequenced	O
.	O
Exon	B-location
2	I-location
was	O
also	O
studied	O
in	O
101	O
children	O
.	O
Our	O
results	O
showed	O
4	O
%	O
of	O
mutations	B-event
in	O
codons	B-location
12	B-location
and	O
13	B-location
and	O
2	O
%	O
in	O
exon	B-location
2	I-location
.	O
Similar	O
to	O
a	O
previous	O
report	O
,	O
we	O
identified	O
7	O
%	O
of	O
mutations	O
among	O
children	O
who	O
were	O
studied	O
for	O
both	O
exons	O
.	O
A	O
new	O
mutation	B-event
in	O
codon	B-location
64	I-location
of	O
the	O
N-ras	O
gene	O
was	O
detected	O
in	O
one	O
patient	O
.	O
No	O
significant	O
clinical	O
differences	O
between	O
patients	O
with	O
and	O
without	O
mutations	O
were	O
detected	O
(	O
sex	O
,	O
age	O
,	O
leukocyte	O
counts	O
at	O
diagnosis	O
,	O
nutritional	O
status	O
,	O
and	O
risk	O
factor	O
according	O
to	O
the	O
BFM	O
protocol	O
)	O
.	O
Children	O
with	O
mutations	O
in	O
codons	B-location
12	B-location
and	O
13	B-location
showed	O
significantly	O
higher	O
reactivity	O
to	O
PAS	O
staining	O
on	O
blast	O
cells	O
than	O
children	O
with	O
a	O
wild	O
type	O
N-ras	O
gene	O
configuration	O
.	O
Comparison	O
of	O
overall	O
-	O
and	O
recurrence	O
-	O
free	O
survival	O
did	O
not	O
show	O
significant	O
difference	O
between	O
groups	O
with	O
and	O
without	O
mutations	O
.	O
Our	O
results	O
suggest	O
that	O
mutations	O
in	O
the	O
ras	O
gene	O
are	O
infrequent	O
in	O
children	O
with	O
ALL	O
at	O
diagnosis	O
and	O
seem	O
to	O
be	O
of	O
low	O
prognostic	O
value	O
.	O
PMID	O
:	O
11699412	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
2001	O
Jul	O
1;9	O
2	O
(	O
1	O
)	O
:	O
136-45	O
beta-Catenin	O
mutation	O
and	O
overexpression	O
in	O
hepatocellular	O
carcinoma	O
:	O
clinicopathologic	O
and	O
prognostic	O
significance	O
.	O
Wong	O
CM	O
,	O
Fan	O
ST	O
,	O
Ng	O
IO	O
.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Hong	O
Kong	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
Pokfulam	O
,	O
Hong	O
Kong	O
.	O
BACKGROUND	O
:	O
beta-Catenin	O
has	O
been	O
recognized	O
as	O
a	O
critical	O
member	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
and	O
inappropriate	O
activation	O
of	O
this	O
pathway	O
has	O
been	O
implicated	O
in	O
carcinogenesis	O
.	O
METHODS	O
:	O
To	O
determine	O
the	O
clinical	O
significance	O
of	O
beta-catenin	O
in	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
,	O
we	O
performed	O
mutational	O
analysis	O
at	O
exon	B-location
3	I-location
of	O
the	O
gene	O
,	O
investigated	O
the	O
subcellular	O
protein	O
expression	O
,	O
and	O
analyzed	O
their	O
clinicopathologic	O
and	O
prognostic	O
significance	O
in	O
60	O
patients	O
with	O
resected	O
primary	O
HCC	O
.	O
RESULTS	O
:	O
By	O
direct	O
DNA	O
sequencing	O
,	O
somatic	O
mutations	B-event
of	O
the	O
beta-catenin	O
gene	O
were	O
detected	O
in	O
7	O
(	O
12	O
%	O
)	O
HCCs	O
.	O
All	O
the	O
mutations	B-event
were	O
found	O
at	O
the	O
region	O
(	O
exon	B-location
3	I-location
)	O
responsible	O
for	O
phosphorylation	O
and	O
ubiquitination	O
,	O
therefore	O
likely	O
to	O
result	O
in	O
stabilization	O
of	O
free	O
cytoplasmic	O
beta-catenin	O
.	O
Nuclear	O
accumulation	O
of	O
the	O
beta-catenin	O
protein	O
,	O
similar	O
to	O
the	O
response	O
to	O
the	O
Wnt	O
signal	O
,	O
was	O
found	O
in	O
10	O
(	O
17	O
%	O
)	O
HCCs	O
and	O
was	O
closely	O
associated	O
with	O
gene	O
mutation	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
the	O
remaining	O
cases	O
,	O
nonnuclear	O
type	O
overexpression	O
,	O
that	O
is	O
,	O
overexpression	O
in	O
the	O
cytoplasm	O
and/or	O
cytoplasmic	O
membrane	O
,	O
was	O
observed	O
in	O
31	O
(	O
62	O
%	O
)	O
HCCs	O
,	O
thus	O
suggesting	O
that	O
the	O
mechanisms	O
leading	O
to	O
beta-catenin	O
overexpression	O
may	O
be	O
heterogeneous	O
.	O
HCCs	O
with	O
a	O
nonnuclear	O
type	O
of	O
beta-catenin	O
overexpression	O
were	O
more	O
frequently	O
larger	O
than	O
5	O
cm	O
in	O
diameter	O
(	O
P	O
=	O
0.022	O
)	O
and	O
had	O
poorer	O
cellular	O
differentiation	O
(	O
P	O
=	O
0.037	O
)	O
,	O
and	O
the	O
patients	O
had	O
significantly	O
shorter	O
disease	O
-	O
free	O
survival	O
lengths	O
(	O
P	O
=	O
0.041	O
)	O
.	O
Review	O
of	O
the	O
data	O
from	O
previous	O
studies	O
in	O
HCC	O
showed	O
that	O
beta-catenin	O
mutations	O
were	O
more	O
frequent	O
in	O
HCV	O
-	O
associated	O
HCC	O
than	O
in	O
HBV	O
-	O
associated	O
ones	O
.	O
CONCLUSIONS	O
:	O
beta-catenin	O
mutation	O
and	O
deregulation	O
may	O
play	O
an	O
important	O
role	O
in	O
hepatocarcinogenesis	O
.	O
Nonnuclear	O
type	O
beta-catenin	O
overexpression	O
appeared	O
to	O
have	O
pathologic	O
and	O
prognostic	O
significance	O
.	O
Copyright	O
2001	O
American	O
Cancer	O
Society	O
.	O
PMID	O
:	O
11443619	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Exp	O
Mol	O
Pathol	O
2001	O
Jun;70	O
(	O
3	O
)	O
:195-200	O
Rapid	O
,	O
efficient	O
genotyping	O
of	O
clinical	O
tumor	O
samples	O
by	O
laser	O
-	O
capture	O
microdissection	O
/	O
PCR	O
/	O
SSCP	O
.	O
Dillon	O
D	O
,	O
Zheng	O
K,	O
Costa	O
J.	O
Department	O
of	O
Pathology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
,	O
Connecticut	O
06520	O
,	O
USA	O
.	O
Background	O
:	O
Mutation	O
analysis	O
is	O
becoming	O
increasingly	O
important	O
in	O
clinical	O
practice	O
,	O
since	O
sporadic	O
mutations	O
in	O
tumors	O
often	O
correlate	O
with	O
prognosis	O
and/or	O
therapeutic	O
response	O
.	O
However	O
,	O
the	O
labor	O
-	O
intensive	O
nature	O
of	O
the	O
molecular	O
analyses	O
has	O
limited	O
the	O
routine	O
clinical	O
use	O
of	O
tumor	O
genotyping	O
.	O
Laser	O
-	O
capture	O
microdissection	O
(	O
LCM	O
)	O
allows	O
procurement	O
of	O
relatively	O
pure	O
tumor	O
cell	O
populations	O
.	O
We	O
have	O
investigated	O
the	O
possibility	O
that	O
the	O
use	O
of	O
laser	O
-	O
capture	O
microdissection	O
would	O
allow	O
elimination	O
of	O
time	O
-	O
consuming	O
intermediate	O
steps	O
in	O
tumor	O
genotyping	O
.	O
Design	O
.	O
Archival	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
seven	O
cases	O
of	O
colorectal	O
adenocarcinoma	O
were	O
laser	O
-	O
and	O
hand	O
-	O
microdissected	O
and	O
subsequently	O
evaluated	O
by	O
PCR	O
/	O
SSCP	O
/	O
sequencing	O
for	O
Ki-ras	O
exon	B-location
1	I-location
and	O
p53	O
exons	B-location
5	B-location
,	O
7	B-location
,	O
and	O
8	B-location
.	O
Results	O
.	O
Mutations	B-event
in	O
Ki-ras	O
exon	B-location
1	I-location
and/or	O
p53	O
exons	B-location
5	B-location
and	O
7	B-location
were	O
detected	O
in	O
five	O
of	O
the	O
seven	O
samples	O
.	O
In	O
the	O
hand	O
-	O
microdissected	O
samples	O
,	O
confident	O
identification	O
of	O
mutations	O
was	O
possible	O
in	O
several	O
cases	O
only	O
after	O
band	O
excision	O
,	O
DNA	O
elution	O
,	O
reamplification	O
,	O
and	O
verification	O
of	O
mutant	O
enrichment	O
by	O
a	O
second	O
SSCP	O
analysis	O
prior	O
to	O
sequencing	O
.	O
In	O
the	O
laser	O
-	O
microdissected	O
samples	O
,	O
confident	O
mutation	O
identification	O
was	O
possible	O
in	O
all	O
cases	O
with	O
direct	O
sequencing	O
of	O
the	O
original	O
PCR	O
product	O
,	O
reducing	O
the	O
time	O
required	O
for	O
molecular	O
analysis	O
to	O
3	O
days	O
.	O
Conclusion	O
.	O
Using	O
laser	O
-	O
capture	O
microdissection	O
,	O
mutant	O
signals	O
are	O
strong	O
enough	O
to	O
sequence	O
directly	O
from	O
original	O
PCR	O
products	O
.	O
With	O
rapid	O
,	O
efficient	O
genotyping	O
by	O
LCM	O
/	O
PCR	O
/	O
SSCP	O
,	O
results	O
can	O
be	O
incorporated	O
directly	O
into	O
the	O
surgical	O
pathology	O
report	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
PMID	O
:	O
11417998	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Nov;45(	O
11	O
)	O
:2187	O
-	O
94	O
No	O
major	O
difference	O
in	O
K-ras	O
and	O
p53	O
abnormalities	O
in	O
sporadic	O
and	O
hereditary	O
nonpolyposis	O
colorectal	O
adenomas	O
.	O
Voskuil	O
DW	O
,	O
Kampman	O
E	O
,	O
van	O
Geloof	O
W	O
,	O
Grubben	O
M,	O
Kok	O
F	O
,	O
van	O
Muijen	O
G	O
,	O
Nagengast	O
F	O
,	O
Vasen	O
H	O
,	O
van't	O
Veer	O
P.	O
Division	O
of	O
Human	O
Nutrition	O
and	O
Epidemiology	O
,	O
Wageningen	O
University	O
,	O
The	O
Netherlands	O
.	O
K-ras	O
and	O
p53	O
gene	O
mutations	O
are	O
known	O
to	O
occur	O
in	O
high	O
frequencies	O
in	O
sporadic	O
colorectal	O
cancers	O
,	O
but	O
findings	O
are	O
inconsistent	O
in	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
(	O
HNPCC	O
)	O
.	O
We	O
compared	O
K-ras	O
codon	B-location
12	I-location
and	O
13	B-location
gene	O
mutations	B-event
and	O
p53	O
protein	O
overexpression	O
in	O
48	O
HNPCC	O
(	O
positive	O
for	O
Amsterdam	O
criteria	O
)	O
and	O
59	O
sporadic	O
colorectal	O
adenomas	O
,	O
to	O
examine	O
whether	O
they	O
may	O
represent	O
similar	O
or	O
different	O
molecular	O
pathways	O
to	O
cancer	O
.	O
In	O
sporadic	O
adenomas	O
K-ras	O
mutations	O
were	O
detected	O
in	O
32	O
%	O
and	O
p53	O
overexpression	O
in	O
31	O
%	O
of	O
the	O
cases	O
.	O
Similarly	O
,	O
K-ras	O
mutations	O
and	O
p53	O
overexpression	O
were	O
both	O
found	O
in	O
25	O
%	O
of	O
HNPCC	O
adenomas	O
.	O
The	O
frequencies	O
of	O
these	O
abnormalities	O
were	O
not	O
significantly	O
different	O
between	O
HNPCC	O
and	O
sporadic	O
adenomas	O
.	O
When	O
taking	O
differences	O
in	O
adenoma	O
size	O
into	O
account	O
,	O
the	O
frequencies	O
were	O
even	O
more	O
similar	O
.	O
In	O
conclusion	O
,	O
these	O
results	O
suggest	O
a	O
similar	O
molecular	O
pathway	O
to	O
adenomas	O
in	O
HNPCC	O
and	O
sporadic	O
carcinogenesis	O
,	O
with	O
respect	O
to	O
involvement	O
of	O
K-ras	O
and	O
p53	O
.	O
PMID	O
:	O
11215737	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dig	O
Dis	O
Sci	O
2000	O
Oct;45(	O
10	O
)	O
:2022	O
-	O
8	O
Combination	O
analysis	O
of	O
genetic	O
alterations	O
and	O
cell	O
proliferation	O
in	O
small	O
intestinal	O
carcinomas	O
.	O
Muneyuki	O
T	O
,	O
Watanabe	O
M,	O
Yamanaka	O
M,	O
Isaji	O
S,	O
Kawarada	O
Y	O
,	O
Yatani	O
R.	O
First	O
Department	O
of	O
Surgery	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Tsu	O
-	O
shi	O
,	O
Japan	O
.	O
We	O
analyzed	O
K-ras	O
and	O
p53	O
mutations	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
loss	B-type
of	I-type
heterozygosity	I-type
(	O
LOH	B-type
)	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
methods	O
,	O
as	O
well	O
as	O
p53	O
expression	O
and	O
the	O
Ki-67	O
labeling	O
index	O
(	O
LI	O
)	O
using	O
immunohistochemistry	O
in	O
10	O
duodenal	O
and	O
10	O
jejunal	O
/	O
ileal	O
carcinomas	O
.	O
K-ras	O
mutations	O
were	O
detected	O
in	O
two	O
duodenal	O
(	O
20	O
%	O
)	O
and	O
three	O
jejunal	O
/	O
ileal	O
(	O
30	O
%	O
)	O
carcinomas	O
and	O
p53	O
mutations	O
in	O
one	O
(	O
10	O
%	O
)	O
and	O
three	O
(	O
30	O
%	O
)	O
,	O
respectively	O
.	O
LOH	B-type
of	O
17p	B-location
was	O
detected	O
in	O
two	O
duodenal	O
(	O
20	O
%	O
)	O
and	O
two	O
jejunal	O
/	O
ileal	O
(	O
20	O
%	O
)	O
carcinomas	O
and	O
p53	O
expression	O
in	O
four	O
duodenal	O
(	O
40	O
%	O
)	O
and	O
four	O
jejunal	O
/	O
ileal	O
(	O
40	O
%	O
)	O
.	O
One	O
duodenal	O
(	O
10	O
%	O
)	O
and	O
two	O
jejunal	O
/	O
ileal	O
(	O
20	O
%	O
)	O
carcinomas	O
demonstrated	O
MSI	O
.	O
LOH	B-type
of	O
APC	O
was	O
detected	O
in	O
three	O
jejunal	O
/	O
ileal	O
(	O
30	O
%	O
)	O
,	O
but	O
none	O
of	O
the	O
duodenal	O
carcinomas	O
.	O
The	O
Ki-67	O
LI	O
was	O
44	O
%	O
in	O
duodenal	O
and	O
52.6	O
%	O
in	O
jejunal	O
/	O
ileal	O
carcinomas	O
.	O
A	O
subset	O
of	O
small	O
intestinal	O
carcinomas	O
showed	O
involvement	O
of	O
K-ras	O
and	O
p53	O
mutations	O
,	O
LOH	B-type
of	O
APC	O
,	O
and	O
MSI	O
.	O
A	O
difference	O
was	O
also	O
apparent	O
for	O
LOH	B-type
of	O
APC	O
between	O
duodenal	O
and	O
jejunal	O
/	O
ileal	O
carcinomas	O
.	O
PMID	O
:	O
11117578	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

J	O
Gastroenterol	O
Hepatol	O
2000	O
Oct;15(	O
10	O
)	O
:1151	O
-	O
7	O
Analysis	O
of	O
K-ras	O
codon	B-location
12	I-location
mutations	B-event
and	O
p53	O
overexpression	O
in	O
colorectal	O
nodule	O
-	O
aggregating	O
tumors	O
.	O
Kusaka	O
T	O
,	O
Fukui	O
H	O
,	O
Sano	O
Y	O
,	O
Ueda	O
Y	O
,	O
Chiba	O
T	O
,	O
Fujimori	O
T.	O
Department	O
of	O
Pathology	O
,	O
Dokkyo	O
University	O
School	O
of	O
Medicine	O
,	O
Shimotsuga	O
,	O
Tochigi	O
,	O
Japan	O
.	O
BACKGROUND	O
AND	O
AIMS	O
:	O
Morphologically	O
,	O
colorectal	O
nodule	O
-	O
aggregating	O
tumors	O
are	O
quite	O
different	O
from	O
polypoid	O
-	O
type	O
colorectal	O
tumors	O
that	O
develop	O
via	O
the	O
adenoma	O
-	O
carcinoma	O
sequence	O
.	O
Although	O
polypoid	O
-	O
type	O
colorectal	O
tumors	O
are	O
well	O
known	O
to	O
have	O
a	O
high	O
incidence	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
,	O
colorectal	O
nodule	O
-	O
aggregating	O
tumors	O
have	O
not	O
been	O
examined	O
in	O
terms	O
of	O
genetic	O
changes	O
and	O
clinicopathological	O
features	O
.	O
In	O
the	O
present	O
study	O
,	O
therefore	O
,	O
we	O
analysed	O
the	O
clinicopathological	O
features	O
,	O
genetic	B-event
changes	I-event
in	O
K-ras	O
codon	B-location
12	I-location
,	O
and	O
p53	O
overexpression	O
in	O
colorectal	O
nodule	O
-	O
aggregating	O
tumors	O
.	O
METHODS	O
:	O
A	O
total	O
of	O
18	O
colorectal	O
nodule	O
-	O
aggregating	O
tumors	O
were	O
surgically	O
resected	O
and	O
then	O
analysed	O
clinicopathologically	O
.	O
Immunohistochemistry	O
and	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformational	O
polymorphism	O
were	O
performed	O
to	O
analyse	O
p53	O
abnormalities	O
in	O
the	O
tumors	O
.	O
K-ras	O
codon	B-location
12	I-location
mutations	B-event
were	O
screened	O
out	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
and	O
analysed	O
by	O
fluorescence	O
direct	O
sequencing	O
.	O
RESULTS	O
:	O
p53	O
overexpression	O
was	O
observed	O
in	O
six	O
lesions	O
(	O
33	O
%	O
)	O
.	O
p53	O
-	O
overexpressing	O
cells	O
were	O
observed	O
in	O
parts	O
of	O
carcinoma	O
or	O
adenoma	O
showing	O
high	O
-	O
grade	O
atypia	O
.	O
Four	O
of	O
the	O
10	O
(	O
40	O
%	O
)	O
samples	O
had	O
a	O
p53	O
gene	O
mutation	O
.	O
Nine	O
of	O
the	O
18	O
(	O
50	O
%	O
)	O
samples	O
had	O
a	O
K-ras	O
codon	B-location
12	I-location
point	B-type
mutation	I-type
.	O
In	O
eight	O
cases	O
(	O
89	O
%	O
)	O
,	O
the	O
mutations	B-event
of	O
the	O
K-ras	O
codon	B-location
12	I-location
were	O
of	O
the	O
same	O
type	O
:	O
GGT	B-state-original
(	O
glycine	B-state-original
)	O
to	O
GTT	B-state-altered
(	O
valine	B-state-altered
)	O
.	O
CONCLUSIONS	O
:	O
The	O
colorectal	O
nodule	O
-	O
aggregating	O
tumor	O
has	O
distinctive	O
characteristics	O
showing	O
a	O
morphological	O
phenotype	O
of	O
the	O
superficial	O
-	O
type	O
tumors	O
and	O
genotype	O
of	O
the	O
polypoid	O
tumors	O
in	O
terms	O
of	O
K-ras	O
gene	O
mutation	O
and	O
p53	O
overexpression	O
.	O
PMID	O
:	O
11106095	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Am	O
J	O
Gastroenterol	O
2000	O
Oct;95(	O
10	O
)	O
:2953	O
-	O
7	O
Impact	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
on	O
survival	O
in	O
patients	O
with	O
left	O
-	O
and	O
right	O
-	O
sided	O
Dukes	O
'	O
C	O
colon	O
cancer	O
.	O
Bleeker	O
WA	O
,	O
Hayes	O
VM	O
,	O
Karrenbeld	O
A	O
,	O
Hofstra	O
RM	O
,	O
Hermans	O
J,	O
Buys	O
CC	O
,	O
Plukker	O
JT.	O
Department	O
of	O
Surgery	O
,	O
Medical	O
Genetics	O
and	O
Pathology	O
,	O
University	O
Hospital	O
Groningen	O
,	O
The	O
Netherlands	O
.	O
OBJECTIVE	O
:	O
It	O
has	O
been	O
suggested	O
that	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
might	O
influence	O
the	O
phenotypic	O
behavior	O
of	O
left	O
-	O
and	O
right	O
-	O
sided	O
colon	O
tumors	O
.	O
We	O
investigated	O
the	O
incidence	O
of	O
these	O
mutations	O
in	O
left	O
-	O
and	O
right	O
-	O
sided	O
colon	O
tumors	O
and	O
their	O
possible	O
influence	O
on	O
survival	O
in	O
a	O
homogeneous	O
group	O
of	O
patients	O
with	O
Dukes	O
'	O
C	O
colon	O
cancers	O
.	O
METHODS	O
:	O
The	O
primary	O
tumors	O
of	O
55	O
patients	O
with	O
a	O
sporadic	O
Dukes	O
'	O
C	O
colon	O
cancer	O
,	O
all	O
treated	O
with	O
adjuvant	O
chemotherapy	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
KRAS	O
and	O
TP53	O
mutations	O
.	O
Mutation	O
detection	O
of	O
the	O
KRAS	O
and	O
TP53	O
genes	O
was	O
performed	O
on	O
paraffin	O
-	O
embedded	O
tumor	O
material	O
,	O
using	O
denaturating	O
gradient	O
gel	O
electrophoresis	O
.	O
The	O
5	O
-	O
yr	O
survival	O
rates	O
of	O
KRAS	O
and	O
TP53	O
mutated	O
tumors	O
were	O
analyzed	O
regarding	O
right	O
-	O
sided	O
tumors	O
(	O
defined	O
as	O
tumors	O
up	O
to	O
the	O
splenic	O
flexure	O
)	O
and	O
left	O
-	O
sided	O
tumors	O
(	O
defined	O
as	O
tumors	O
from	O
the	O
splenic	O
flexure	O
to	O
the	O
rectosigmoid	O
peritoneal	O
reflection	O
)	O
.	O
RESULTS	O
:	O
KRAS	O
mutations	O
occurred	O
more	O
frequently	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
(	O
R	O
=	O
38	O
%	O
(	O
10	O
/	O
26	O
)	O
;	O
L	O
=	O
10	O
%	O
(	O
3	O
/	O
29	O
)	O
;	O
chi2	O
test	O
:	O
p	O
=	O
0.014	O
)	O
.	O
KRAS	O
mutations	O
did	O
not	O
influence	O
survival	O
in	O
patients	O
with	O
right	O
-	O
sided	O
colon	O
tumors	O
.	O
Patients	O
with	O
KRAS	O
mutation	O
-	O
negative	O
tumors	O
in	O
the	O
right	O
colon	O
,	O
however	O
,	O
had	O
a	O
significantly	O
worse	O
survival	O
than	O
patients	O
with	O
left	O
-	O
sided	O
KRAS	O
mutation	O
-	O
negative	O
tumors	O
(	O
5	O
-	O
yr	O
survival	O
;	O
R	O
:	O
34	O
%	O
vs	O
L	O
:	O
65	O
%	O
,	O
log	O
-	O
rank	O
test	O
:	O
p	O
=	O
0.007	O
)	O
.	O
TP53	O
mutations	O
of	O
a	O
possible	O
causative	O
nature	O
were	O
found	O
in	O
24	O
tumors	O
(	O
44	O
%	O
)	O
.	O
Neither	O
the	O
incidence	O
(	O
R	O
=	O
42	O
%	O
(	O
11	O
/	O
26	O
)	O
;	O
L	O
=	O
45	O
%	O
(	O
13	O
/	O
29	O
)	O
)	O
nor	O
the	O
survival	O
of	O
TP53	O
mutated	O
tumors	O
differed	O
significantly	O
between	O
left	O
-	O
and	O
right	O
-	O
sided	O
tumors	O
.	O
Furthermore	O
,	O
survival	O
of	O
patients	O
with	O
TP53	O
mutation	O
-	O
negative	O
tumors	O
did	O
not	O
differ	O
significantly	O
between	O
left	O
-	O
and	O
right	O
-	O
sided	O
tumors	O
.	O
CONCLUSIONS	O
:	O
There	O
seems	O
to	O
be	O
no	O
difference	O
in	O
survival	O
rate	O
between	O
patients	O
with	O
KRAS	O
mutated	O
and	O
KRAS	O
negative	O
Dukes	O
'	O
C	O
colon	O
tumors	O
;	O
however	O
,	O
KRAS	O
mutations	O
are	O
more	O
frequently	O
found	O
in	O
the	O
right	O
colon	O
compared	O
to	O
the	O
left	O
colon	O
.	O
TP53	O
mutations	O
do	O
not	O
have	O
predominance	O
for	O
either	O
side	O
of	O
the	O
colon	O
,	O
and	O
there	O
are	O
no	O
differences	O
in	O
survival	O
in	O
patients	O
with	O
left	O
-	O
sided	O
versus	O
right	O
-	O
sided	O
tumors	O
.	O
Patients	O
with	O
KRAS	O
-	O
nonmutated	O
tumors	O
in	O
the	O
right	O
colon	O
did	O
have	O
a	O
worse	O
survival	O
compared	O
to	O
those	O
with	O
such	O
tumors	O
in	O
the	O
left	O
colon	O
.	O
This	O
suggests	O
that	O
other	O
genetic	O
factors	O
may	O
play	O
a	O
role	O
in	O
tumor	O
genesis	O
in	O
this	O
subgroup	O
of	O
patients	O
.	O
PMID	O
:	O
11051374	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Mod	O
Pathol	O
2000	O
Oct;13(	O
10	O
)	O
:1066	O
-	O
71	O
Mutational	O
analysis	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
in	O
uterine	O
endometrioid	O
carcinoma	O
.	O
Schlosshauer	O
PW	O
,	O
Pirog	O
EC	O
,	O
Levine	O
RL	O
,	O
Ellenson	O
LH.	O
Department	O
of	O
Pathology	O
,	O
Joan	O
and	O
Sanford	O
I	O
.	O
Weill	O
Medical	O
College	O
of	O
Cornell	O
University	O
,	O
New	O
York	O
,	O
USA	O
.	O
Despite	O
recent	O
studies	O
,	O
the	O
molecular	O
genetic	O
events	O
responsible	O
for	O
the	O
development	O
of	O
uterine	O
endometrioid	O
carcinoma	O
(	O
UEC	O
)	O
remain	O
incompletely	O
characterized	O
.	O
Mutations	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
gene	O
have	O
been	O
recently	O
reported	O
in	O
a	O
small	O
percentage	O
of	O
UECs	O
and	O
in	O
the	O
endometrioid	O
variant	O
of	O
ovarian	O
carcinoma	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
involved	O
in	O
the	O
development	O
of	O
female	O
genital	O
tract	O
tumors	O
with	O
endometrioid	O
morphology	O
.	O
The	O
Wnt	O
pathway	O
is	O
a	O
critical	O
pathway	O
in	O
the	O
development	O
of	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
with	O
mutations	O
occurring	O
in	O
the	O
beta-catenin	O
(	O
CTNNB1	O
)	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
genes	O
in	O
10	O
to	O
15	O
%	O
and	O
85	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
Because	O
UEC	O
and	O
CRC	O
share	O
other	O
molecular	O
genetic	O
alterations	O
and	O
histologic	O
features	O
and	O
previous	O
studies	O
of	O
UEC	O
have	O
not	O
reported	O
an	O
analysis	O
of	O
the	O
APC	O
gene	O
,	O
we	O
chose	O
to	O
further	O
elucidate	O
the	O
role	O
of	O
the	O
Wnt	O
pathway	O
in	O
UEC	O
.	O
To	O
this	O
end	O
,	O
we	O
analyzed	O
32	O
cases	O
of	O
UEC	O
for	O
mutations	O
of	O
the	O
CTNNB1	O
and	O
APC	O
genes	O
.	O
Mutations	O
of	O
CTNNB1	O
were	O
present	O
in	O
six	O
of	O
32	O
(	O
18	O
%	O
)	O
cases	O
:	O
four	O
grade	O
1	O
carcinomas	O
,	O
one	O
grade	O
2	O
,	O
and	O
one	O
grade	O
3	O
carcinoma	O
.	O
Five	O
missense	B-type
mutations	I-type
were	O
identified	O
,	O
three	O
involving	O
Ser	O
/	O
Thr	O
phosphorylation	O
sites	O
and	O
two	O
adjacent	O
to	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
One	O
case	O
contained	O
a	O
deletion	B-type
encompassing	O
codons	B-location
34	I-location
to	I-location
37	I-location
,	O
which	O
includes	O
a	O
Ser	O
phosphorylation	O
site	O
.	O
No	O
mutations	B-event
resulting	O
in	O
truncation	O
of	O
the	O
APC	O
protein	O
were	O
found	O
.	O
Our	O
results	O
support	O
a	O
role	O
for	O
the	O
Wnt	O
signaling	O
pathway	O
via	O
mutation	O
of	O
CTNNB1	O
,	O
but	O
not	O
APC	O
,	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
UECs	O
.	O
PMID	O
:	O
11048799	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Pathol	O
Res	O
Pract	O
2000	O
;196(9	O
)	O
:601	O
-	O
5	O
Ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
analysis	O
in	O
cardiac	O
myxomas	O
.	O
Karga	O
H	O
,	O
Papaioannou	O
P	O
,	O
Karayianni	O
M,	O
Papadimitriou	O
K	O
,	O
Priftis	O
D	O
,	O
Voujuklakis	O
T	O
,	O
Migdou	O
B	O
,	O
Nanas	O
J,	O
Papapetrou	O
P.	O
Endocrine	O
Unit	O
,	O
Alexandra	O
Hospital	O
,	O
Athens	O
,	O
Greece	O
.	O
Although	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
are	O
implicated	O
in	O
the	O
development	O
of	O
several	O
human	O
tumors	O
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
the	O
pathogenesis	O
of	O
primary	O
cardiac	O
tumors	O
.	O
Paraffin	O
-	O
embedded	O
tissue	O
from	O
19	O
cardiac	O
myxomas	O
were	O
investigated	O
for	O
the	O
presence	O
of	O
ras	O
oncogenes	O
and	O
p53	O
tumor	O
suppressor	O
gene	O
abnormalities	O
.	O
Immunohistochemical	O
analysis	O
was	O
used	O
to	O
identify	O
the	O
accumulation	O
of	O
p21	O
-	O
ras	O
and	O
p53	O
proteins	O
.	O
A	O
polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
amplify	O
exons	B-location
1	I-location
and	O
2	B-location
of	O
the	O
ras	O
genes	O
and	O
exons	B-location
5	I-location
to	I-location
8	I-location
of	O
the	O
p53	O
gene	O
.	O
The	O
PCR	O
products	O
were	O
analyzed	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
by	O
direct	O
DNA	O
sequencing	O
.	O
Three	O
of	O
19	O
myxomas	O
showed	O
strong	O
positive	O
staining	O
for	O
the	O
ras	O
p21	O
protein	O
.	O
In	O
contrast	O
,	O
nuclear	O
p53	O
was	O
not	O
detectable	O
in	O
any	O
of	O
the	O
myxomas	O
.	O
Among	O
the	O
ras	O
p21	O
immunopositive	O
myxomas	O
,	O
2	O
were	O
heterozygous	O
for	O
a	O
missense	B-type
point	I-type
mutation	I-type
of	O
the	O
K-ras	O
,	O
Gly	B-state-original
12	B-location
Asp	B-state-altered
.	O
Further	O
screening	O
of	O
the	O
remaining	O
myxomas	O
showed	O
no	O
mutation	B-event
or	O
even	O
silent	O
polymorphism	O
in	O
any	O
exon	O
of	O
the	O
ras	O
and	O
p53	O
.	O
The	O
results	O
suggest	O
that	O
although	O
genetic	O
alterations	O
of	O
ras	O
oncogenes	O
and	O
p53	O
are	O
uncommon	O
events	O
in	O
cardiac	O
myxomas	O
,	O
ras	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
a	O
subgroup	O
of	O
this	O
type	O
of	O
tumor	O
.	O
PMID	O
:	O
10997733	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE	O
]	O

Arch	O
Pathol	O
Lab	O
Med	O
2000	O
Jun;124(	O
6)	O
:836	O
-	O
9	O
ras	O
gene	O
mutations	O
in	O
salivary	O
gland	O
tumors	O
.	O
Yoo	O
J,	O
Robinson	O
RA.	O
Department	O
of	O
Pathology	O
,	O
Catholic	O
University	O
,	O
St	O
Vincent	O
Hospital	O
,	O
Suwon	O
,	O
Republic	O
of	O
Korea	O
.	O
OBJECTIVE	O
:	O
To	O
assess	O
the	O
prevalence	O
of	O
activating	O
mutations	O
in	O
K-ras	O
and	O
H-ras	O
genes	O
in	O
salivary	O
gland	O
tumors	O
with	O
ductal	O
or	O
acinar	O
differentiation	O
and	O
to	O
evaluate	O
their	O
potential	O
correlation	O
with	O
clinical	O
parameters	O
.	O
DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
tissue	O
samples	O
of	O
salivary	O
gland	O
carcinomas	O
were	O
investigated	O
by	O
the	O
application	O
of	O
a	O
direct	O
sequence	O
analysis	O
procedure	O
with	O
automated	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
ras	O
sequences	O
.	O
SETTING	O
:	O
Tertiary	O
care	O
teaching	O
hospital	O
.	O
PATIENTS	O
:	O
Twenty-four	O
patients	O
with	O
salivary	O
gland	O
carcinoma	O
were	O
surgically	O
treated	O
.	O
Nine	O
had	O
adenocarcinoma	O
,	O
1	O
had	O
adenosquamous	O
carcinoma	O
,	O
11	O
had	O
mucoepidermoid	O
carcinoma	O
,	O
and	O
3	O
had	O
acinic	O
cell	O
carcinoma	O
.	O
RESULTS	O
:	O
Point	B-type
mutations	I-type
were	O
detected	O
in	O
7	O
(	O
29	O
%	O
)	O
of	O
the	O
24	O
carcinomas	O
examined	O
.	O
The	O
K-ras	O
gene	O
was	O
mutated	O
in	O
only	O
2	O
samples	O
(	O
8	O
%	O
)	O
:	O
a	O
GGC	B-state-original
-	O
to	O
-	O
ATC	B-state-altered
mutation	B-event
at	O
codon	B-location
13	I-location
in	O
an	O
adenocarcinoma	O
and	O
a	O
GGC	B-state-original
-	O
to	O
-	O
GTC	B-state-altered
transversion	B-type
mutation	B-event
at	O
codon	B-location
13	I-location
in	O
a	O
mucoepidermoid	O
carcinoma	O
.	O
Five	O
(	O
21	O
%	O
)	O
harbored	O
H-ras	O
mutations	O
:	O
4	O
contained	O
a	O
GGC	B-state-original
-	O
to	O
-	O
GTC	B-state-altered
transversion	B-type
mutation	B-event
at	O
codon	B-location
12	I-location
and	O
1	O
had	O
2	O
distinct	O
mutations	B-event
,	O
the	O
same	O
G	B-state-original
-	O
to	O
-	O
T	B-state-altered
at	O
codon	B-location
12	I-location
as	O
was	O
shown	O
in	O
the	O
other	O
cases	O
and	O
a	O
GGT	B-state-original
-	O
to	O
-	O
GGA	B-state-altered
heterozygous	O
mutation	O
at	O
codon	B-location
13	I-location
.	O
All	O
the	O
H-ras	O
mutations	O
were	O
in	O
the	O
group	O
of	O
mucoepidermoid	O
carcinoma	O
lesions	O
(	O
45	O
%	O
;	O
5	O
/	O
11	O
)	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
K-ras	O
gene	O
alteration	O
is	O
probably	O
not	O
an	O
important	O
factor	O
in	O
the	O
oncogenesis	O
of	O
human	O
salivary	O
gland	O
tumors	O
.	O
However	O
,	O
mutational	O
activation	O
of	O
the	O
H-ras	O
gene	O
appears	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
salivary	O
gland	O
mucoepidermoid	O
carcinomas	O
.	O
PMID	O
:	O
10835516	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
2000	O
Apr	O
1;60(	O
7)	O
:1800	O
-	O
4	O
Relative	O
reciprocity	O
of	O
NRAS	O
and	O
PTEN	O
/	O
MMAC1	O
alterations	O
in	O
cutaneous	O
melanoma	O
cell	O
lines	O
.	O
Tsao	O
H	O
,	O
Zhang	O
X	O
,	O
Fowlkes	O
K	O
,	O
Haluska	O
FG.	O
Department	O
of	O
Dermatology	O
,	O
Massachusetts	O
General	O
Hospital	O
and	O
Dana	O
-	O
Farber	O
/	O
Partners	O
CancerCare	O
,	O
Boston	O
02114	O
,	O
USA	O
.	O
Both	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
,	O
PTEN	O
/	O
MMAC1	O
,	O
and	O
oncogenic	O
activation	O
of	O
RAS	O
have	O
been	O
described	O
in	O
human	O
cutaneous	O
melanoma	O
.	O
In	O
mice	O
,	O
activation	O
of	O
a	O
RAS	O
-	O
containing	O
pathway	O
is	O
a	O
necessary	O
step	O
in	O
the	O
pathogenesis	O
of	O
murine	O
melanomas	O
.	O
Because	O
PTEN	O
negatively	O
regulates	O
on	O
the	O
downstream	O
effects	O
of	O
phosphatidylinositol-3-kinase	O
(	O
PI3-K	O
)	O
,	O
we	O
hypothesized	O
that	O
the	O
loss	B-type
of	O
PTEN	O
/	O
MMAC1	O
and	O
the	O
activation	O
of	O
RAS	O
may	O
be	O
largely	O
equivalent	O
because	O
RAS	O
is	O
a	O
known	O
positive	O
upstream	O
regulator	O
of	O
PI3-K	O
.	O
We	O
expanded	O
our	O
previous	O
survey	O
of	O
PTEN	O
/	O
MMAC1	O
mutations	O
and	O
analyzed	O
the	O
RAS	O
status	O
of	O
53	O
cutaneous	O
melanoma	O
cell	O
lines	O
,	O
18	O
glioma	O
cell	O
lines	O
,	O
and	O
17	O
uncultured	O
cutaneous	O
melanoma	O
metastasis	O
.	O
Overall	O
,	O
51	O
%	O
of	O
the	O
cell	O
lines	O
had	O
alterations	O
in	O
either	O
PTEN	O
/	O
MMAC1	O
or	O
RAS	O
.	O
We	O
found	O
16	O
cell	O
lines	O
(	O
30	O
%	O
)	O
with	O
alterations	O
in	O
PTEN	O
/	O
MMAC1	O
and	O
11	O
cell	O
lines	O
(	O
21	O
%	O
)	O
with	O
activating	O
NRAS	O
mutations	O
;	O
only	O
1	O
cell	O
line	O
had	O
concurrent	O
alterations	O
in	O
both	O
genes	O
.	O
Moreover	O
,	O
glioma	O
cell	O
lines	O
with	O
a	O
high	O
frequency	O
of	O
PTEN	O
/	O
MMAC1	O
inactivation	O
had	O
no	O
identifiable	O
RAS	O
alterations	O
.	O
Ectopic	O
expression	O
of	O
PTEN	O
in	O
several	O
cutaneous	O
melanoma	O
cell	O
lines	O
suppressed	O
colony	O
formation	O
irrespective	O
of	O
PTEN	O
/	O
MMAC1	O
status	O
;	O
furthermore	O
,	O
PTEN	O
expression	O
in	O
cell	O
lines	O
carrying	O
activated	O
RAS	O
also	O
suppressed	O
colony	O
formation	O
.	O
The	O
relative	O
reciprocity	O
of	O
PTEN	O
/	O
MMAC1	O
abrogation	O
and	O
NRAS	O
activation	O
suggests	O
that	O
the	O
two	O
genetic	O
changes	O
,	O
in	O
a	O
subset	O
of	O
cutaneous	O
melanomas	O
,	O
are	O
functionally	O
overlapping	O
.	O
PMID	O
:	O
10766161	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Clin	O
Chem	O
Lab	O
Med	O
1999	O
Jul;37(	O
7)	O
:723	O
-	O
7	O
A	O
relationship	O
between	O
K-ras	O
gene	O
mutations	O
and	O
some	O
clinical	O
and	O
histologic	O
variables	O
in	O
patients	O
with	O
primary	O
colorectal	O
carcinoma	O
.	O
Beranek	O
M,	O
Bures	O
J,	O
Palicka	O
V	O
,	O
Jandik	O
P	O
,	O
Langr	O
F	O
,	O
Nejedla	O
E.	O
Institute	O
of	O
Clinical	O
Biochemistry	O
and	O
Diagnostics	O
,	O
University	O
Hospital	O
,	O
Hradec	O
Kralove	O
,	O
Czech	O
Republic	O
.	O
Mutations	O
in	O
the	O
Kirsten	O
ras	O
2	O
(	O
K-ras	O
)	O
gene	O
were	O
described	O
as	O
early	O
events	O
in	O
the	O
process	O
of	O
colorectal	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
a	O
possible	O
relationship	O
between	O
the	O
presence	O
of	O
K-ras	O
mutation	O
in	O
samples	O
of	O
primary	O
colorectal	O
carcinomas	O
and	O
the	O
clinico	O
-	O
pathological	O
data	O
of	O
the	O
investigated	O
patients	O
.	O
Mutation	O
in	O
codon	B-location
12	I-location
of	O
the	O
K-ras	O
gene	O
was	O
determined	O
in	O
18	O
of	O
53	O
colorectal	O
carcinomas	O
(	O
34	O
%	O
)	O
in	O
our	O
group	O
of	O
patients	O
.	O
The	O
presence	O
of	O
K-ras	O
gene	O
mutations	O
was	O
not	O
related	O
to	O
gender	O
,	O
age	O
of	O
subject	O
at	O
diagnosis	O
,	O
staging	O
or	O
cancer	O
location	O
(	O
p	O
>	O
0.05	O
)	O
.	O
Sixteen	O
of	O
the	O
42	O
(	O
38	O
%	O
)	O
moderately	O
differentiated	O
carcinomas	O
,	O
and	O
two	O
of	O
the	O
eight	O
(	O
25	O
%	O
)	O
well	O
differentiated	O
carcinomas	O
contained	O
K-ras	O
mutation	O
in	O
codon	B-location
12	I-location
,	O
but	O
none	O
of	O
the	O
three	O
poorly	O
differentiated	O
carcinomas	O
contained	O
the	O
mutation	B-event
.	O
Moderately	O
differentiated	O
tumours	O
contained	O
an	O
aspartate	B-state-generic
code	O
GAT	B-state-generic
(	O
in	O
eight	O
cases	O
)	O
,	O
a	O
valine	B-state-generic
code	O
GTT	B-state-generic
(	O
in	O
six	O
cases	O
)	O
,	O
an	O
alanine	B-state-generic
code	O
GCT	B-state-generic
(	O
in	O
one	O
case	O
)	O
and	O
a	O
serine	B-state-generic
code	O
AGT	B-state-generic
(	O
in	O
one	O
case	O
)	O
in	O
codon	B-location
12	I-location
.	O
Well	O
differentiated	O
tumours	O
contained	O
only	O
the	O
valine	B-state-generic
code	O
GTT	B-state-generic
(	O
two	O
cases	O
)	O
.	O
Our	O
results	O
show	O
that	O
the	O
frequency	O
of	O
mutations	O
in	O
the	O
K-ras	O
gene	O
in	O
carcinomas	O
in	O
Central	O
Europe	O
is	O
not	O
different	O
from	O
the	O
frequencies	O
found	O
in	O
other	O
parts	O
of	O
the	O
world	O
.	O
The	O
homogeneous	O
incidence	O
of	O
K-ras	O
mutation	O
does	O
not	O
seem	O
to	O
be	O
related	O
to	O
ethnic	O
factors	O
,	O
dietary	O
habits	O
,	O
or	O
the	O
composition	O
of	O
the	O
diet	O
.	O
PMID	O
:	O
10510729	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Sep	O
1;59(	O
17	O
)	O
:4257	O
-	O
60	O
Frequent	O
somatic	O
mutations	O
of	O
the	O
beta-catenin	O
gene	O
in	O
intestinal	O
-	O
type	O
gastric	O
cancer	O
.	O
Park	O
WS	O
,	O
Oh	O
RR	O
,	O
Park	O
JY	O
,	O
Lee	O
SH	O
,	O
Shin	O
MS	O
,	O
Kim	O
YS	O
,	O
Kim	O
SY	O
,	O
Lee	O
HK	O
,	O
Kim	O
PJ	O
,	O
Oh	O
ST	O
,	O
Yoo	O
NJ	O
,	O
Lee	O
JY	O
.	O
Department	O
of	O
Pathology	O
and	O
Cancer	O
Research	O
Institute	O
,	O
Catholic	O
University	O
Medical	O
College	O
,	O
Seoul	O
,	O
Korea	O
.	O
The	O
increased	O
level	O
of	O
cytoplasmic	O
beta-catenin	O
through	O
the	O
mutations	O
to	O
either	O
beta-catenin	O
or	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
has	O
been	O
proposed	O
as	O
an	O
important	O
oncogenic	O
step	O
in	O
various	O
tumors	O
.	O
Gastric	O
cancer	O
showed	O
frequent	O
genetic	O
alterations	O
of	O
the	O
APC	O
gene	O
,	O
and	O
the	O
risk	O
for	O
gastric	O
cancer	O
in	O
familial	O
adenomatosus	O
polyposis	O
patients	O
is	O
10	O
times	O
higher	O
than	O
that	O
in	O
the	O
general	O
population	O
.	O
These	O
findings	O
raise	O
the	O
possibility	O
that	O
mutations	O
of	O
beta-catenin	O
may	O
also	O
be	O
associated	O
with	O
the	O
development	O
of	O
gastric	O
cancer	O
.	O
We	O
detected	O
seven	O
somatic	O
mutations	B-event
in	O
a	O
portion	O
of	O
exon	B-location
3	I-location
encoding	O
for	O
the	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
consensus	O
region	O
of	O
the	O
beta-catenin	O
gene	O
in	O
43	O
gastric	O
cancers	O
.	O
All	O
of	O
these	O
mutations	B-event
were	O
missense	B-type
mutations	I-type
,	O
of	O
which	O
five	O
are	O
in	O
the	O
highly	O
conserved	O
aspartic	B-state-original
acid	I-state-original
32	B-location
and	O
two	O
are	O
in	O
serine	B-state-original
29	B-location
;	O
all	O
of	O
these	O
seven	O
mutations	B-event
were	O
detected	O
exclusively	O
in	O
intestinal	O
-	O
type	O
gastric	O
cancers	O
(	O
7	O
of	O
26	O
;	O
26.9	O
%	O
)	O
,	O
but	O
not	O
in	O
the	O
diffuse	O
-	O
type	O
(	O
0	O
of	O
17	O
)	O
.	O
We	O
concluded	O
that	O
disruption	O
of	O
the	O
APC	O
/	O
beta-catenin	O
/	O
T	O
cell	O
factor	O
-	O
lymphoid	O
enhancer	O
binding	O
factor	O
pathway	O
might	O
play	O
an	O
important	O
role	O
especially	O
in	O
the	O
development	O
of	O
intestinal	O
-	O
type	O
gastric	O
cancer	O
.	O
PMID	O
:	O
10485468	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
1999	O
Aug;15(	O
2	O
)	O
:391	O
-	O
8	O
Sampling	O
technique	O
influences	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
of	O
colorectal	O
cancer	O
patients	O
.	O
Schimanski	O
CC	O
,	O
Sutter	O
C	O
,	O
Linnemann	O
U	O
,	O
Berger	O
MR	O
.	O
Unit	O
of	O
Toxicology	O
and	O
Chemotherapy	O
,	O
German	O
Cancer	O
Research	O
Centre	O
,	O
69120	O
Heidelberg	O
,	O
Germany	O
.	O
Based	O
on	O
three	O
colorectal	O
cancer	O
cell	O
lines	O
with	O
specified	O
K-ras	O
status	O
,	O
a	O
sensitive	O
PCR	O
-	O
RFLP	O
assay	O
was	O
established	O
detecting	O
one	O
K-ras	O
mutant	O
among	O
106	O
wild	O
-	O
type	O
cells	O
.	O
Using	O
this	O
assay	O
for	O
tissues	O
of	O
124	O
colorectal	O
cancer	O
patients	O
,	O
59	O
tumor	O
(	O
46	O
%	O
)	O
and	O
11	O
mucosa	O
samples	O
(	O
9	O
%	O
)	O
were	O
found	O
to	O
harbor	O
a	O
K-ras	O
mutation	O
.	O
When	O
using	O
the	O
same	O
scalpel	O
for	O
collecting	O
tumor	O
and	O
mucosa	O
tissues	O
(	O
group	O
A	O
)	O
,	O
18	O
%	O
of	O
the	O
patients	O
had	O
a	O
matching	O
K-ras	O
mutation	O
in	O
both	O
tissues	O
,	O
but	O
this	O
coincidence	O
was	O
seen	O
in	O
3	O
%	O
of	O
patients	O
only	O
,	O
when	O
separate	O
scalpels	O
were	O
used	O
(	O
group	O
B	O
)	O
.	O
Thus	O
we	O
conclude	O
that	O
the	O
sampling	O
technique	O
used	O
for	O
collecting	O
specimens	O
is	O
a	O
major	O
contributor	O
to	O
the	O
detection	O
of	O
K-ras	O
mutations	O
in	O
normal	O
appearing	O
mucosa	O
when	O
a	O
highly	O
sensitive	O
detection	O
technique	O
is	O
used	O
.	O
PMID	O
:	O
10402253	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1999	O
Apr	O
1;59(	O
7)	O
:1442	O
-	O
4	O
Beta-catenin	O
mutations	O
are	O
more	O
frequent	O
in	O
small	O
colorectal	O
adenomas	O
than	O
in	O
larger	O
adenomas	O
and	O
invasive	O
carcinomas	O
.	O
Samowitz	O
WS	O
,	O
Powers	O
MD	O
,	O
Spirio	O
LN	O
,	O
Nollet	O
F	O
,	O
van	O
Roy	O
F	O
,	O
Slattery	O
ML.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Utah	O
Health	O
Sciences	O
Center	O
,	O
Salt	O
Lake	O
City	O
84132	O
,	O
USA	O
.	O
Loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
from	O
exon	B-location
3	I-location
of	O
beta-catenin	O
has	O
been	O
identified	O
in	O
approximately	O
half	O
of	O
colorectal	O
tumors	O
which	O
lack	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
mutations	O
,	O
but	O
the	O
overall	O
contribution	O
of	O
beta-catenin	O
mutations	O
to	O
sporadic	O
colorectal	O
tumorigenesis	O
is	O
unclear	O
.	O
We	O
therefore	O
used	O
PCR	O
to	O
amplify	O
and	O
sequence	O
exon	B-location
3	I-location
of	O
beta-catenin	O
from	O
202	O
sporadic	O
colorectal	O
tumors	O
.	O
Exon	B-location
3	I-location
beta-catenin	O
mutations	O
were	O
identified	O
in	O
6	O
of	O
48	O
small	O
(	O
<	O
1	O
cm	O
)	O
adenomas	O
,	O
2	O
of	O
82	O
large	O
(	O
>	O
or	O
=	O
1	O
cm	O
)	O
adenomas	O
,	O
and	O
1	O
of	O
72	O
invasive	O
carcinomas	O
.	O
Eight	O
of	O
the	O
nine	O
mutations	B-event
,	O
including	O
all	O
of	O
those	O
in	O
the	O
small	O
adenomas	O
and	O
the	O
invasive	O
cancer	O
,	O
involved	O
loss	O
of	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
.	O
The	O
percentage	O
of	O
beta-catenin	O
mutations	O
in	O
small	O
adenomas	O
(	O
12.5	O
%	O
)	O
was	O
significantly	O
greater	O
than	O
that	O
in	O
large	O
adenomas	O
(	O
2.4	O
%	O
)	O
and	O
invasive	O
cancers	O
(	O
1.4	O
%	O
;	O
P	O
=	O
0.05	O
and	O
P	O
=	O
0.02	O
,	O
respectively	O
)	O
.	O
We	O
conclude	O
that	O
mutation	O
of	O
beta-catenin	O
can	O
be	O
an	O
early	O
,	O
perhaps	O
initiating	O
,	O
event	O
in	O
colorectal	O
tumorigenesis	O
.	O
Small	O
adenomas	O
with	O
beta-catenin	O
mutations	O
do	O
not	O
appear	O
to	O
be	O
as	O
likely	O
to	O
progress	O
to	O
larger	O
adenomas	O
and	O
invasive	O
carcinomas	O
as	O
other	O
adenomas	O
,	O
however	O
,	O
with	O
the	O
result	O
that	O
beta-catenin	O
mutations	O
are	O
only	O
rarely	O
seen	O
in	O
invasive	O
cancers	O
.	O
This	O
suggests	O
that	O
APC	O
and	O
beta-catenin	O
mutations	O
are	O
not	O
functionally	O
equivalent	O
,	O
and	O
that	O
the	O
APC	O
gene	O
may	O
have	O
other	O
tumor	O
suppressor	O
functions	O
besides	O
the	O
degradation	O
of	O
beta-catenin	O
.	O
PMID	O
:	O
10197610	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1999	O
Apr;21(	O
4)	O
:410	O
-	O
3	O
A	O
common	O
human	O
skin	O
tumour	O
is	O
caused	O
by	O
activating	O
mutations	O
in	O
beta-catenin	O
.	O
Chan	O
EF	O
,	O
Gat	O
U	O
,	O
McNiff	O
JM	O
,	O
Fuchs	O
E.	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
Department	O
of	O
Molecular	O
Genetics	O
and	O
Cell	O
Biology	O
,	O
The	O
University	O
of	O
Chicago	O
,	O
Illinois	O
60637	O
,	O
USA	O
.	O
WNT	O
signalling	O
orchestrates	O
a	O
number	O
of	O
developmental	O
programs	O
.	O
In	O
response	O
to	O
this	O
stimulus	O
,	O
cytoplasmic	O
beta-catenin	O
(	O
encoded	O
by	O
CTNNB1	O
)	O
is	O
stabilized	O
,	O
enabling	O
downstream	O
transcriptional	O
activation	O
by	O
members	O
of	O
the	O
LEF	O
/	O
TCF	O
family	O
.	O
One	O
of	O
the	O
target	O
genes	O
for	O
beta-catenin	O
/	O
TCF	O
encodes	O
c-MYC	O
,	O
explaining	O
why	O
constitutive	O
activation	O
of	O
the	O
WNT	O
pathway	O
can	O
lead	O
to	O
cancer	O
,	O
particularly	O
in	O
the	O
colon	O
.	O
Most	O
colon	O
cancers	O
arise	O
from	O
mutations	O
in	O
the	O
gene	O
encoding	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
,	O
a	O
protein	O
required	O
for	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
beta-catenin	O
,	O
but	O
a	O
small	O
percentage	O
of	O
colon	O
and	O
some	O
other	O
cancers	O
harbour	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Recently	O
,	O
we	O
discovered	O
that	O
transgenic	O
mice	O
expressing	O
an	O
activated	O
beta-catenin	O
are	O
predisposed	O
to	O
developing	O
skin	O
tumours	O
resembling	O
pilomatricomas	O
.	O
Given	O
that	O
the	O
skin	O
of	O
these	O
adult	O
mice	O
also	O
exhibits	O
signs	O
of	O
de	O
novo	O
hair	O
-	O
follicle	O
morphogenesis	O
,	O
we	O
wondered	O
whether	O
human	O
pilomatricomas	O
might	O
originate	O
from	O
hair	O
matrix	O
cells	O
and	O
whether	O
they	O
might	O
possess	O
beta-catenin	O
-	O
stabilizing	O
mutations	O
.	O
Here	O
,	O
we	O
explore	O
the	O
cell	O
origin	O
and	O
aetiology	O
of	O
this	O
common	O
human	O
skin	O
tumour	O
.	O
We	O
found	O
nuclear	O
LEF-1	O
in	O
the	O
dividing	O
tumour	O
cells	O
,	O
providing	O
biochemical	O
evidence	O
that	O
pilomatricomas	O
are	O
derived	O
from	O
hair	O
matrix	O
cells	O
.	O
At	O
least	O
75	O
%	O
of	O
these	O
tumours	O
possess	O
mutations	O
affecting	O
the	O
amino	O
-	O
terminal	O
segment	O
,	O
normally	O
involved	O
in	O
phosphorylation	O
-	O
dependent	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
protein	O
.	O
This	O
percentage	O
of	O
CTNNB1	O
mutations	O
is	O
greater	O
than	O
in	O
all	O
other	O
human	O
tumours	O
examined	O
thus	O
far	O
,	O
and	O
directly	O
implicates	O
beta-catenin	O
/	O
LEF	O
misregulation	O
as	O
the	O
major	O
cause	O
of	O
hair	O
matrix	O
cell	O
tumorigenesis	O
in	O
humans	O
.	O
PMID	O
:	O
10192393	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Gastroenterol	O
1998	O
Jun;33(	O
3	O
)	O
:390	O
-	O
6	O
Detection	O
of	O
Ki-ras	O
and	O
p53	O
gene	O
mutations	O
in	O
tissue	O
and	O
pancreatic	O
juice	O
from	O
pancreatic	O
adenocarcinomas	O
.	O
Kondoh	O
S,	O
Kaino	O
M,	O
Okita	O
S,	O
Ryozawa	O
S,	O
Akiyama	O
T	O
,	O
Okita	O
K.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Yamaguchi	O
University	O
School	O
of	O
Medicine	O
,	O
Ube	O
,	O
Japan	O
.	O
Pancreatic	O
carcinomas	O
have	O
a	O
high	O
incidence	O
of	O
Ki-ras	O
mutations	O
,	O
and	O
the	O
genetic	O
change	O
is	O
thought	O
to	O
occur	O
at	O
an	O
early	O
stage	O
in	O
the	O
carcinogenesis	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
usefulness	O
of	O
detecting	O
genetic	O
mutations	O
in	O
pure	O
pancreatic	O
juice	O
(	O
PPJ	O
)	O
.	O
DNA	O
was	O
extracted	O
from	O
tissue	O
specimens	O
of	O
pancreatic	O
carcinomas	O
and	O
from	O
cells	O
in	O
PPJ	O
,	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
.	O
Two	O
types	O
of	O
mobility	O
shifts	O
that	O
indicate	O
Ki-ras	O
mutations	O
were	O
observed	O
in	O
13	O
of	O
the	O
20	O
(	O
65	O
%	O
)	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
.	O
Ten	O
of	O
15	O
specimens	O
(	O
67	O
%	O
)	O
of	O
PPJ	O
collected	O
from	O
patients	O
with	O
pancreatic	O
carcinomas	O
showed	O
two	O
types	O
of	O
mobility	O
shifts	O
.	O
Conventional	O
imaging	O
techniques	O
did	O
not	O
show	O
two	O
in	O
10	O
of	O
these	O
patients	O
.	O
PPJ	O
from	O
patients	O
with	O
non	O
-	O
cancerous	O
pancreatic	O
diseases	O
showed	O
no	O
Ki-ras	O
mutations	O
.	O
The	O
p53	O
tumor	O
suppressor	O
gene	O
,	O
examined	O
by	O
PCR	O
-	O
SSCP	O
analysis	O
,	O
was	O
mutated	O
in	O
8	O
of	O
the	O
20	O
tissue	O
specimens	O
obtained	O
by	O
operation	O
or	O
autopsy	O
(	O
40	O
%	O
)	O
.	O
The	O
detection	O
of	O
Ki-ras	O
and	O
p53	O
mutations	O
in	O
PPJ	O
could	O
be	O
useful	O
for	O
the	O
early	O
diagnosis	O
of	O
pancreatic	O
carcinomas	O
,	O
especially	O
for	O
neoplastic	O
lesions	O
of	O
the	O
intraductal	O
type	O
.	O
PMID	O
:	O
9658319	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
1998	O
Jul	O
1;83(	O
1	O
)	O
:122	O
-	O
9	O
A	O
c-rasHa	O
mutation	O
in	O
the	O
metastasis	O
of	O
a	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-	O
18	O
positive	O
penile	O
squamous	O
cell	O
carcinoma	O
suggests	O
a	O
cooperative	O
effect	O
between	O
HPV-18	O
and	O
c-rasHa	O
activation	O
in	O
malignant	O
progression	O
.	O
Leis	O
PF	O
,	O
Stevens	O
KR	O
,	O
Baer	O
SC	O
,	O
Kadmon	O
D	O
,	O
Goldberg	O
LH	O
,	O
Wang	O
XJ	O
.	O
Department	O
of	O
Dermatology	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Houston	O
,	O
Texas	O
77030	O
,	O
USA	O
.	O
BACKGROUND	O
:	O
Human	O
papillomaviruses	O
(	O
HPV	O
)	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
anogenital	O
squamous	O
epithelial	O
tumors	O
.	O
Of	O
the	O
65	O
HPV	O
strains	O
,	O
subtypes	O
HPV-16	O
and	O
HPV-18	O
frequently	O
are	O
associated	O
with	O
malignant	O
conditions	O
and	O
are	O
capable	O
of	O
transforming	O
keratinocytes	O
in	O
vitro	O
.	O
However	O
,	O
additional	O
cellular	O
changes	O
are	O
necessary	O
to	O
confer	O
tumorigenicity	O
to	O
HPV	O
-	O
infected	O
cells	O
.	O
Secondary	O
events	O
implicated	O
in	O
the	O
progression	O
to	O
malignancy	O
include	O
loss	O
of	O
tumor	O
suppressor	O
genes	O
such	O
as	O
p53	O
and/or	O
activation	O
of	O
cellular	O
oncogenes	O
such	O
as	O
c-rasHa	O
.	O
METHODS	O
:	O
Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
identify	O
HPV-16	O
or	O
HPV-18	O
genetic	O
sequence	O
in	O
primary	O
penile	O
squamous	O
cell	O
carcinoma	O
and	O
two	O
inguinal	O
lymph	O
node	O
metastases	O
.	O
p53	O
and	O
c-rasHa	O
loci	O
were	O
analyzed	O
by	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O
RESULTS	O
:	O
HPV-18	O
but	O
not	O
HPV-16	O
infection	O
was	O
found	O
in	O
the	O
primary	O
carcinoma	O
and	O
in	O
inguinal	O
metastases	O
occurring	O
5	O
and	O
7	O
years	O
after	O
the	O
initial	O
lesion	O
.	O
Sequence	O
analysis	O
did	O
not	O
identify	O
any	O
p53	O
mutations	O
in	O
the	O
primary	O
carcinoma	O
or	O
its	O
metastases	O
.	O
However	O
,	O
although	O
the	O
primary	O
lesion	O
and	O
the	O
5	O
-	O
year	O
metastasis	O
encoded	O
wild	O
-	O
type	O
c-rasHa	O
,	O
the	O
7	O
-	O
year	O
metastasis	O
had	O
a	O
missense	B-type
mutation	I-type
within	O
c-rasHa	O
codon	B-location
61	I-location
.	O
CONCLUSIONS	O
:	O
To	O
the	O
authors	O
'	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
activating	O
c-rasHa	O
mutation	O
associated	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
penis	O
.	O
The	O
presence	O
of	O
activated	O
c-rasHa	O
in	O
the	O
second	O
metastasis	O
but	O
not	O
in	O
the	O
first	O
metastasis	O
or	O
the	O
primary	O
lesion	O
suggests	O
that	O
activation	O
of	O
c-rasHa	O
may	O
be	O
a	O
late	O
event	O
in	O
the	O
malignant	O
progression	O
of	O
HPV-18	O
-	O
associated	O
penile	O
squamous	O
cell	O
carcinoma	O
.	O
Analysis	O
of	O
additional	O
samples	O
from	O
primary	O
lesions	O
and	O
their	O
resultant	O
metastases	O
is	O
necessary	O
to	O
elucidate	O
the	O
incidence	O
and	O
significance	O
of	O
c-rasHa	O
activation	O
in	O
penile	O
squamous	O
cell	O
carcinoma	O
.	O
PMID	O
:	O
9655301	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Lett	O
1998	O
Apr	O
24;126(	O
2	O
)	O
:179	O
-	O
85	O
Role	O
of	O
K-ras	O
mutations	O
in	O
colorectal	O
carcinoma	O
.	O
Chiang	O
JM	O
.	O
Division	O
of	O
Colon	O
and	O
Rectal	O
Surgery	O
,	O
Chang	O
Gung	O
Memorial	O
Hospital	O
,	O
Taipei	O
,	O
Taiwan	O
.	O
In	O
order	O
to	O
investigate	O
whether	O
two	O
common	O
types	O
of	O
colorectal	O
cancer	O
with	O
different	O
gross	O
appearances	O
share	O
the	O
same	O
incidence	O
of	O
K-ras	O
mutation	O
,	O
the	O
occurrence	O
of	O
a	O
point	B-type
mutation	I-type
in	O
codon	B-location
12	I-location
or	O
codon	B-location
13	I-location
of	O
the	O
K-ras	O
oncogene	O
was	O
determined	O
in	O
50	O
cases	O
of	O
colorectal	O
carcinoma	O
.	O
The	O
PCR	O
technique	O
was	O
employed	O
,	O
followed	O
by	O
RFLP	O
analysis	O
and	O
sequencing	O
to	O
identify	O
specific	O
point	B-type
mutations	I-type
.	O
No	O
correlation	O
was	O
found	O
between	O
the	O
presence	O
of	O
a	O
K-ras	O
gene	O
mutation	O
and	O
histological	O
parameters	O
.	O
A	O
strong	O
association	O
was	O
found	O
between	O
K-ras	O
mutations	O
and	O
the	O
gross	O
polypoid	O
appearance	O
of	O
colorectal	O
carcinoma	O
(	O
polypoid	O
73	O
%	O
versus	O
ulcerative	O
8	O
%	O
)	O
.	O
The	O
results	O
indicate	O
a	O
preferential	O
association	O
with	O
the	O
K-ras	O
oncogene	O
involved	O
in	O
polypoid	O
type	O
colorectal	O
carcinoma	O
.	O
PMID	O
:	O
9585064	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1998	O
Mar	O
1;58(	O
5	O
)	O
:1021	O
-	O
6	O
Activation	O
of	O
the	O
beta-catenin	O
gene	O
by	O
interstitial	O
deletions	B-type
involving	O
exon	B-location
3	I-location
in	O
primary	O
colorectal	O
carcinomas	O
without	O
adenomatous	O
polyposis	O
coli	O
mutations	O
.	O
Iwao	O
K	O
,	O
Nakamori	O
S,	O
Kameyama	O
M,	O
Imaoka	O
S,	O
Kinoshita	O
M,	O
Fukui	O
T	O
,	O
Ishiguro	O
S,	O
Nakamura	O
Y	O
,	O
Miyoshi	O
Y.	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Biomedical	O
Research	O
Center	O
,	O
Osaka	O
University	O
Medical	O
School	O
,	O
Suita	O
City	O
,	O
Japan	O
.	O
Among	O
222	O
primary	O
colorectal	O
cancers	O
we	O
examined	O
,	O
58	O
showed	O
no	O
detectable	O
APC	O
mutations	O
by	O
the	O
protein	O
truncation	O
test	O
.	O
We	O
screened	O
those	O
58	O
tumors	O
for	O
somatic	O
mutations	O
in	O
the	O
beta-catenin	O
gene	O
.	O
Although	O
amino	B-type
acid	I-type
substitutions	I-type
in	O
serine	B-state-original
or	O
threonine	B-state-original
residues	O
in	O
exon	B-location
3	I-location
had	O
been	O
reported	O
,	O
we	O
found	O
no	O
such	O
mutations	B-event
;	O
however	O
,	O
in	O
seven	O
tumors	O
,	O
we	O
detected	O
somatic	O
interstitial	O
deletions	B-event
of	O
234	O
-	O
760	O
bp	O
,	O
each	O
of	O
which	O
included	O
all	O
or	O
part	O
of	O
exon	B-location
3	I-location
.	O
Short	O
nucleotide	O
sequences	O
at	O
both	O
ends	O
of	O
each	O
deletion	B-event
were	O
either	O
identical	O
or	O
complementary	O
,	O
indicating	O
that	O
repeated	O
or	O
inversely	O
repeated	O
sequences	O
were	O
involved	O
in	O
the	O
somatic	O
rearrangements	B-type
.	O
Reverse	O
transcription	O
-	O
PCR	O
experiments	O
using	O
RNAs	O
isolated	O
from	O
three	O
of	O
these	O
seven	O
tumors	O
detected	O
transcripts	O
that	O
lacked	O
exon	B-location
3	I-location
,	O
in	O
addition	O
to	O
the	O
normal	O
transcript	O
.	O
In	O
one	O
of	O
these	O
cases	O
,	O
we	O
confirmed	O
accumulation	O
of	O
aberrant	O
beta-catenin	O
protein	O
in	O
cytoplasm	O
and	O
nuclei	O
of	O
cancer	O
cells	O
by	O
Western	O
and	O
immunohistochemical	O
analyses	O
.	O
This	O
result	O
suggested	O
that	O
,	O
in	O
the	O
absence	O
of	O
a	O
peptide	O
encoded	O
by	O
exon	B-location
3	I-location
,	O
beta-catenin	O
is	O
stabilized	O
and	O
has	O
a	O
dominant	O
oncogenic	O
effect	O
on	O
colorectal	O
tumorigenesis	O
.	O
PMID	O
:	O
9500465	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1997	O
Sep;11(	O
9	O
)	O
:1442	O
-	O
6	O
Tandem	B-type
duplications	I-type
of	O
the	O
FLT3	O
receptor	O
gene	O
are	O
associated	O
with	O
leukemic	O
transformation	O
of	O
myelodysplasia	O
.	O
Horiike	O
S,	O
Yokota	O
S,	O
Nakao	O
M,	O
Iwai	O
T	O
,	O
Sasai	O
Y	O
,	O
Kaneko	O
H	O
,	O
Taniwaki	O
M,	O
Kashima	O
K	O
,	O
Fujii	O
H	O
,	O
Abe	O
T	O
,	O
Misawa	O
S.	O
Department	O
of	O
Internal	O
Medicine	O
III	O
,	O
Kyoto	O
Prefectural	O
University	O
of	O
Medicine	O
,	O
Japan	O
.	O
We	O
recently	O
reported	O
an	O
internal	O
tandem	B-type
duplication	I-type
of	O
the	O
human	O
flt3	O
receptor	O
gene	O
(	O
FLT3	O
)	O
as	O
a	O
somatic	O
mutation	B-event
in	O
17	O
%	O
of	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
.	O
The	O
present	O
study	O
revealed	O
the	O
duplication	B-type
at	O
the	O
juxtamembrane	O
and	O
the	O
first	O
tyrosine	O
kinase	O
domains	O
of	O
FLT3	O
in	O
seven	O
of	O
92	O
(	O
8	O
%	O
)	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
and	O
AML	O
with	O
trilineage	O
myelodysplasia	O
(	O
AML	O
/	O
TMDS	O
)	O
,	O
the	O
diseases	O
which	O
may	O
represent	O
neoplastic	O
changes	O
of	O
pluripotent	O
stem	O
cells	O
.	O
A	O
tandem	B-type
duplication	I-type
of	O
exon	B-location
11	I-location
of	O
FLT3	O
was	O
harbored	O
by	O
two	O
of	O
58	O
(	O
3	O
%	O
)	O
patients	O
with	O
MDS	O
and	O
five	O
of	O
34	O
(	O
15	O
%	O
)	O
with	O
overt	O
leukemia	O
,	O
including	O
MDS	O
-	O
derived	O
leukemia	O
,	O
AML	O
/	O
TMDS	O
and	O
therapy	O
-	O
related	O
leukemia	O
.	O
Although	O
the	O
duplicated	O
regions	O
varied	O
within	O
exon	B-location
11	I-location
in	O
each	O
case	O
,	O
they	O
occurred	O
in	O
-	O
frame	O
,	O
and	O
altered	O
mRNA	O
expressions	O
were	O
demonstrated	O
by	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
.	O
Two	O
cases	O
of	O
MDS	O
with	O
a	O
FLT3	O
duplication	O
transformed	O
to	O
overt	O
leukemia	O
within	O
a	O
few	O
months	O
.	O
Longitudinal	O
analyses	O
in	O
two	O
other	O
patients	O
with	O
leukemia	O
revealed	O
that	O
the	O
duplication	B-type
was	O
a	O
late	O
genetic	O
event	O
during	O
the	O
disease	O
course	O
;	O
one	O
of	O
whom	O
showed	O
two	O
independent	O
duplications	B-type
of	O
FLT3	O
at	O
the	O
terminal	O
therapy	O
-	O
resistant	O
phase	O
.	O
Of	O
seven	O
patients	O
with	O
the	O
FLT3	O
duplication	B-type
,	O
six	O
had	O
abnormal	O
karyotypes	O
,	O
and	O
four	O
harbored	O
a	O
point	B-type
mutation	I-type
of	O
the	O
N-RAS	O
and/or	O
TP53	O
genes	O
.	O
Patients	O
with	O
FLT3	O
mutations	O
have	O
poor	O
prognoses	O
.	O
This	O
study	O
uncovered	O
the	O
fact	O
that	O
the	O
accumulation	O
of	O
genetic	O
events	O
,	O
including	O
FLT3	O
duplication	B-type
,	O
correlates	O
with	O
leukemic	O
transformation	O
from	O
antecedent	O
myelodysplasia	O
and	O
with	O
subsequent	O
disease	O
progression	O
.	O
PMID	O
:	O
9305595	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
Arch	O
Allergy	O
Immunol	O
1997	O
May	O
-	O
Jul;113(	O
1	O
-	O
3	O
)	O
:184	O
-	O
6	O
c-kit	O
mutation	O
in	O
a	O
population	O
of	O
patients	O
with	O
mastocytosis	O
.	O
Nagata	O
H	O
,	O
Okada	O
T	O
,	O
Worobec	O
AS	O
,	O
Semere	O
T	O
,	O
Metcalfe	O
DD.	O
Department	O
of	O
Otolaryngology	O
,	O
Chiba	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
.	O
The	O
c-kit	O
Asp	B-state-original
816	B-location
Val	B-state-altered
activating	O
mutation	B-event
is	O
found	O
in	O
all	O
patients	O
with	O
mastocytosis	O
with	O
an	O
associated	O
hematologic	O
disorder	O
,	O
and	O
at	O
least	O
in	O
a	O
subset	O
of	O
patients	O
with	O
indolent	O
mastocytosis	O
.	O
The	O
case	O
of	O
an	O
11	O
-	O
month	O
-	O
old	O
child	O
is	O
presented	O
who	O
was	O
categorized	O
as	O
having	O
indolent	O
mastocytosis	O
,	O
and	O
where	O
the	O
Asp	B-state-original
816	B-location
Val	B-state-altered
mutation	B-event
was	O
identified	O
in	O
lesional	O
skin	O
,	O
but	O
not	O
in	O
bone	O
marrow	O
or	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
populations	O
.	O
The	O
significance	O
of	O
these	O
findings	O
is	O
discussed	O
.	O
PMID	O
:	O
9130517	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Dis	O
Colon	O
Rectum	O
1997	O
Feb;40(	O
2	O
)	O
:161	O
-	O
7	O
Ki-ras	O
point	B-type
mutation	I-type
in	O
different	O
types	O
of	O
colorectal	O
carcinomas	O
in	O
early	O
stages	O
.	O
Kojima	O
M,	O
Konishi	O
F	O
,	O
Tsukamoto	O
T	O
,	O
Yamashita	O
K	O
,	O
Kanazawa	O
K.	O
Department	O
of	O
Surgery	O
,	O
Jichi	O
Medical	O
School	O
,	O
Tochigi	O
,	O
Japan	O
.	O
PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
elucidate	O
pathways	O
of	O
carcinogenesis	O
in	O
the	O
colon	O
and	O
rectum	O
by	O
investigating	O
Ki-ras	O
point	B-type
mutation	I-type
in	O
different	O
types	O
of	O
colorectal	O
carcinomas	O
in	O
the	O
early	O
stage	O
.	O
METHODS	O
:	O
We	O
analyzed	O
rates	O
of	O
Ki-ras	O
codon	B-location
12	I-location
mutations	B-event
in	O
34	O
small	O
,	O
polypoid	O
-	O
type	O
carcinomas	O
(	O
Tis	O
or	O
T1	O
)	O
,	O
21	O
superficial	O
-	O
type	O
carcinomas	O
(	O
Tis	O
or	O
T1	O
)	O
,	O
and	O
42	O
advanced	O
carcinomas	O
(	O
T2	O
,	O
T3	O
,	O
and	O
T4	O
)	O
.	O
RESULTS	O
:	O
Frequency	O
of	O
Ki-ras	O
mutations	B-event
in	O
superficial	O
-	O
type	O
carcinomas	O
was	O
14.3	O
percent	O
(	O
3	O
/	O
21	O
)	O
,	O
which	O
was	O
significantly	O
lower	O
than	O
50	O
percent	O
(	O
17	O
/	O
34	O
)	O
in	O
small	O
polypoid	O
carcinomas	O
and	O
40.5	O
percent	O
(	O
17	O
/	O
42	O
)	O
in	O
advanced	O
carcinomas	O
.	O
These	O
data	O
suggest	O
that	O
another	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
that	O
does	O
not	O
involve	O
Ki-ras	O
point	B-type
mutation	I-type
might	O
exist	O
.	O
Among	O
the	O
17	O
small	O
polypoid	O
carcinomas	O
with	O
Ki-ras	O
point	B-type
mutation	I-type
in	O
which	O
both	O
adenomatous	O
and	O
carcinomatous	O
tissue	O
were	O
examined	O
,	O
12	O
showed	O
a	O
mutation	B-event
of	O
the	O
same	O
type	O
in	O
both	O
carcinomatous	O
and	O
adenomatous	O
tissues	O
.	O
In	O
two	O
cases	O
,	O
mutation	B-event
was	O
present	O
only	O
in	O
carcinomatous	O
tissue	O
and	O
not	O
in	O
adenomatous	O
tissue	O
;	O
in	O
the	O
other	O
three	O
cases	O
,	O
Ki-ras	O
point	B-type
mutation	I-type
was	O
present	O
only	O
in	O
adenomatous	O
tissue	O
but	O
not	O
in	O
carcinomatous	O
tissue	O
.	O
CONCLUSIONS	O
:	O
These	O
data	O
suggest	O
that	O
carcinoma	O
in	O
a	O
small	O
polypoid	O
lesion	O
does	O
not	O
always	O
develop	O
from	O
pre	O
-	O
existing	O
adenoma	O
with	O
Ki-ras	O
point	B-type
mutation	I-type
;	O
in	O
a	O
small	O
number	O
of	O
the	O
polypoid	O
-	O
type	O
early	O
carcinomas	O
,	O
polyclonal	O
composition	O
concerning	O
the	O
Ki-ras	O
gene	O
may	O
exist	O
.	O
PMID	O
:	O
9075750	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Yonsei	O
Med	O
J	O
1996	O
Dec;37(	O
6)	O
:371	O
-	O
9	O
A	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
activated	O
H-ras	O
oncogene	O
with	O
a	O
point	B-type
mutation	I-type
at	O
codon	B-location
12	B-location
and	O
61	B-location
.	O
Hong	O
SJ	O
,	O
Lee	O
T	O
,	O
Park	O
YS	O
,	O
Lee	O
KO	O
,	O
Chung	O
BH	O
,	O
Lee	O
SH.	O
Department	O
of	O
Urology	O
,	O
Yonsei	O
University	O
College	O
of	O
Medicine	O
,	O
Seoul	O
,	O
Korea	O
.	O
To	O
investigate	O
the	O
incidence	O
of	O
the	O
H-ras	O
gene	O
activation	O
in	O
bladder	O
tumor	O
and	O
the	O
feasibility	O
of	O
using	O
urinary	O
washout	O
samples	O
for	O
screening	O
,	O
a	O
series	O
of	O
33	O
human	O
bladder	O
tumors	O
and	O
their	O
preoperatively	O
collected	O
urinary	O
washout	O
samples	O
were	O
screened	O
using	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
(	O
polymerase	O
chain	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
)	O
to	O
detect	O
a	O
point	B-type
mutation	I-type
of	O
the	O
H-ras	O
gene	O
.	O
Five	O
tumors	O
were	O
found	O
to	O
harbor	O
H-ras	O
mutations	O
where	O
two	O
tumors	O
had	O
a	O
glycine	B-state-original
to	O
valine	B-state-altered
(	O
G	B-state-original
-->	O
T	B-state-altered
)	O
change	O
in	O
codon	B-location
12	I-location
and	O
three	O
tumors	O
had	O
a	O
glutamine	B-state-original
to	O
lysine	B-state-altered
(	O
C	B-state-original
-->	O
A	B-state-altered
)	O
change	O
in	O
codon	B-location
61	I-location
,	O
respectively	O
.	O
Moreover	O
,	O
we	O
could	O
also	O
detect	O
the	O
same	O
point	B-type
mutations	I-type
of	O
the	O
H-ras	O
gene	O
in	O
corresponding	O
urine	O
washout	O
samples	O
.	O
The	O
incidence	O
of	O
H-ras	O
mutation	O
in	O
Korean	O
bladder	O
cancer	O
was	O
estimated	O
at	O
approximately	O
15.2	O
%	O
.	O
In	O
conclusion	O
,	O
a	O
mutant	O
specific	O
PCR	O
-	O
RFLP	O
method	O
for	O
the	O
detection	O
of	O
H-ras	O
gene	O
mutation	O
is	O
useful	O
for	O
screening	O
or	O
postoperative	O
follow	O
-	O
up	O
of	O
bladder	O
tumor	O
due	O
to	O
its	O
simplicity	O
and	O
high	O
specificity	O
even	O
in	O
urinary	O
samples	O
.	O
PMID	O
:	O
9048488	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Lab	O
Invest	O
1997	O
Jan;76(	O
1	O
)	O
:153	O
-	O
9	O
Sporadic	O
and	O
Thorotrast	O
-	O
induced	O
angiosarcomas	O
of	O
the	O
liver	O
manifest	O
frequent	O
and	O
multiple	O
point	B-type
mutations	I-type
in	O
K-ras-2	O
.	O
Przygodzki	O
RM	O
,	O
Finkelstein	O
SD	O
,	O
Keohavong	O
P	O
,	O
Zhu	O
D	O
,	O
Bakker	O
A	O
,	O
Swalsky	O
PA	O
,	O
Soini	O
Y	O
,	O
Ishak	O
KG	O
,	O
Bennett	O
WP	O
.	O
Laboratory	O
of	O
Human	O
Carcinogenesis	O
,	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
USA	O
.	O
Hepatic	O
angiosarcoma	O
(	O
HA	O
)	O
is	O
an	O
uncommon	O
neoplasm	O
associated	O
with	O
known	O
etiologic	O
factors	O
in	O
25	O
%	O
to	O
42	O
%	O
of	O
cases	O
.	O
It	O
is	O
,	O
however	O
,	O
one	O
of	O
the	O
most	O
common	O
sarcomas	O
found	O
in	O
the	O
liver	O
.	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
was	O
to	O
find	O
mutations	O
in	O
the	O
K-ras-2	O
oncogene	O
in	O
sporadic	O
and	O
Thorotrast	O
(	O
TT	O
)	O
-	O
induced	O
HA	O
.	O
Point	B-type
mutations	I-type
in	O
K-ras-2	O
were	O
sought	O
in	O
archival	O
,	O
formalin	O
-	O
fixed	O
tissue	O
blocks	O
from	O
24	O
patients	O
with	O
angiosarcoma	O
.	O
Of	O
these	O
,	O
19	O
cases	O
were	O
sporadic	O
and	O
5	O
were	O
TT	O
-	O
induced	O
.	O
Mutational	O
analysis	O
was	O
performed	O
by	O
topographic	O
microdissection	O
with	O
PCR	O
amplification	O
followed	O
by	O
genotyping	O
.	O
Specific	O
mutations	O
were	O
determined	O
by	O
two	O
independent	O
methods	O
:	O
(a)	O
direct	O
sequencing	O
of	O
the	O
PCR	O
product	O
confirmed	O
by	O
rePCR	O
and	O
by	O
using	O
a	O
different	O
sequencing	O
primer	O
,	O
and	O
(b)	O
PCR	O
-	O
based	O
selective	O
enrichment	O
of	O
mutant	O
DNA	O
by	O
endonuclease	O
digestion	O
followed	O
by	O
heteroduplex	O
DNA	O
analysis	O
using	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
Eleven	O
K-ras-2	O
point	B-type
mutations	I-type
were	O
detected	O
in	O
7	O
of	O
24	O
(	O
29	O
%	O
)	O
tumors	O
,	O
including	O
5	O
of	O
19	O
(	O
26	O
%	O
)	O
sporadic	O
HA	O
and	O
2	O
of	O
5	O
(	O
40	O
%	O
)	O
TT	O
-	O
induced	O
HA	O
.	O
There	O
were	O
seven	O
G:C	B-state-original
>	O
A:T	B-state-altered
and	O
four	O
G:C	B-state-original
>	O
T:A	B-state-altered
mutations	B-event
.	O
All	O
seven	O
mutated	O
tumors	O
contained	O
a	O
codon	B-location
12	I-location
-	O
aspartate	B-state-altered
amino	B-type
acid	I-type
substitution	I-type
.	O
In	O
addition	O
,	O
a	O
second	O
codon	B-location
12	I-location
-	O
cysteine	B-state-altered
mutant	O
cell	O
population	O
was	O
present	O
in	O
one	O
of	O
two	O
codon	B-location
12	I-location
-	O
aspartate	B-state-altered
mutated	O
TT	O
-	O
induced	O
HA	O
and	O
in	O
three	O
of	O
five	O
codon	B-location
12	I-location
-	O
aspartate	B-state-altered
sporadic	O
tumors	O
.	O
Of	O
these	O
four	O
tumors	O
,	O
three	O
contained	O
both	O
aspartate	B-state-altered
and	O
cysteine	B-state-altered
mutations	B-event
and	O
were	O
composed	O
of	O
multiple	O
nodules	O
;	O
the	O
fourth	O
was	O
a	O
single	O
mass	O
.	O
Seventeen	O
tumors	O
had	O
multiple	O
nodules	O
;	O
whereas	O
5	O
had	O
a	O
K-ras-2	O
mutation	B-event
,	O
12	O
were	O
wild	O
-	O
type	O
.	O
The	O
molecular	O
pathology	O
of	O
both	O
sporadic	O
and	O
TT	O
-	O
induced	O
HA	O
is	O
characterized	O
by	O
a	O
high	O
rate	O
of	O
K-ras-2	O
mutations	B-event
characteristic	O
of	O
oxidative	O
damage	O
(	O
ie	O
,	O
G:C	B-state-original
>	O
A:T	B-state-altered
and	O
G:C	B-state-original
>	O
T:A	B-state-altered
mutations	B-event
)	O
resulting	O
in	O
two	O
mutated	O
population	O
sets	O
:	O
codon	B-location
12	I-location
GGT	B-state-original
>	O
GAT	B-state-altered
and	O
GGT	B-state-original
>	O
TGT	B-state-altered
(	O
glycine	B-state-original
to	O
aspartic	B-state-altered
acid	I-state-altered
and	O
cysteine	B-state-altered
)	O
.	O
This	O
is	O
,	O
to	O
date	O
,	O
the	O
first	O
study	O
to	O
characterize	O
the	O
K-ras-2	O
gene	O
mutations	O
within	O
human	O
sporadic	O
and	O
TT	O
-	O
induced	O
HA	O
by	O
direct	O
sequence	O
analysis	O
and	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
.	O
These	O
data	O
further	O
support	O
the	O
hypothesis	O
linking	O
adduct	O
-	O
forming	O
vinyl	O
chloride	O
exposure	O
to	O
HA	O
containing	O
a	O
much	O
higher	O
frequency	O
of	O
K-ras-2	O
mutations	O
and	O
a	O
mutational	O
spectrum	O
characteristic	O
of	O
chloroethylene	O
oxide	O
,	O
a	O
carcinogenic	O
metabolite	O
of	O
vinyl	O
chloride	O
.	O
PMID	O
:	O
9010458	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leuk	O
Res	O
1996	O
Nov-	O
Dec;20(	O
11	O
-	O
12	O
)	O
:901	O
-	O
3	O
RAS	O
gene	O
mutations	O
in	O
Chinese	O
leukaemia	O
patients	O
and	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
leukaemia	O
.	O
He	O
LZ	O
,	O
Stephenson	O
J,	O
He	O
GY	O
,	O
Mufti	O
GJ.	O
Department	O
of	O
Haematological	O
Medicine	O
,	O
King	O
's	O
College	O
School	O
of	O
Medicine	O
and	O
Dentistry	O
,	O
London	O
,	O
UK.	O
We	O
investigated	O
mutations	O
of	O
N-RAS	O
and	O
K-RAS	O
by	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
oligonucleotide	O
hybridization	O
techniques	O
in	O
40	O
cases	O
of	O
Chinese	O
leukaemia	O
patients	O
and	O
17	O
presently	O
healthy	O
members	O
of	O
a	O
family	O
with	O
high	O
incidence	O
of	O
acute	O
myeloid	O
leukaemia	O
.	O
The	O
results	O
showed	O
only	O
two	O
patients	O
carried	O
the	O
mutation	B-event
in	O
codon	B-location
12	I-location
of	O
N-RAS	O
.	O
Strikingly	O
,	O
however	O
,	O
in	O
both	O
cases	O
the	O
malignancies	O
involved	O
lymphoid	O
lineage	O
.	O
There	O
was	O
no	O
hereditary	O
RAS	O
mutation	O
in	O
the	O
members	O
of	O
the	O
remarkable	O
family	O
.	O
PMID	O
:	O
9009246	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Nat	O
Genet	O
1996	O
Mar;12(	O
3	O
)	O
:312	O
-	O
4	O
Somatic	O
c-KIT	O
activating	O
mutation	O
in	O
urticaria	O
pigmentosa	O
and	O
aggressive	O
mastocytosis	O
:	O
establishment	O
of	O
clonality	O
in	O
a	O
human	O
mast	O
cell	O
neoplasm	O
.	O
Longley	O
BJ	O
,	O
Tyrrell	O
L,	O
Lu	O
SZ	O
,	O
Ma	O
YS	O
,	O
Langley	O
K	O
,	O
Ding	O
TG	O
,	O
Duffy	O
T	O
,	O
Jacobs	O
P	O
,	O
Tang	O
LH	O
,	O
Modlin	O
I.	O
Department	O
of	O
Dermatology	O
,	O
Yale	O
University	O
School	O
of	O
Medicine	O
,	O
New	O
Haven	O
Connecticut	O
06510	O
,	O
USA	O
.	O
Mastocytosis	O
is	O
characterized	O
by	O
accumulations	O
of	O
mast	O
cells	O
in	O
various	O
organs	O
(	O
1	O
)	O
.	O
Most	O
cases	O
are	O
indolent	O
and	O
confined	O
to	O
the	O
skin	O
,	O
where	O
discrete	O
mast	O
cell	O
infiltrates	O
are	O
associated	O
increased	O
epidermal	O
melanin	O
,	O
a	O
clinical	O
picture	O
known	O
as	O
urticaria	O
pigmentosa	O
(	O
UP	O
)	O
.	O
Other	O
forms	O
of	O
mastocytosis	O
combine	O
UP	O
with	O
aggressive	O
involvement	O
of	O
other	O
organs	O
or	O
with	O
haemotologic	O
abnormalities	O
(	O
1	O
-	O
4	O
)	O
.	O
It	O
is	O
not	O
known	O
whether	O
all	O
forms	O
of	O
mastocytosis	O
are	O
true	O
neoplasms	O
or	O
whether	O
some	O
might	O
represent	O
reactive	O
hyperplasias	O
(	O
5	O
-	O
7	O
)	O
.	O
The	O
c-KIT	O
proto	O
-	O
oncogene	O
encodes	O
a	O
type	O
III	O
receptor	O
tyrosine	O
kinase	O
(	O
KIT	O
)	O
that	O
is	O
critical	O
to	O
the	O
development	O
and	O
survival	O
of	O
mast	O
cells	O
and	O
melanocytes	O
(	O
8	O
-	O
11	O
)	O
.	O
The	O
ligand	O
for	O
KIT	O
(	O
KL	O
)	O
can	O
stimulate	O
mast	O
cell	O
development	O
,	O
proliferation	O
,	O
and	O
mediator	O
release	O
(	O
9	O
,	O
12	O
-	O
17	O
)	O
,	O
as	O
well	O
as	O
melanocyte	O
proliferation	O
and	O
pigment	O
production	O
(	O
18	O
-	O
20	O
)	O
.	O
To	O
determine	O
the	O
role	O
of	O
c-KIT	O
in	O
the	O
pathogenesis	O
of	O
mastocytosis	O
,	O
we	O
examined	O
tissue	O
and	O
cells	O
isolated	O
from	O
a	O
patient	O
with	O
UP	O
and	O
aggressive	O
systemic	O
mastocytosis	O
with	O
massive	O
splenic	O
involvement	O
.	O
We	O
found	O
a	O
mutation	O
that	O
results	O
in	O
constitutive	O
activation	O
and	O
expression	O
of	O
c-KIT	O
in	O
mast	O
cells	O
of	O
both	O
skin	O
and	O
spleen	O
.	O
This	O
is	O
the	O
first	O
in	O
situ	O
demonstration	O
of	O
an	O
activation	O
c-KIT	O
mutation	O
in	O
neoplastic	O
cells	O
.	O
It	O
also	O
demonstrates	O
the	O
clonal	O
and	O
neoplastic	O
nature	O
of	O
this	O
form	O
of	O
mastocytes	O
.	O
PMID	O
:	O
8589724	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Mod	O
Pathol	O
1993	O
Mar;6(	O
2	O
)	O
:129	O
-	O
32	O
H-ras-1	O
point	B-type
mutations	I-type
in	O
soft	O
tissue	O
sarcomas	O
.	O
Wilke	O
W	O
,	O
Maillet	O
M,	O
Robinson	O
R.	O
Department	O
of	O
Pathology	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
.	O
The	O
H-ras-1	O
protooncogene	O
is	O
activated	O
by	O
single	B-type
base	I-type
substitutions	I-type
occurring	O
in	O
either	O
codon	B-location
12	B-location
,	O
13	B-location
,	O
or	O
61	B-location
.	O
These	O
mutations	B-event
have	O
been	O
described	O
with	O
varying	O
frequencies	O
in	O
several	O
human	O
tumor	O
types	O
.	O
Since	O
ras	O
oncogenes	O
were	O
first	O
discovered	O
as	O
the	O
transforming	O
sequences	O
of	O
Harvey	O
and	O
Kirsten	O
murine	O
sarcoma	O
viruses	O
(	O
which	O
also	O
contain	O
activating	O
point	B-type
mutations	I-type
compared	O
to	O
the	O
homologous	O
cellular	O
sequences	O
)	O
,	O
we	O
wished	O
to	O
investigate	O
the	O
possibility	O
that	O
ras	O
mutations	O
might	O
also	O
occur	O
in	O
human	O
sarcomas	O
.	O
We	O
extracted	O
DNA	O
from	O
six	O
malignant	O
fibrous	O
histiocytomas	O
(	O
MFH	O
)	O
,	O
three	O
embryonal	O
rhabdomyosarcomas	O
(	O
ER	O
)	O
,	O
one	O
alveolar	O
rhabdomyosarcoma	O
,	O
one	O
pleomorphic	O
rhabdomyosarcoma	O
,	O
and	O
one	O
leiomyosarcoma	O
.	O
The	O
DNA	O
from	O
regions	B-location
flanking	I-location
codons	I-location
12	I-location
/	I-location
13	I-location
and	O
codon	B-location
61	I-location
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
sequenced	O
with	O
an	O
automated	O
DNA	O
sequencer	O
.	O
As	O
controls	O
,	O
we	O
amplified	O
and	O
sequenced	O
normal	O
DNA	O
(	O
placenta	O
)	O
and	O
DNA	O
with	O
known	O
point	B-type
mutations	I-type
(	O
T24	O
bladder	O
carcinoma	O
cells	O
)	O
.	O
We	O
found	O
three	O
cases	O
with	O
mutations	B-event
,	O
all	O
occurring	O
in	O
codon	B-location
12	I-location
.	O
One	O
ER	O
showed	O
a	O
G	B-state-original
-	O
to	O
-	O
T	B-state-altered
mutation	B-event
in	O
the	O
second	B-location
position	I-location
of	I-location
codon	I-location
12	I-location
(	O
coding	O
for	O
valine	B-state-altered
instead	O
of	O
glycine	B-state-original
)	O
.	O
Two	O
MFHs	O
showed	O
G	B-state-original
-	O
to	O
-	O
A	B-state-altered
mutations	B-event
in	O
the	O
second	B-location
position	I-location
of	I-location
codon	I-location
12	I-location
(	O
coding	O
for	O
aspartic	B-state-altered
acid	O
instead	O
of	O
glycine	B-state-original
)	O
.	O
Although	O
a	O
limited	O
number	O
of	O
cases	O
were	O
sampled	O
,	O
we	O
conclude	O
that	O
study	O
of	O
H-ras-1	O
mutations	O
may	O
be	O
relevant	O
to	O
MFH	O
and	O
ER	O
.	O
Additional	O
studies	O
of	O
N	O
and	O
K	O
-	O
ras	O
mutations	O
as	O
well	O
as	O
more	O
cases	O
investigating	O
H-ras	O
will	O
be	O
required	O
before	O
we	O
can	O
ascertain	O
the	O
significance	O
of	O
ras	O
mutations	O
in	O
the	O
oncogenesis	O
of	O
human	O
soft	O
tissue	O
sarcomas	O
.	O
PMID	O
:	O
8483882	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Leukemia	O
1993	O
Mar;7(	O
3	O
)	O
:469	O
-	O
71	O
Amplification	B-type
of	O
c-MYC	B-location
oncogene	O
and	O
point	B-type
mutation	I-type
of	O
N-RAS	O
oncogene	O
point	B-type
mutation	I-type
in	O
acute	O
myelocytic	O
leukemias	O
with	O
double	B-type
minute	I-type
chromosomes	I-type
.	O
Tanaka	O
K	O
,	O
Takechi	O
M,	O
Nishimura	O
S,	O
Oguma	O
N	O
,	O
Kamada	O
N.	O
Department	O
of	O
Hematology	O
,	O
Hiroshima	O
University	O
,	O
Japan	O
.	O
Two	O
patients	O
with	O
acute	O
myelocytic	O
leukemia	O
(	O
AML	O
)	O
showing	O
double	B-type
minute	I-type
(	I-type
dmin	I-type
)	I-type
chromosomes	I-type
were	O
analysed	O
to	O
identify	O
oncogene	O
activation	O
.	O
Cytogenetic	O
analysis	O
showed	O
1	O
-	O
53	O
dmin	B-type
chromosomes	I-type
with	O
the	O
normal	O
karyotype	O
in	O
the	O
first	O
patient	O
and	O
1	O
-	O
84	O
dmin	B-type
chromosomes	I-type
with	O
complex	O
chromosome	O
aberrations	O
.	O
Analysis	O
of	O
DNA	O
from	O
two	O
patients	O
revealed	O
five	O
-	O
to	O
ten	O
fold	O
amplification	B-type
of	O
c-MYC	B-location
oncogene	O
in	O
the	O
leukemic	O
cells	O
.	O
The	O
other	O
sixteen	O
oncogenes	O
studied	O
showed	O
no	O
increase	O
in	O
the	O
gene	O
content	O
.	O
Furthermore	O
,	O
a	O
transforming	O
gene	O
,	O
N-RAS	O
was	O
detected	O
in	O
the	O
first	O
patient	O
by	O
nude	O
mouse	O
tumorigenicity	O
assay	O
(	O
in	O
vivo	O
selection	O
assay	O
)	O
.	O
These	O
results	O
suggest	O
that	O
the	O
amplification	B-type
of	O
c-MYC	B-location
gene	O
is	O
common	O
in	O
dmin	B-type
-	O
positive	O
AML	O
patients	O
and	O
co	O
-	O
ordination	O
of	O
c-MYC	O
and	O
N-RAS	O
oncogene	O
might	O
also	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
AML	O
patients	O
.	O
PMID	O
:	O
8445953	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Genet	O
Cytogenet	O
1994	O
May;74(	O
1	O
)	O
:40	O
-	O
9	O
Cytogenetic	O
studies	O
,	O
ras	O
mutation	O
,	O
and	O
clinical	O
characteristics	O
in	O
primary	O
myelodysplastic	O
syndrome	O
.	O
A	O
study	O
on	O
68	O
Chinese	O
patients	O
in	O
Taiwan	O
.	O
Tien	O
HF	O
,	O
Wang	O
CH	O
,	O
Chuang	O
SM	O
,	O
Chow	O
JM	O
,	O
Lee	O
FY	O
,	O
Liu	O
MC	O
,	O
Chen	O
YC	O
,	O
Shen	O
MC	O
,	O
Lin	O
DT	O
,	O
Lin	O
KH.	O
Department	O
of	O
Internal	O
Medicine	O
,	O
National	O
Taiwan	O
University	O
Hospital	O
,	O
Taipei	O
,	O
R.O.C.	O
Cytogenetics	O
and	O
clinical	O
features	O
were	O
studied	O
for	O
68	O
Chinese	O
patients	O
with	O
primary	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O
Ras	O
mutation	O
was	O
analyzed	O
in	O
25	O
of	O
them	O
.	O
Thirty-four	O
patients	O
(	O
50	O
%	O
)	O
had	O
clonal	O
chromosomal	O
abnormalities	O
at	O
initial	O
analysis	O
.	O
The	O
most	O
common	O
cytogenetic	B-event
aberrations	I-event
were	O
-	B-type
7	B-location
,	O
+	B-type
8	B-location
,	O
5q	B-location
-	B-type
,	O
and	O
20q	B-location
-	B-type
,	O
which	O
occurred	O
in	O
11	O
(	O
16.2	O
%	O
)	O
,	O
seven	O
(	O
10.3	O
%	O
)	O
,	O
five	O
(	O
7.4	O
%	O
)	O
and	O
three	O
patients	O
,	O
respectively	O
.	O
The	O
incidence	O
of	O
-	B-type
7	B-location
was	O
higher	O
and	O
that	O
of	O
5q	B-location
-	O
lower	O
in	O
our	O
patients	O
than	O
in	O
patients	O
from	O
most	O
other	O
geographic	O
areas	O
.	O
The	O
17	O
patients	O
with	O
multiple	O
chromosomal	O
abnormalities	O
had	O
a	O
significantly	O
shorter	O
median	O
survival	O
(	O
9	O
months	O
)	O
than	O
the	O
34	O
patients	O
with	O
normal	O
karyotype	O
(	O
33	O
months	O
)	O
and	O
the	O
17	O
patients	O
with	O
patients	O
with	O
single	O
anomalies	O
(	O
26	O
months	O
)	O
.	O
Evolution	O
to	O
acute	O
leukemia	O
occurred	O
in	O
20	O
patients	O
(	O
29	O
%	O
)	O
after	O
a	O
median	O
interval	O
of	O
8	O
months	O
following	O
the	O
diagnosis	O
.	O
Patients	O
with	O
multiple	O
cytogenetic	O
changes	O
at	O
initial	O
analysis	O
or	O
in	O
subsequent	O
studies	O
had	O
a	O
significantly	O
higher	O
frequency	O
of	O
acute	O
transformation	O
than	O
others	O
(	O
55	O
%	O
vs.	O
18.6	O
%	O
,	O
p	O
=	O
0.007	O
)	O
;	O
the	O
same	O
was	O
not	O
true	O
if	O
only	O
the	O
data	O
of	O
initial	O
study	O
were	O
considered	O
.	O
Serial	O
cytogenetic	O
studies	O
are	O
important	O
in	O
patient	O
follow	O
-	O
up	O
.	O
N-ras	O
mutation	O
was	O
detected	O
in	O
5	O
(	O
20	O
%	O
)	O
of	O
25	O
patients	O
within	O
the	O
study	O
.	O
There	O
was	O
no	O
correlation	O
between	O
the	O
gene	O
mutation	O
and	O
acute	O
transformation	O
.	O
But	O
combing	O
the	O
data	O
of	O
N-ras	O
mutation	O
and	O
cytogenetics	O
,	O
patients	O
with	O
either	O
the	O
N-ras	O
mutation	O
or	O
clonal	O
chromosomal	O
abnormalities	O
were	O
at	O
significantly	O
higher	O
risk	O
for	O
developing	O
acute	O
leukemia	O
than	O
those	O
with	O
neither	O
of	O
the	O
changes	O
(	O
77	O
%	O
vs.	O
25	O
%	O
)	O
.	O
PMID	O
:	O
8194046	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1994	O
Apr	O
15	O
;83(	O
8	O
)	O
:2248	O
-	O
54	O
Mutations	O
of	O
the	O
N-ras	O
gene	O
in	O
juvenile	O
chronic	O
myelogenous	O
leukemia	O
.	O
Miyauchi	O
J,	O
Asada	O
M,	O
Sasaki	O
M,	O
Tsunematsu	O
Y	O
,	O
Kojima	O
S,	O
Mizutani	O
S.	O
Department	O
of	O
Virology	O
,	O
National	O
Children	O
's	O
Medical	O
Research	O
Center	O
,	O
Tokyo	O
,	O
Japan	O
.	O
Juvenile	O
chronic	O
myelogenous	O
leukemia	O
(	O
JCML	O
)	O
,	O
a	O
myeloproliferative	O
disorder	O
of	O
childhood	O
,	O
is	O
distinct	O
from	O
adult	O
-	O
type	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
and	O
bears	O
resemblance	O
to	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMMoL	O
)	O
.	O
Since	O
mutations	O
in	O
the	O
N-ras	O
gene	O
have	O
been	O
found	O
at	O
high	O
frequencies	O
in	O
CMMoL	O
,	O
but	O
only	O
rarely	O
in	O
CML	O
,	O
we	O
analyzed	O
mutations	O
activating	O
the	O
N-ras	O
gene	O
in	O
20	O
patients	O
with	O
JCML	O
.	O
We	O
used	O
the	O
strategy	O
for	O
analysis	O
of	O
gene	O
mutations	O
based	O
on	O
in	O
vitro	O
DNA	O
amplification	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
followed	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and/or	O
direct	O
sequence	O
analysis	O
.	O
Nucleotide	O
sequence	O
analysis	O
showed	O
single	B-type
nucleotide	I-type
substitutions	I-type
involving	O
codons	B-location
12	B-location
,	O
13	B-location
,	O
or	O
61	B-location
in	O
six	O
of	O
20	O
patients	O
(	O
30	O
%	O
)	O
.	O
Four	O
of	O
six	O
patients	O
with	O
mutations	B-event
were	O
in	O
chronic	O
phase	O
and	O
the	O
other	O
two	O
in	O
blast	O
crisis	O
,	O
indicating	O
no	O
apparent	O
correlation	O
with	O
disease	O
stage	O
.	O
Most	O
of	O
the	O
patients	O
with	O
mutations	B-event
were	O
in	O
the	O
older	O
age	O
group	O
with	O
poor	O
prognosis	O
,	O
although	O
one	O
patient	O
in	O
the	O
younger	O
age	O
group	O
also	O
harbored	O
the	O
mutation	B-event
.	O
These	O
data	O
suggest	O
that	O
N-ras	O
gene	O
mutations	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
and/or	O
prognosis	O
of	O
JCML	O
and	O
provide	O
further	O
evidence	O
that	O
JCML	O
is	O
an	O
entity	O
distinct	O
from	O
CML	O
.	O
PMID	O
:	O
8161790	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Br	O
J	O
Haematol	O
1994	O
Jun;87(	O
2	O
)	O
:235	O
-	O
42	O
Establishment	O
and	O
characterization	O
of	O
a	O
novel	O
myeloid	O
cell	O
line	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
the	O
myelodysplastic	O
syndrome	O
.	O
Tohyama	O
K	O
,	O
Tsutani	O
H	O
,	O
Ueda	O
T	O
,	O
Nakamura	O
T	O
,	O
Yoshida	O
Y.	O
First	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Fukui	O
Medical	O
School	O
,	O
Japan	O
.	O
A	O
novel	O
long	O
-	O
term	O
cultured	O
myeloid	O
cell	O
line	O
was	O
established	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O
This	O
cell	O
line	O
,	O
designated	O
MDS92	O
,	O
proliferated	O
in	O
the	O
presence	O
of	O
interleukin-3	O
or	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
transiently	O
in	O
the	O
presence	O
of	O
Steel	O
factor	O
,	O
with	O
a	O
tendency	O
for	O
gradual	O
maturation	O
,	O
and	O
formed	O
myeloid	O
colonies	O
in	O
the	O
semi	O
-	O
solid	O
culture	O
condition	O
.	O
In	O
addition	O
,	O
the	O
MDS92	O
cell	O
line	O
represented	O
rather	O
complicated	O
karyotypic	O
abnormalities	O
including	O
the	O
deletion	B-type
of	O
fifth	B-location
and	O
seventh	B-location
chromosomes	B-location
and	O
a	O
point	B-type
mutation	I-type
at	O
codon	B-location
12	I-location
of	O
the	O
N-ras	O
oncogene	O
.	O
These	O
characteristics	O
of	O
the	O
MDS92	O
cell	O
line	O
are	O
exclusively	O
compatible	O
with	O
the	O
property	O
of	O
preleukaemia	O
.	O
PMID	O
:	O
7947263	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Jpn	O
J	O
Cancer	O
Res	O
1994	O
Aug;85(	O
8	O
)	O
:847	O
-	O
52	O
State	O
of	O
adenomatous	O
polyposis	O
coli	O
gene	O
and	O
ras	O
oncogenes	O
in	O
Japanese	O
prostate	O
cancer	O
.	O
Suzuki	O
H	O
,	O
Aida	O
S,	O
Akimoto	O
S,	O
Igarashi	O
T	O
,	O
Yatani	O
R,	O
Shimazaki	O
J.	O
Department	O
of	O
Urology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
.	O
Genetic	O
alterations	O
of	O
ras	O
oncogenes	O
(	O
K	O
-	O
,	O
H	O
-	O
and	O
N	O
-	O
ras	O
)	O
and	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
in	O
tissues	O
of	O
prostate	O
cancer	O
from	O
Japanese	O
patients	O
were	O
examined	O
using	O
PCR	O
-	O
SSCP	O
(	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
)	O
analysis	O
and	O
direct	O
sequencing	O
.	O
Tissues	O
from	O
8	O
cases	O
of	O
untreated	O
stage	O
B	O
prostate	O
cancer	O
surgically	O
removed	O
and	O
from	O
10	O
cases	O
of	O
endocrine	O
therapy	O
-	O
resistant	O
metastatic	O
disease	O
obtained	O
at	O
autopsy	O
were	O
used	O
in	O
the	O
present	O
study	O
.	O
In	O
four	O
out	O
of	O
18	O
cases	O
(	O
22	O
%	O
)	O
,	O
ras	O
point	B-type
mutations	I-type
were	O
found	O
,	O
two	O
in	O
either	O
codon	B-location
12	B-location
or	O
61	B-location
of	O
K-ras	O
and	O
two	O
in	O
either	O
13	B-location
or	O
61	B-location
of	O
H-ras	O
.	O
These	O
point	B-type
mutations	I-type
were	O
detected	O
in	O
one	O
of	O
the	O
stage	O
B	O
cases	O
(	O
13	O
%	O
)	O
and	O
in	O
three	O
of	O
the	O
autopsy	O
cases	O
(	O
30	O
%	O
)	O
.	O
All	O
these	O
cases	O
were	O
poorly	O
differentiated	O
adenocarcinoma	O
.	O
In	O
autopsy	O
cases	O
showing	O
ras	O
mutation	B-event
in	O
cancerous	O
prostate	O
,	O
the	O
same	O
alteration	B-event
was	O
observed	O
in	O
metastatic	O
tissues	O
.	O
No	O
APC	O
gene	O
mutation	O
was	O
detected	O
in	O
any	O
sample	O
,	O
although	O
polymorphism	O
was	O
found	O
in	O
some	O
cases	O
.	O
These	O
results	O
indicate	O
that	O
ras	O
oncogene	O
mutations	O
are	O
related	O
to	O
the	O
progression	O
of	O
prostate	O
cancer	O
,	O
whereas	O
APC	O
gene	O
alteration	O
is	O
not	O
involved	O
in	O
tumorigenesis	O
and	O
development	O
of	O
this	O
cancer	O
.	O
PMID	O
:	O
7928631	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Cancer	O
Res	O
Clin	O
Oncol	O
1995	O
;121(	O
1	O
)	O
:23	O
-	O
30	O
Analysis	O
of	O
ras	O
mutations	O
in	O
human	O
melanocytic	O
lesions	O
:	O
activation	O
of	O
the	O
ras	O
gene	O
seems	O
to	O
be	O
associated	O
with	O
the	O
nodular	O
type	O
of	O
human	O
malignant	O
melanoma	O
.	O
Jafari	O
M,	O
Papp	O
T	O
,	O
Kirchner	O
S,	O
Diener	O
U	O
,	O
Henschler	O
D	O
,	O
Burg	O
G	O
,	O
Schiffmann	O
D.	O
Institute	O
of	O
Pharmacology	O
and	O
Toxicology	O
,	O
University	O
of	O
Wurzburg	O
,	O
Germany	O
.	O
We	O
have	O
analyzed	O
the	O
Ha-ras	O
,	O
Ki-ras	O
and	O
N-ras	O
gene	O
for	O
point	B-type
mutations	I-type
at	O
codons	B-location
12	I-location
,	O
13	B-location
and	O
61	B-location
via	O
restriction	O
fragment	O
length	O
polymorphism	O
/	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
subsequent	O
direct	O
sequencing	O
in	O
non	O
-	O
cultured	O
fresh	O
-	O
frozen	O
tissues	O
of	O
16	O
superficial	O
spreading	O
melanomas	O
(	O
SSM	O
)	O
,	O
13	O
nodular	O
malignant	O
melanomas	O
(	O
NMM	O
)	O
,	O
2	O
lentigo	O
malignant	O
melanomas	O
(	O
LMM	O
)	O
,	O
1	O
dysplastic	O
nevus	O
,	O
1	O
congenital	O
nevus	O
and	O
5	O
normal	O
nevi	O
from	O
38	O
patients	O
.	O
Mutations	B-event
were	O
found	O
in	O
4	O
melanoma	O
samples	O
,	O
all	O
belonging	O
to	O
the	O
nodular	O
malignant	O
type	O
.	O
Three	O
of	O
them	O
were	O
mutated	O
in	O
N-ras	O
and	O
one	O
in	O
the	O
Ha-ras	O
gene	O
.	O
Mutation	B-event
in	O
N-ras	O
was	O
also	O
detected	O
in	O
the	O
congenital	O
nevus	O
.	O
All	O
mutations	B-event
were	O
exclusively	O
located	O
at	O
the	O
first	B-location
two	I-location
base	I-location
pairs	I-location
of	I-location
codon	I-location
61	I-location
.	O
No	O
Ki-ras	O
mutation	O
was	O
detected	O
in	O
any	O
lesion	O
.	O
No	O
mutation	O
could	O
be	O
found	O
in	O
SSM	O
and	O
LMM	O
in	O
addition	O
to	O
dysplastic	O
and	O
normal	O
nevi	O
.	O
The	O
frequency	O
of	O
ras	O
mutation	O
in	O
NMM	O
was	O
31	O
%	O
,	O
whereas	O
in	O
SSM	O
it	O
was	O
0	O
%	O
.	O
Our	O
study	O
suggests	O
(a)	O
an	O
association	O
between	O
ras	O
mutations	O
(	O
mainly	O
N-ras	O
)	O
and	O
the	O
NMM	O
as	O
a	O
subgroup	O
of	O
human	O
melanoma	O
;	O
(b)	O
that	O
activation	O
of	O
Ki-ras	O
is	O
not	O
involved	O
in	O
the	O
pathogenesis	O
of	O
melanoma	O
.	O
The	O
role	O
of	O
UV	O
radiation	O
in	O
point	B-type
mutations	I-type
of	O
ras	O
genes	O
in	O
human	O
melanoma	O
is	O
discussed	O
.	O
PMID	O
:	O
7860615	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Invest	O
Dermatol	O
1995	O
May	O
;104(	O
5	O
)	O
:868	O
-	O
71	O
Ras	O
gene	O
mutations	O
:	O
a	O
rare	O
event	O
in	O
nonmetastatic	O
primary	O
malignant	O
melanoma	O
.	O
Wagner	O
SN	O
,	O
Ockenfels	O
HM	O
,	O
Wagner	O
C	O
,	O
Hofler	O
H	O
,	O
Goos	O
M.	O
Department	O
of	O
Dermatology	O
,	O
University	O
Essen	O
,	O
Germany	O
.	O
Ras	O
gene	O
mutations	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
a	O
variety	O
of	O
human	O
tumors	O
.	O
Mutated	O
ras	O
genes	O
have	O
been	O
isolated	O
from	O
human	O
melanoma	O
cell	O
lines	O
,	O
but	O
subsequent	O
studies	O
indicated	O
that	O
ras	O
gene	O
mutations	O
may	O
be	O
a	O
rare	O
event	O
in	O
melanocytic	O
lesions	O
.	O
Recently	O
,	O
a	O
study	O
reported	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
correlated	O
with	O
increasing	O
invasion	O
level	O
.	O
To	O
address	O
this	O
inconsistency	O
in	O
the	O
published	O
data	O
,	O
we	O
analyzed	O
50	O
primary	O
melanomas	O
to	O
correlate	O
invasion	O
level	O
,	O
tumor	O
thickness	O
,	O
histologic	O
typing	O
,	O
and	O
body	O
localization	O
with	O
point	B-type
mutations	I-type
around	O
codons	B-location
12	I-location
/	O
13	B-location
/	O
61	B-location
of	O
the	O
three	O
ras	O
genes	O
.	O
After	O
micro	O
-	O
dissection	O
of	O
paraffin	O
-	O
embedded	O
tumor	O
tissue	O
,	O
ras	O
gene	O
mutations	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
tumor	O
DNA	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O
Only	O
two	O
melanomas	O
exhibited	O
ras	O
gene	O
mutations	B-event
,	O
one	O
sample	O
containing	O
a	O
transition	B-type
from	O
A	B-state-original
to	O
G	B-state-altered
at	O
position	B-location
2	I-location
of	I-location
N-ras	I-location
codon	I-location
61	I-location
and	O
the	O
other	O
exhibiting	O
a	O
transversion	B-type
from	O
C	B-state-original
to	O
A	B-state-altered
at	O
position	B-location
1	I-location
and	O
a	O
transition	B-type
from	O
A	B-state-original
to	O
G	B-state-altered
at	O
position	B-location
2	I-location
of	I-location
N-ras	I-location
codon	I-location
61	I-location
.	O
Both	O
tumors	O
were	O
classified	O
as	O
Clark	O
level	O
IV	O
,	O
with	O
a	O
tumor	O
thickness	O
of	O
2.5	O
and	O
1.2	O
mm	O
,	O
respectively	O
.	O
Both	O
were	O
typed	O
as	O
superficial	O
spreading	O
melanoma	O
and	O
localized	O
to	O
intermittently	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
The	O
low	O
frequency	O
of	O
ras	O
mutations	O
in	O
malignant	O
melanoma	O
and	O
the	O
lack	O
of	O
ras	O
mutations	O
in	O
melanoma	O
samples	O
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
argue	O
against	O
the	O
hypothesis	O
of	O
ras	O
mutations	O
as	O
a	O
marker	O
of	O
progression	O
in	O
malignant	O
melanoma	O
and	O
the	O
suggestion	O
that	O
ras	O
mutations	O
occur	O
predominantly	O
in	O
melanomas	O
from	O
constantly	O
sun	O
-	O
exposed	O
body	O
sites	O
.	O
PMID	O
:	O
7738369	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1984	O
Jun;81(	O
12	O
)	O
:3670	O
-	O
4	O
Mechanism	O
of	O
activation	O
of	O
an	O
N-ras	O
oncogene	O
of	O
SW-1271	O
human	O
lung	O
carcinoma	O
cells	O
.	O
Yuasa	O
Y	O
,	O
Gol	O
RA	O
,	O
Chang	O
A	O
,	O
Chiu	O
IM	O
,	O
Reddy	O
EP	O
,	O
Tronick	O
SR	O
,	O
Aaronson	O
SA	O
.	O
An	O
N-ras	O
-	O
related	O
transforming	O
gene	O
was	O
detected	O
in	O
the	O
human	O
lung	O
carcinoma	O
cell	O
line	O
SW-1271	O
and	O
molecularly	O
cloned	O
.	O
The	O
lesion	O
responsible	O
for	O
its	O
acquisition	O
of	O
transforming	O
activity	O
was	O
localized	O
to	O
a	O
single	O
nucleotide	O
transition	B-type
from	O
A	B-state-original
to	O
G	B-state-altered
in	O
codon	B-location
61	I-location
of	O
the	O
predicted	O
protein	O
.	O
This	O
lesion	O
in	O
the	O
second	B-location
exon	I-location
results	O
in	O
the	O
substitution	B-type
of	O
arginine	B-state-altered
for	O
glutamine	B-state-original
at	O
this	O
position	O
.	O
These	O
findings	O
,	O
together	O
with	O
previous	O
studies	O
,	O
indicate	O
that	O
the	O
activation	O
of	O
ras	O
oncogenes	O
in	O
human	O
tumors	O
is	O
most	O
commonly	O
due	O
to	O
point	B-type
mutations	I-type
at	O
one	O
of	O
two	O
major	O
"	O
hot	O
spots	O
"	O
in	O
the	O
ras	O
coding	O
sequence	O
.	O
PMID	O
:	O
6587382	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Biochem	O
Biophys	O
Res	O
Commun	O
1987	O
Jul	O
15	O
;146(	O
1	O
)	O
:247	O
-	O
52	O
A	O
point	B-type
mutation	I-type
at	O
codon	B-location
13	I-location
of	O
the	O
N-ras	O
oncogene	O
in	O
a	O
human	O
stomach	O
cancer	O
.	O
Nishida	O
J,	O
Kobayashi	O
Y	O
,	O
Hirai	O
H	O
,	O
Takaku	O
F.	O
A	O
surgically	O
removed	O
human	O
stomach	O
cancer	O
with	O
the	O
histological	O
diagnosis	O
of	O
poorly	O
differentiated	O
adenocarcinoma	O
contained	O
an	O
activated	O
N-ras	O
oncogene	O
detected	O
by	O
an	O
in	O
vivo	O
selection	O
assay	O
in	O
nude	O
mice	O
using	O
transfected	O
NIH3T3	O
cells	O
.	O
Analysis	O
using	O
synthetic	O
20	O
-	O
mer	O
oligonucleotide	O
probes	O
revealed	O
a	O
point	B-type
mutation	I-type
from	O
G	B-state-original
to	O
C	B-state-altered
at	O
the	O
first	B-location
letter	I-location
of	I-location
codon	I-location
13	I-location
of	O
the	O
N-ras	O
gene	O
resulting	O
in	O
the	O
substitution	B-type
of	O
arginine	B-state-altered
for	O
glycine	B-state-original
.	O
This	O
is	O
the	O
first	O
observation	O
of	O
an	O
activated	O
N-ras	O
oncogene	O
in	O
human	O
stomach	O
cancers	O
.	O
PMID	O
:	O
3038106	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1989	O
Dec;74(	O
8	O
)	O
:2629	O
-	O
33	O
Mutations	O
of	O
the	O
ras	O
protooncogenes	O
in	O
chronic	O
myelogenous	O
leukemia	O
:	O
a	O
high	O
frequency	O
of	O
ras	O
mutations	O
in	O
bcr	B-event
/	I-event
abl	I-event
rearrangement	I-event
-	O
negative	O
chronic	O
myelogenous	O
leukemia	O
.	O
Cogswell	O
PC	O
,	O
Morgan	O
R,	O
Dunn	O
M,	O
Neubauer	O
A	O
,	O
Nelson	O
P	O
,	O
Poland	O
-	O
Johnston	O
NK	O
,	O
Sandberg	O
AA	O
,	O
Liu	O
E.	O
Department	O
of	O
Medicine	O
,	O
University	O
of	O
North	O
Carolina	O
,	O
Chapel	O
Hill	O
27599	O
.	O
Seventy	O
cases	O
of	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
ras	O
mutations	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
oligonucleotide	O
hybridization	O
,	O
and	O
direct	O
PCR	O
sequencing	O
.	O
All	O
cases	O
had	O
preceding	O
cytogenetic	O
and	O
bcr	B-event
rearrangement	I-event
studies	O
.	O
Aberrant	O
ras	O
genes	O
were	O
detected	O
in	O
none	O
of	O
39	O
patients	O
with	O
Philadelphia	B-event
(	I-event
Ph	I-event
)	I-event
chromosome	I-event
or	O
bcr	B-event
/	I-event
abl	I-event
rearrangement	I-event
positive	O
chronic	O
-	O
phase	O
CML	O
and	O
in	O
only	O
1	O
of	O
18	O
patients	O
in	O
blast	O
crisis	O
,	O
suggesting	O
that	O
ras	O
mutations	O
have	O
little	O
or	O
no	O
role	O
in	O
initiation	O
or	O
progression	O
of	O
common	O
CML	O
.	O
Seven	O
of	O
13	O
,	O
or	O
54	O
%	O
of	O
patients	O
with	O
bcr	B-event
/	I-event
abl	I-event
rearrangement	I-event
negative	O
chronic	O
phase	O
CML	O
(	O
atypical	O
CML	O
)	O
harbored	O
mutations	O
in	O
ras	O
,	O
however	O
.	O
This	O
high	O
incidence	O
of	O
ras	O
mutations	O
,	O
together	O
with	O
the	O
absence	O
of	O
bcr	B-event
/	I-event
abl	I-event
rearrangement	I-event
,	O
provides	O
evidence	O
that	O
atypical	O
CML	O
is	O
an	O
entity	O
that	O
is	O
molecularly	O
distinct	O
from	O
common	O
CML	O
.	O
Moreover	O
,	O
the	O
clinical	O
characteristics	O
and	O
the	O
high	O
frequency	O
of	O
ras	O
mutations	O
suggest	O
that	O
atypical	O
CML	O
may	O
constitute	O
a	O
subset	O
of	O
the	O
myelodysplastic	O
syndrome	O
and	O
may	O
be	O
best	O
classified	O
as	O
a	O
variant	O
of	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMML	O
)	O
.	O
PMID	O
:	O
2684296	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1989	O
Aug;86(	O
16	O
)	O
:6372	O
-	O
6	O
Oncogene	O
activation	O
in	O
human	O
benign	O
tumors	O
of	O
the	O
skin	O
(	O
keratoacanthomas	O
)	O
:	O
is	O
HRAS	O
involved	O
in	O
differentiation	O
as	O
well	O
as	O
proliferation	O
?	O
Corominas	O
M,	O
Kamino	O
H	O
,	O
Leon	O
J,	O
Pellicer	O
A.	O
Department	O
of	O
Pathology	O
,	O
New	O
York	O
University	O
Medical	O
Center	O
,	O
NY	O
10016	O
.	O
In	O
vitro	O
DNA	O
amplification	O
followed	O
by	O
oligonucleotide	O
mismatch	O
hybridization	O
was	O
used	O
to	O
study	O
the	O
frequency	O
of	O
HRAS	O
mutations	O
in	O
the	O
benign	O
self	O
-	O
regressing	O
skin	O
tumors	O
keratoacanthomas	O
and	O
in	O
squamous	O
cell	O
carcinomas	O
.	O
We	O
used	O
freshly	O
obtained	O
keratoacanthomas	O
as	O
well	O
as	O
Formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissues	O
from	O
both	O
types	O
of	O
tumors	O
.	O
DNA	O
from	O
50	O
samples	O
of	O
each	O
tumor	O
type	O
was	O
analyzed	O
for	O
activating	O
mutations	B-event
involving	O
codons	B-location
12	B-location
and	O
61	B-location
.	O
A	O
relatively	O
high	O
percentage	O
(	O
30	O
%	O
)	O
of	O
HRAS	O
mutations	O
was	O
found	O
in	O
the	O
keratoacanthomas	O
compared	O
with	O
13	O
%	O
in	O
the	O
squamous	O
cell	O
carcinomas	O
.	O
The	O
most	O
frequent	O
mutation	B-event
identified	O
is	O
the	O
A-T	B-state-original
-	O
to	O
-	O
T.A	B-state-altered
transversion	B-type
in	O
the	O
second	B-location
position	I-location
of	I-location
codon	I-location
61	I-location
.	O
The	O
present	O
findings	O
demonstrate	O
the	O
involvement	O
of	O
the	O
HRAS	O
oncogene	O
in	O
human	O
benign	O
tumors	O
.	O
Moreover	O
,	O
they	O
indicate	O
that	O
an	O
activated	O
HRAS	O
oncogene	O
is	O
not	O
sufficient	O
to	O
maintain	O
a	O
neoplastic	O
phenotype	O
and	O
argue	O
against	O
a	O
role	O
of	O
HRAS	O
in	O
the	O
progression	O
of	O
skin	O
tumorigenesis	O
.	O
PMID	O
:	O
2668964	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Oncogene	O
1989	O
May	O
;4(	O
5	O
)	O
:609	O
-	O
14	O
Mechanisms	O
of	O
ras	O
mutation	O
in	O
myelodysplastic	O
syndrome	O
.	O
Yunis	O
JJ	O
,	O
Boot	O
AJ	O
,	O
Mayer	O
MG	O
,	O
Bos	O
JL.	O
Department	O
of	O
Laboratory	O
Medicine	O
and	O
Pathology	O
,	O
University	O
of	O
Minnesota	O
Medical	O
School	O
,	O
Minneapolis	O
.	O
Using	O
synthetic	O
oligonucleotide	O
hybridization	O
,	O
we	O
have	O
found	O
a	O
ras	O
mutation	O
in	O
11	O
of	O
27	O
patients	O
(	O
41	O
%	O
)	O
with	O
primary	O
or	O
non	O
-	O
therapy	O
related	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O
This	O
high	O
incidence	O
of	O
mutation	O
,	O
mainly	O
of	O
the	O
N-ras	O
oncogene	O
,	O
was	O
generally	O
found	O
in	O
patients	O
with	O
disease	O
progression	O
to	O
acute	O
leukemia	O
(	O
8	O
of	O
11	O
patients	O
=	O
73	O
%	O
)	O
.	O
Two	O
general	O
mechanisms	O
of	O
ras	O
mutation	O
were	O
found	O
.	O
In	O
five	O
patients	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
only	O
a	O
fraction	O
of	O
the	O
cells	O
;	O
sometimes	O
appearing	O
in	O
late	O
stages	O
of	O
the	O
disease	O
,	O
suggesting	O
that	O
it	O
can	O
occur	O
in	O
a	O
differentiated	O
cell	O
clone	O
.	O
In	O
six	O
other	O
patients	O
,	O
the	O
ras	O
mutation	O
was	O
present	O
in	O
the	O
great	O
majority	O
of	O
bone	O
marrow	O
or	O
blood	O
cells	O
.	O
The	O
mutation	O
was	O
detected	O
in	O
mature	O
normal	O
lymphocytes	O
and	O
persisted	O
following	O
a	O
complete	O
clinical	O
remission	O
in	O
two	O
of	O
these	O
patients	O
,	O
implying	O
that	O
the	O
ras	O
mutation	O
can	O
occur	O
in	O
an	O
early	O
stage	O
of	O
cell	O
differentiation	O
or	O
stem	O
cell	O
.	O
Patients	O
with	O
a	O
ras	O
mutation	O
had	O
a	O
median	O
survival	O
of	O
nine	O
months	O
(	O
all	O
patients	O
dead	O
)	O
compared	O
to	O
16	O
patients	O
without	O
a	O
ras	O
mutation	O
that	O
had	O
a	O
median	O
follow	O
-	O
up	O
of	O
16	O
months	O
(	O
10	O
patients	O
alive	O
;	O
P	O
less	O
than	O
0.005	O
)	O
.	O
Since	O
9	O
of	O
the	O
11	O
patients	O
(	O
82	O
%	O
)	O
with	O
a	O
ras	O
mutation	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
monocytic	O
component	O
at	O
diagnosis	O
or	O
during	O
disease	O
evolution	O
,	O
it	O
is	O
possible	O
that	O
in	O
myeloid	O
disorders	O
a	O
ras	O
mutation	O
is	O
preferentially	O
associated	O
with	O
myelomonocytic	O
cell	O
differentiation	O
.	O
PMID	O
:	O
2657575	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Blood	O
1990	O
Apr	O
15;75(	O
8	O
)	O
:1684	O
-	O
90	O
The	O
pattern	O
of	O
mutational	O
involvement	O
of	O
RAS	O
genes	O
in	O
human	O
hematologic	O
malignancies	O
determined	O
by	O
DNA	O
amplification	O
and	O
direct	O
sequencing	O
.	O
Ahuja	O
HG	O
,	O
Foti	O
A	O
,	O
Bar	O
-	O
Eli	O
M,	O
Cline	O
MJ.	O
Department	O
of	O
Medicine	O
,	O
Jonsson	O
Cancer	O
Center	O
,	O
UCLA	O
School	O
of	O
Medicine	O
90024	O
-	O
1678	O
.	O
DNA	O
from	O
161	O
patients	O
with	O
various	O
forms	O
of	O
hematologic	O
malignancies	O
were	O
investigated	O
for	O
mutations	B-event
in	O
exons	B-location
1	B-location
and	O
2	B-location
of	O
the	O
N-RAS	O
,	O
K-RAS	O
and	O
Ha-RAS	O
gene	O
by	O
direct	O
sequencing	O
of	O
DNA	O
amplified	O
in	O
vitro	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Mutations	B-event
involving	O
either	O
codons	B-location
11	B-location
,	O
12	B-location
,	O
or	O
13	B-location
of	O
the	O
N-RAS	O
gene	O
were	O
identified	O
in	O
18	O
of	O
the	O
161	O
patients	O
.	O
The	O
relative	O
frequencies	O
of	O
N-RAS	O
gene	O
mutations	O
in	O
these	O
hematologic	O
disorders	O
was	O
as	O
follows	O
:	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
15	O
%	O
;	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
,	O
14	O
%	O
;	O
myelodysplastic	O
syndromes	O
,	O
24	O
%	O
;	O
and	O
myeloid	O
and	O
lymphoid	O
blast	O
crisis	O
of	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
,	O
3	O
%	O
.	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
of	O
mutations	O
and	O
cytologic	O
features	O
or	O
immunophenotype	O
of	O
these	O
malignancies	O
.	O
Mutations	B-event
involving	O
codons	B-location
12	B-location
or	O
13	B-location
were	O
equally	O
prevalent	O
,	O
with	O
a	O
glycine	B-state-original
to	O
aspartic	B-state-altered
acid	I-state-altered
substitution	B-type
being	O
the	O
most	O
frequently	O
encountered	O
change	O
.	O
A	O
single	O
T-ALL	O
case	O
had	O
a	O
codon	B-location
11	I-location
mutation	B-event
resulting	O
in	O
substitution	B-type
of	O
alanine	B-state-original
with	O
threonine	B-state-altered
.	O
We	O
failed	O
to	O
find	O
mutations	B-event
in	O
exons	B-location
1	B-location
and	O
2	B-location
of	O
the	O
K-RAS	O
or	O
Ha-RAS	O
genes	O
in	O
any	O
case	O
except	O
a	O
single	O
AML	O
with	O
a	O
mutation	B-event
in	O
codon	B-location
61	I-location
of	O
the	O
K-RAS	O
gene	O
.	O
Also	O
,	O
no	O
mutations	O
were	O
identified	O
in	O
chronic	O
phase	O
of	O
CML	O
,	O
chronic	O
lymphocytic	O
leukemia	O
.	O
Ph1	B-event
positive	O
ALL	O
,	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
,	O
Hodgkin	O
's	O
disease	O
,	O
or	O
multiple	O
myeloma	O
.	O
These	O
results	O
indicate	O
that	O
RAS	O
mutations	B-event
,	O
especially	O
those	O
involving	O
exon	B-location
1	I-location
of	O
the	O
N-RAS	O
gene	O
,	O
are	O
frequent	O
only	O
in	O
a	O
subset	O
of	O
hematologic	O
malignancies	O
.	O
PMID	O
:	O
2183888	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Cancer	O
Res	O
1991	O
May	O
15;51(	O
10	O
)	O
:2690	O
-	O
3	O
High	O
rates	O
of	O
ras	O
codon	B-location
61	I-location
mutation	B-event
in	O
thyroid	O
tumors	O
in	O
an	O
iodide	O
-	O
deficient	O
area	O
.	O
Shi	O
YF	O
,	O
Zou	O
MJ	O
,	O
Schmidt	O
H	O
,	O
Juhasz	O
F	O
,	O
Stensky	O
V	O
,	O
Robb	O
D	O
,	O
Farid	O
NR	O
.	O
Thyroid	O
Research	O
Laboratory	O
,	O
Health	O
Sciences	O
Centre	O
,	O
St.	O
John	O
's	O
,	O
Newfoundland	O
,	O
Canada	O
.	O
Using	O
polymerase	O
chain	O
reaction	O
and	O
sequence	O
-	O
specific	O
oligonucleotide	O
hybridization	O
,	O
the	O
frequency	O
of	O
three	O
ras	O
oncogene	O
mutations	O
(	O
N-ras	O
,	O
Ha-ras	O
,	O
and	O
K-ras	O
)	O
in	O
thyroid	O
tumors	O
(	O
25	O
adenomas	O
,	O
16	O
follicular	O
carcinomas	O
,	O
and	O
22	O
papillary	O
carcinomas	O
)	O
was	O
investigated	O
in	O
both	O
iodide	O
-	O
deficient	O
and	O
iodide	O
-	O
sufficient	O
areas	O
.	O
The	O
ras	O
oncogene	O
mutation	O
rate	O
was	O
significantly	O
higher	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
being	O
85	O
versus	O
17	O
%	O
in	O
the	O
adenomas	O
,	O
and	O
50	O
versus	O
10	O
%	O
in	O
the	O
follicular	O
carcinomas	O
.	O
No	O
mutations	O
were	O
found	O
in	O
papillary	O
carcinomas	O
.	O
The	O
most	O
common	O
mutation	B-event
site	O
was	O
Ha-ras	O
codon	B-location
61	I-location
with	O
Gln	B-state-original
----	O
Arg	B-state-altered
substitution	B-type
.	O
Two	O
ras	O
mutations	B-event
at	O
codon	B-location
61	I-location
(	O
Gln	B-state-original
----	O
Lys	B-state-altered
in	O
N-ras	O
and	O
Gln	B-state-original
----	O
Arg	B-state-altered
in	O
Ha-ras	O
)	O
were	O
found	O
in	O
a	O
microfollicular	O
adenoma	O
specimen	O
from	O
Eastern	O
Hungary	O
.	O
We	O
conclude	O
that	O
dietary	O
iodine	O
may	O
modulate	O
ras	O
oncogene	O
mutations	O
,	O
and	O
that	O
in	O
the	O
iodide	O
-	O
deficient	O
area	O
,	O
ras	O
oncogene	O
activation	O
may	O
play	O
a	O
more	O
important	O
role	O
in	O
the	O
initiation	O
and/or	O
maintenance	O
of	O
follicular	O
tumors	O
.	O
Additional	O
factors	O
are	O
,	O
however	O
,	O
necessary	O
to	O
initiate	O
carcinogenesis	O
.	O
PMID	O
:	O
2021946	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

J	O
Clin	O
Endocrinol	O
Metab	O
1992	O
Apr;74(	O
4)	O
:914	O
-	O
9	O
Ras	O
mutations	O
in	O
human	O
pituitary	O
tumors	O
.	O
Karga	O
HJ	O
,	O
Alexander	O
JM	O
,	O
Hedley	O
-	O
Whyte	O
ET	O
,	O
Klibanski	O
A	O
,	O
Jameson	O
JL.	O
Department	O
of	O
Medicine	O
,	O
Massachusetts	O
General	O
General	O
Hospital	O
,	O
Boston	O
02114	O
.	O
The	O
cellular	O
basis	O
for	O
pituitary	O
neoplasia	O
is	O
poorly	O
understood	O
.	O
Mutations	B-event
that	O
activate	O
the	O
ras	O
protooncogenes	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
different	O
types	O
of	O
human	O
cancers	O
and	O
potentially	O
represent	O
one	O
of	O
the	O
genetic	O
alterations	O
that	O
occur	O
in	O
pituitary	O
tumors	O
.	O
In	O
this	O
study	O
we	O
examined	O
19	O
pituitary	O
tumors	O
for	O
the	O
occurrence	O
of	O
ras	O
mutations	O
.	O
The	O
tumor	O
types	O
included	O
11	O
nonfunctioning	O
adenomas	O
,	O
6	O
somatotroph	O
adenomas	O
,	O
and	O
2	O
prolactinomas	O
.	O
Each	O
of	O
the	O
three	O
ras	O
genes	O
(	O
K-ras	O
,	O
N-ras	O
,	O
and	O
H-ras	O
)	O
was	O
amplified	O
from	O
pituitary	O
tumor	O
DNA	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O
Oligonucleotide	O
-	O
specific	O
hybridization	O
was	O
used	O
to	O
screen	O
for	O
mutations	O
that	O
inhibit	O
GTPase	O
activity	O
and	O
cause	O
activation	O
of	O
the	O
ras	O
oncogene	O
.	O
No	O
ras	O
mutations	O
were	O
observed	O
in	O
18	O
of	O
the	O
pituitary	O
adenomas	O
.	O
However	O
,	O
a	O
mutation	B-event
was	O
identified	O
in	O
codon	B-location
12	I-location
of	O
the	O
H-ras	O
gene	O
(	O
Gly	B-state-original
to	O
Val	B-state-altered
)	O
in	O
a	O
recurrent	O
prolactinoma	O
that	O
was	O
highly	O
invasive	O
and	O
ultimately	O
proved	O
to	O
be	O
fatal	O
.	O
We	O
conclude	O
that	O
ras	O
mutations	O
are	O
uncommon	O
in	O
pituitary	O
adenomas	O
,	O
but	O
may	O
provide	O
a	O
marker	O
for	O
highly	O
invasive	O
tumors	O
.	O
PMID	O
:	O
1312542	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Hum	O
Pathol	O
2001	O
Nov;32	O
(	O
11	O
)	O
:	O
1203	O
-	O
8	O
Heterogeneous	O
genetic	O
alterations	O
in	O
ovarian	O
mucinous	O
tumors	O
:	O
application	O
and	O
usefulness	O
of	O
laser	O
capture	O
microdissection	O
.	O
Takeshima	O
Y	O
,	O
Amatya	O
VJ	O
,	O
Daimaru	O
Y	O
,	O
Nakayori	O
F	O
,	O
Nakano	O
T	O
,	O
Inai	O
K.	O
Second	O
Department	O
of	O
Pathology	O
,	O
Hiroshima	O
University	O
School	O
of	O
Medicine	O
,	O
Hiroshima	O
,	O
Japan	O
.	O
Histologic	O
observation	O
of	O
ovarian	O
mucinous	O
tumors	O
suggests	O
that	O
there	O
is	O
a	O
multistep	O
transition	O
through	O
the	O
accumulation	O
of	O
genetic	O
alterations	O
.	O
We	O
analyzed	O
loss	B-type
of	I-type
heterozygosity	I-type
(	O
LOH	B-type
)	O
and	O
replication	B-type
error	I-type
(	O
RER	B-type
)	O
on	O
TP53	O
and	O
D17S855	O
as	O
well	O
as	O
K-ras	O
point	B-type
mutations	I-type
of	O
the	O
heterogeneous	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
in	O
26	O
cases	O
of	O
ovarian	O
mucinous	O
tumor	O
.	O
The	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
technique	O
has	O
been	O
applied	O
to	O
the	O
study	O
of	O
K-ras	O
point	B-type
mutation	I-type
in	O
10	O
cases	O
.	O
As	O
for	O
genetic	O
alterations	O
for	O
LOH	B-type
or	O
RER	B-type
on	O
TP53	O
and	O
D17S855	O
,	O
2	O
(	O
1	O
borderline	O
tumor	O
and	O
1	O
carcinoma	O
)	O
of	O
14	O
cases	O
and	O
4	O
(	O
1	O
borderline	O
tumor	O
and	O
3	O
carcinomas	O
)	O
of	O
12	O
cases	O
,	O
respectively	O
,	O
showed	O
genetic	O
heterogeneities	O
in	O
different	O
histologic	O
areas	O
.	O
Six	O
(	O
2	O
borderline	O
tumors	O
and	O
4	O
carcinomas	O
)	O
of	O
18	O
cases	O
showed	O
heterogeneity	O
of	O
K-ras	O
point	B-type
mutation	I-type
in	O
the	O
different	O
histologic	O
areas	O
of	O
the	O
same	O
tumor	O
,	O
and	O
5	O
(	O
1	O
cystadenoma	O
with	O
Brenner	O
tumor	O
component	O
,	O
2	O
borderline	O
tumors	O
,	O
and	O
2	O
carcinomas	O
)	O
of	O
10	O
cases	O
showed	O
heterogeneous	O
K-ras	O
mutation	O
pattern	O
in	O
the	O
same	O
tumor	O
when	O
the	O
LCM	O
technique	O
was	O
used	O
.	O
Atypical	O
areas	O
tended	O
to	O
show	O
K-ras	O
point	B-type
mutations	I-type
frequently	O
.	O
Out	O
of	O
3	O
cases	O
of	O
mixed	O
mucinous	O
cystadenoma	O
and	O
Brenner	O
tumor	O
,	O
1	O
case	O
showed	O
K-ras	O
point	B-type
mutation	I-type
in	O
the	O
Brenner	O
tumor	O
area	O
but	O
not	O
in	O
the	O
area	O
of	O
mucinous	O
cystadenoma	O
.	O
These	O
preliminary	O
results	O
suggest	O
that	O
a	O
subset	O
of	O
ovarian	O
mucinous	O
tumors	O
occur	O
through	O
multistep	O
carcinogenesis	O
and	O
show	O
that	O
LCM	O
is	O
useful	O
for	O
molecular	O
pathologic	O
studies	O
.	O
Copyright	O
2001	O
by	O
W.B.	O
Saunders	O
Company	O
Publication	O
Types	O
:	O
Evaluation	O
Studies	O
PMID	O
:	O
11727259	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Med	O
Electron	O
Microsc	O
2002	O
Mar;35	O
(	O
1	O
)	O
:	O
9-15	O
Mutation	O
of	O
beta-catenin	O
gene	O
in	O
endometrial	O
cancer	O
but	O
not	O
in	O
associated	O
hyperplasia	O
.	O
Ashihara	O
K,	O
Saito	O
T	O
,	O
Mizumoto	O
H,	O
Nishimura	O
M,	O
Tanaka	O
R	O
,	O
Kudo	O
R.	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
Sapporo	O
Medical	O
University	O
,	O
S-1	O
,	O
W-16	O
,	O
Chuo-ku	O
,	O
Sapporo	O
060	O
-0061	O
,	O
Japan	O
.	O
Endometrial	O
hyperplasia	O
is	O
a	O
recognized	O
effect	O
of	O
excessive	O
or	O
unopposed	O
estrogen	O
stimulation	O
and	O
is	O
considered	O
to	O
be	O
a	O
precancerous	O
condition	O
of	O
endometrial	O
adenocarcinoma	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
in	O
the	O
human	O
endometrium	O
is	O
changed	O
according	O
to	O
cell	O
proliferation	O
,	O
suggesting	O
a	O
role	O
of	O
intercellular	O
transduction	O
in	O
cell	O
-	O
growth	O
control	O
in	O
human	O
endometrium	O
,	O
not	O
only	O
in	O
the	O
physiological	O
condition	O
but	O
also	O
in	O
the	O
carcinogenic	O
endometrium	O
.	O
In	O
the	O
present	O
study	O
,	O
to	O
clarify	O
at	O
which	O
stage	O
of	O
endometrial	O
carcinogenesis	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
,	O
we	O
analyzed	O
the	O
subcellular	O
localization	O
of	O
beta-catenin	O
by	O
immunohistochemistry	O
,	O
and	O
we	O
analyzed	O
exon	B-location
3	I-location
of	O
the	O
beta-catenin	O
gene	O
,	O
in	O
25	O
patients	O
-	O
with	O
endometrial	O
hyperplasia	O
and	O
20	O
patients	O
with	O
endometrial	O
cancers	O
associated	O
with	O
endometrial	O
hyperplasia	O
,	O
digesting	O
DNA	O
from	O
the	O
cancer	O
and	O
hyperplasia	O
parts	O
,	O
separately	O
.	O
Fourteen	O
of	O
the	O
25	O
(	O
56.0	O
%	O
)	O
endometrial	O
hyperplasia	O
samples	O
,	O
12	O
(	O
60.0	O
%	O
)	O
endometrial	O
cancers	O
,	O
and	O
11	O
(	O
55.0	O
%	O
)	O
associated	O
hyperplasias	O
of	O
the	O
20	O
endometrial	O
cancers	O
associated	O
with	O
hyperplasia	O
showed	O
nuclear	O
localization	O
of	O
beta-catenin	O
.	O
Mutation	O
in	O
exon	B-location
3	I-location
of	O
the	O
beta-catenin	O
gene	O
was	O
found	O
in	O
2	O
of	O
the	O
20	O
endometrial	O
cancer	O
samples	O
;	O
however	O
,	O
it	O
was	O
not	O
found	O
in	O
the	O
25	O
endometrial	O
hyperplasias	O
or	O
the	O
20	O
associated	O
hyperplasias	O
.	O
The	O
results	O
suggest	O
that	O
molecular	O
alteration	O
of	O
the	O
beta-catenin	O
gene	O
occurs	O
in	O
atypical	O
hyperplasia	O
or	O
cancer	O
,	O
rather	O
than	O
in	O
simple	O
or	O
complex	O
hyperplasia	O
without	O
atypia	O
,	O
during	O
endometrial	O
carcinogenesis	O
.	O
PMID	O
:	O
12111402	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Int	O
J	O
Oncol	O
2002	O
Jun;20	O
(	O
6	O
)	O
:	O
1263	O
-	O
8	O
Frequent	O
detection	O
of	O
K-ras	O
mutation	O
in	O
stool	O
samples	O
of	O
colorectal	O
carcinoma	O
patients	O
after	O
improved	O
DNA	O
extraction	O
:	O
comparison	O
with	O
tissue	O
samples	O
.	O
Ito	O
Y	O
,	O
Kobayashi	O
S	O
,	O
Taniguchi	O
T	O
,	O
Kainuma	O
O	O
,	O
Hara	O
T	O
,	O
Ochiai	O
T.	O
Department	O
of	O
Surgery	O
,	O
Shimizu	O
Kosei	O
General	O
Hospital	O
,	O
Chiba	O
,	O
Japan	O
.	O
Fecal	O
occult	O
blood	O
testing	O
is	O
widely	O
used	O
in	O
the	O
clinical	O
screening	O
of	O
colorectal	O
tumors	O
.	O
However	O
,	O
this	O
method	O
has	O
so	O
frequent	O
false	O
-	O
positive	O
results	O
that	O
more	O
accurate	O
screening	O
-	O
strategy	O
should	O
be	O
established	O
.	O
Although	O
the	O
molecular	O
screening	O
using	O
K-ras	O
gene	O
mutation	O
in	O
stools	O
has	O
been	O
attempted	O
to	O
improve	O
the	O
results	O
,	O
the	O
low	O
rate	O
of	O
DNA	O
extraction	O
from	O
stools	O
leaves	O
this	O
measurement	O
under	O
utility	O
value	O
.	O
In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
or	O
not	O
our	O
applied	O
DNA	O
extraction	O
method	O
from	O
stools	O
could	O
produce	O
enough	O
DNA	O
for	O
the	O
molecular	O
screening	O
of	O
colorectal	O
tumors	O
by	O
K-ras	O
gene	O
mutations	O
in	O
stools	O
.	O
We	O
applied	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
solution	O
to	O
improve	O
human	O
DNA	O
extraction	O
from	O
stools	O
and	O
a	O
mutant	O
-	O
allele	O
-	O
sensitive	O
amplification	O
(	O
MASA	O
)	O
method	O
to	O
detect	O
K-ras	O
mutation	O
within	O
codon	B-location
12	I-location
.	O
We	O
were	O
able	O
to	O
confirm	O
the	O
stool	O
DNA	O
by	O
identifying	O
K-ras	O
fragments	O
in	O
all	O
the	O
20	O
patients	O
.	O
Tissue	O
K-ras	O
mutation	O
was	O
identified	O
in	O
4	O
(	O
2	O
cancers	O
and	O
2	O
adenomas	O
)	O
of	O
20	O
patients	O
.	O
Stool	O
K-ras	O
mutations	O
were	O
found	O
in	O
6	O
patients	O
,	O
3	O
tissue	O
K-ras	O
mutation	O
positive	O
patients	O
(	O
2	O
cancers	O
and	O
an	O
adenoma	O
)	O
and	O
3	O
tissue	O
K-ras	O
mutation	O
negative	O
patients	O
.	O
These	O
results	O
indicate	O
that	O
it	O
is	O
possible	O
to	O
extract	O
enough	O
DNA	O
from	O
human	O
stool	O
samples	O
of	O
all	O
patients	O
with	O
colorectal	O
tumors	O
for	O
K-ras	O
mutation	O
studies	O
.	O
K-ras	O
mutations	O
are	O
more	O
frequently	O
detected	O
in	O
stools	O
than	O
in	O
resected	O
colorectal	O
tumors	O
.	O
This	O
study	O
indicates	O
that	O
K-ras	O
mutation	O
screening	O
in	O
stools	O
for	O
colorectal	O
cancer	O
may	O
include	O
not	O
only	O
a	O
primary	O
colorectal	O
cancer	O
but	O
also	O
precancerous	O
lesions	O
in	O
all	O
parts	O
of	O
a	O
gastrointestinal	O
tract	O
.	O
PMID	O
:	O
12012008	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Am	O
J	O
Pathol	O
2002	O
May	O
;160	O
(	O
5	O
)	O
:1567	O
-72	O
KIT	O
mutations	O
are	O
common	O
in	O
incidental	O
gastrointestinal	O
stromal	O
tumors	O
one	O
centimeter	O
or	O
less	O
in	O
size	O
.	O
Corless	O
CL	O
,	O
McGreevey	O
L,	O
Haley	O
A	O
,	O
Town	O
A	O
,	O
Heinrich	O
MC	O
.	O
Department	O
of	O
Pathology	O
,	O
Division	O
of	O
Hematology	O
/Oncology	O
,	O
Oregon	O
Health	O
and	O
Science	O
University	O
,	O
Portland	O
,	O
97201	O
,	O
USA	O
.	O
corrlessc@ohsu.edu	O
Gastrointestinal	O
stromal	O
tumors	O
(	O
GISTs	O
)	O
are	O
mesenchymal	O
neoplasms	O
of	O
the	O
gut	O
wall	O
that	O
express	O
the	O
receptor	O
tyrosine	O
kinase	O
KIT	O
.	O
Somatic	O
mutations	O
that	O
result	O
in	O
constitutive	O
activation	O
of	O
KIT	O
kinase	O
have	O
been	O
identified	O
in	O
a	O
number	O
of	O
studies	O
of	O
GISTs	O
,	O
although	O
the	O
reported	O
frequency	O
of	O
these	O
mutations	O
has	O
varied	O
over	O
a	O
wide	O
range	O
(	O
20	O
to	O
92	O
%	O
)	O
.	O
Several	O
reports	O
have	O
suggested	O
that	O
KIT	O
gene	O
mutations	O
are	O
more	O
common	O
in	O
malignant	O
GISTs	O
than	O
in	O
benign	O
lesions	O
,	O
and	O
it	O
has	O
been	O
proposed	O
that	O
mutations	O
in	O
exon	B-location
11	I-location
of	O
KIT	O
are	O
a	O
negative	O
prognostic	O
factor	O
.	O
To	O
maximize	O
sensitivity	O
for	O
KIT	O
mutations	O
we	O
have	O
adapted	O
denaturing	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
as	O
a	O
method	O
for	O
screening	O
polymerase	O
chain	O
reaction	O
amplimers	O
of	O
exons	B-location
9	I-location
,	O
11	B-location
,	O
13	B-location
,	O
and	O
17	B-location
from	O
GIST	O
genomic	O
DNA	O
.	O
This	O
approach	O
was	O
used	O
to	O
assess	O
the	O
frequency	O
of	O
KIT	O
mutations	O
in	O
13	O
morphologically	O
benign	O
,	O
incidentally	O
discovered	O
,	O
GISTs	O
identified	O
at	O
autopsy	O
,	O
endoscopy	O
,	O
or	O
laparotomy	O
for	O
unrelated	O
disease	O
.	O
Representing	O
the	O
smallest	O
pathologically	O
recognizable	O
GISTs	O
,	O
these	O
lesions	O
ranged	O
in	O
size	O
from	O
4	O
to	O
10	O
mm	O
in	O
diameter	O
and	O
were	O
all	O
immunohistochemically	O
positive	O
for	O
KIT	O
.	O
Eleven	O
of	O
the	O
13	O
tumors	O
had	O
sequence	O
-	O
confirmed	O
mutations	O
in	O
KIT	O
,	O
including	O
10	O
mutations	O
in	O
exon	B-location
11	I-location
(	O
77	O
%	O
)	O
and	O
one	O
mutation	O
in	O
exon	B-event
9	I-event
(	O
7.7	O
%	O
)	O
.	O
The	O
remaining	O
two	O
tumors	O
were	O
wild	O
type	O
for	O
exons	B-location
9	I-location
,	O
11	B-location
,	O
and	O
17	B-location
;	O
one	O
of	O
these	O
was	O
also	O
analyzed	O
for	O
exon	B-location
13	I-location
and	O
was	O
wild	O
type	O
in	O
this	O
exon	B-location
as	O
well	O
.	O
The	O
mutations	O
found	O
in	O
the	O
incidental	O
GISTs	O
were	O
identical	O
to	O
those	O
that	O
have	O
been	O
documented	O
in	O
larger	O
GISTs	O
.	O
In	O
addition	O
,	O
the	O
overall	O
frequency	O
of	O
mutations	B-event
in	O
the	O
incidental	O
tumors	O
(	O
85	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
we	O
previously	O
reported	O
in	O
a	O
series	O
of	O
72	O
advanced	O
/	O
metastatic	O
GISTs	O
(	O
86	O
%	O
)	O
,	O
strongly	O
supporting	O
the	O
view	O
that	O
activating	O
mutations	O
in	O
KIT	O
are	O
acquired	O
very	O
early	O
in	O
the	O
development	O
of	O
most	O
GISTs	O
.	O
The	O
findings	O
suggest	O
that	O
KIT	O
mutations	O
per	O
se	O
are	O
of	O
little	O
prognostic	O
importance	O
in	O
GISTs	O
.	O
PMID	O
:	O
12000708	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

Eur	O
J	O
Gastroenterol	O
Hepatol	O
2002	O
Apr;14(	O
4	O
)	O
:	O
445-	O
8	O
Gastrointestinal	O
stromal	O
tumour	O
of	O
the	O
oesophagus	O
:	O
significance	O
of	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
c-kit	O
gene	O
.	O
Iijima	O
S	O
,	O
Maesawa	O
C	O
,	O
Sato	O
N	O
,	O
Ikeda	O
K,	O
Inaba	O
T	O
,	O
Akiyama	O
Y	O
,	O
Ishida	O
K,	O
Saito	O
K,	O
Masuda	O
T.	O
Departments	O
of	O
Pathology	O
,	O
Iwate	O
Medical	O
University	O
School	O
of	O
Medicine	O
,	O
Uchimaru	O
19-1	O
,	O
020	O
-	O
8505	O
Morioka	O
,	O
Japan	O
.	O
Oesophageal	O
gastrointestinal	O
stromal	O
tumours	O
(	O
GISTs	O
)	O
are	O
rare	O
in	O
comparison	O
to	O
those	O
of	O
the	O
stomach	O
and	O
intestines	O
.	O
Recently	O
,	O
it	O
has	O
been	O
clarified	O
that	O
mutations	O
of	O
the	O
c-kit	O
gene	O
resulting	O
in	O
gain	B-type
of	I-type
function	I-type
might	O
be	O
associated	O
with	O
histogenesis	O
of	O
this	O
type	O
of	O
tumour	O
arising	O
in	O
the	O
stomach	O
and	O
intestines	O
.	O
We	O
describe	O
an	O
oesophageal	O
GIST	O
on	O
immunohistochemical	O
and	O
genetic	O
analyses	O
of	O
the	O
gene	O
.	O
A	O
71	O
-	O
year	O
-	O
old	O
man	O
had	O
an	O
intramural	O
tumour	O
of	O
the	O
middle	O
third	O
of	O
the	O
oesophagus	O
.	O
Tumour	O
cells	O
were	O
composed	O
predominantly	O
of	O
spindle	O
-	O
shaped	O
and	O
partially	O
epithelioid	O
cells	O
.	O
They	O
were	O
diffusely	O
positive	O
for	O
CD117	O
.	O
Six	O
base	O
deletion	B-type
resulting	O
in	O
in	B-type
-	I-type
frame	I-type
mutation	I-type
of	O
the	O
c-kit	O
gene	O
was	O
confirmed	O
at	O
codon	B-location
556	I-location
-	I-location
558	I-location
(	O
cag	B-location
tgg	I-location
aag	I-location
to	I-location
cag	I-location
)	O
of	O
exon	B-location
11	I-location
.	O
Patients	O
with	O
mutations	O
of	O
the	O
c-kit	O
gene	O
revealed	O
worse	O
prognoses	O
in	O
GISTs	O
arising	O
from	O
other	O
locations	O
.	O
A	O
long	O
-	O
term	O
follow	O
-	O
up	O
observation	O
is	O
needed	O
for	O
the	O
case	O
.	O
PMID	O
:	O
11943962	O
[	O
PubMed	O
-	O
indexed	O
for	O
MEDLINE]	O

